{"PMC7282834": [["IntroductionMost businesses and public services rely on enterprise software such as enterprise resource planning (ERP) or customer relationship management (CRM), to name a few.", [["customer relationship management", "TREATMENT", 122, 154]]], ["Because every company has its unique organization, processes and culture, no off-the-shelf software directly fits.", [["culture", "TEST", 65, 72]]], ["These customers need the vendors to provide mechanisms for performing deep customization, that goes beyond the vendors\u2019 prediction.IntroductionDeep customization may affect any parts of a software product, including the user interface (UI), the business logic (BL), the database schemas (DB) or any combination thereof.", [["deep customization", "TREATMENT", 70, 88], ["IntroductionDeep customization", "TREATMENT", 131, 161]]], ["Nowadays, software vendors are migrating their software products to the Cloud.", [["Cloud", "OBSERVATION_MODIFIER", 72, 77]]], ["Software vendors desperately need novel deep customization solutions for the Cloud-based multi-tenant SaaS model.IntroductionMore recently, leveraging the microservices architecture [1, 6, 14] for enabling deep customization of multi-tenant SaaS is a very promising direction as presented in [8\u201312].", [["SaaS", "CHEMICAL", 241, 245], ["SaaS", "SIMPLE_CHEMICAL", 241, 245], ["multi-tenant SaaS", "PROTEIN", 228, 245], ["novel deep customization solutions", "TREATMENT", 34, 68], ["the Cloud-based multi-tenant SaaS model", "TREATMENT", 73, 112]]], ["These microservices-based customization approaches vary in how they balance isolation and assimilation.", [["These microservices", "TREATMENT", 0, 19]]], ["Isolation guarantees tenant-specific customization only affects that one single tenant, whereas assimilation guarantees that customization capability can alter anything in the main software product.", [["Isolation guarantees", "TREATMENT", 0, 20]]], ["Intrusive microservices [9, 10, 12] provide tight assimilation at the cost of security (tenant isolation), whereas the non-intrusive approach called MiSC-Cloud [7, 8, 11] trades assimilation for higher security.", [["Intrusive microservices", "TREATMENT", 0, 23], ["tight assimilation", "TREATMENT", 44, 62], ["security (tenant isolation", "TREATMENT", 78, 104]]], ["MiSC-Cloud orchestrates customization using microservices via API gateways.IntroductionIn this paper, we present an event-based non-intrusive deep customization approach for multi-tenant SaaS using microservices as part of the MiSC-Cloud framework [8].", [["non-intrusive deep customization approach", "TREATMENT", 128, 169]]], ["The event-based approach, in combination with the synchronous way of customization in [8], shows how the MiSC-Cloud framework can coordinate the execution of the BL components (microservices) of the main product as well as the customization microservices of tenants to obtain the desired customization effects in the multi-tenant context.IntroductionThe remainder of this paper is structured as follows: Sect.", [["main", "OBSERVATION_MODIFIER", 199, 203]]], ["2 defines deep customization.", [["deep customization", "OBSERVATION", 10, 28]]], ["4, we show a proof-of-concept for the proposed approach by applying it on a reference application for microservice architecture by Microsoft .", [["the proposed approach", "TREATMENT", 34, 55], ["microservice architecture", "TREATMENT", 102, 127]]], ["6 our conclusions and possible future research directions.Deep CustomizationBy contrast with other customization means such as settings, scripting languages or API, deep customization demands that one can possibly make any change to the system, as one can do with direct access to the source code.", [["Deep CustomizationBy contrast", "TREATMENT", 58, 87]]], ["Deep customization turns out difficult in multi-tenant SaaS environments, where all tenants originally run the same code (UI, BL and DB).", [["Deep customization", "TREATMENT", 0, 18]]], ["This work focuses on the customization of BL, especially based on events.", [["BL", "CANCER", 42, 44]]], ["In this way, customization microservices communicate with the main product, either in a synchronous way by requesting data and waiting for the response (RPC-like), or in an asynchronous way, by publishing and subscribing to events (pub/sub).", [["RPC", "TEST", 153, 156]]], ["The customization of UI and DB can be found in [8\u201312].Main Components for Enabling Event-Based Customization ::: Event-Based Customization ApproachAmong the five main components of the MiSC-Cloud framework as presented in [7, 8], we focus on presenting the Tenant Manager and the Event Bus as the key parts of the event-based customization approach.", [["UI and DB", "TREATMENT", 21, 30]]], ["The API gateways, IAM Service, and WebMVC Customizer are the same as we described in [8].Main Components for Enabling Event-Based Customization ::: Event-Based Customization ApproachThe Tenant Manager is a service that manages the registration of customization microservices including the events registered for customization for different tenants.", [["customization microservices", "TREATMENT", 247, 274], ["different tenants", "PROBLEM", 329, 346]]], ["The service has a simple database that stores all the tenants that are using the application, all the different events that exist in the main product and finally all the customization microservices that exist for tenants and specific events.", [["tenants", "PROBLEM", 213, 220]]], ["Therefore, the prerequisite for enabling event-based customization is that the main product already has (part of) its logic flow orchestrated via events.", [["main", "OBSERVATION_MODIFIER", 79, 83]]], ["If the main product already has an Event Bus, such an Event Bus can be extended to enable event-based customization.", [["main", "OBSERVATION_MODIFIER", 7, 11]]], ["It is important to note that a software product can be re-engineered to enable event-based logic orchestration at the back-end via an Event Bus.", [["back", "ANATOMY", 118, 122]]], ["Different migration approaches from monolithic to microservices architecture already show some patterns and practices to migrate from synchronous calls into event-based communication between microservices [4, 13].", [["Different migration approaches", "TREATMENT", 0, 30], ["monolithic to microservices architecture", "TREATMENT", 36, 76], ["migration", "OBSERVATION_MODIFIER", 10, 19]]], ["Moreover, software vendors can also create user or system events within their software product to allow authorized event-based integration with external systems (of their customers).", [["external systems", "TREATMENT", 144, 160]]], ["This event-based integration is similar to the traditional way of offering a rich REST API for synchronous integration, e.g., using traditional GET-PUT-POST statements.Event-Based Customization Flow ::: Event-Based Customization ApproachA customization microservice can subscribe to an event that is published to the Event Bus when something notable happens, such as when another microservice (of the main product or another tenant-specific customization) updates a business entity.", [["PUT", "DNA", 148, 151], ["a rich REST API", "TREATMENT", 75, 90], ["synchronous integration", "TREATMENT", 95, 118], ["traditional GET", "TREATMENT", 132, 147]]], ["We design the event bus as a multi-tenant interface with the tenant-specific APIs needed to subscribe and unsubscribe to events and to publish events.Event-Based Customization Flow ::: Event-Based Customization ApproachThe flow of processing events in the original Event Bus implementation must be changed for customization purposes.", [["processing events", "PROBLEM", 231, 248], ["customization purposes", "TEST", 310, 332], ["flow", "OBSERVATION_MODIFIER", 223, 227]]], ["Before publishing events to the consumers, it checks with the Tenant Manager for any customization that has been registered for any event and tenant (see Fig. 1).", [["any customization", "TREATMENT", 81, 98]]], ["Then, the tenant\u2019s microservice can republish the event to the Event Bus, along with a flag that instructs the Event Bus to not check for customization again, to avoid an infinite loop.", [["an infinite loop", "PROBLEM", 168, 184]]]], "98a3b0606a67d829816c1d934e2d1a7196985151": [["IntroductionThe rate of expansion of medical knowledge is increasing rapidly, and it is frequently difficult for clinicians to keep abreast of important new literature.", [["expansion", "OBSERVATION_MODIFIER", 24, 33], ["increasing", "OBSERVATION_MODIFIER", 58, 68], ["rapidly", "OBSERVATION_MODIFIER", 69, 76]]], ["For example, several recently published randomized controlled trials in critical care have demonstrated mortality benefits [1] [2] [3] [4] [5] , but uptake of new knowledge into clinical practice is often delayed [6] [7] [8] .", [["[1] [2] [3] [4", "SIMPLE_CHEMICAL", 123, 137], ["[6] [7] [8]", "SIMPLE_CHEMICAL", 213, 224], ["randomized controlled trials", "TREATMENT", 40, 68], ["mortality benefits", "TEST", 104, 122]]], ["Improving access to this knowledge base at the point of care may lead to better clinical decision making, which could improve patient outcome, reduce costs and optimize bed utilization [9] .", [["patient", "ORGANISM", 126, 133], ["patient", "SPECIES", 126, 133]]], ["A study evaluating a mobile computerized cart to make evidence available to clinicians in an internal medicine setting [12] demonstrated that evidence-based medicine was more likely to be incorporated into patient care when the computerized system was used.", [["patient", "ORGANISM", 206, 213], ["patient", "SPECIES", 206, 213], ["A study", "TEST", 0, 7]]], ["Because of their portability, handheld devices may be more practical tools for disseminating knowledge to the point of care.", [["handheld devices", "TREATMENT", 30, 46]]], ["Despite the popularity of handheld devices in medicine, few studies have evaluated the usefulness of this technology [13] .", [["handheld devices", "TREATMENT", 26, 42], ["few studies", "TEST", 56, 67]]], ["Before widespread dissemination of this type of technology can be encouraged, its impact must be thoroughly evaluated [14] .", [["widespread", "OBSERVATION_MODIFIER", 7, 17], ["dissemination", "OBSERVATION", 18, 31]]], ["In the present study we evaluated whether it would be feasible and effective to provide updateable reference information from a central academic centre to handheld computers used by critical care specialists in community hospitals.Study design, participants and settingA total of 17 intensivists at four community hospital intensive care units (ICUs) in the Greater Toronto Area participated in the present prospective interventional study.InterventionAfter training, each physician was equipped with a handheld computing device (Palm M505; Palm Inc., Milpitas, CA, USA) loaded with medical reference material pertinent to the critical care physician.", [["participants", "SPECIES", 245, 257], ["the present study", "TEST", 3, 20], ["prospective interventional study", "TEST", 407, 439], ["a handheld computing device", "TREATMENT", 501, 528]]], ["Commercially available medical reference software was also incorporated, namely PEPID ED (PEPID LLC, Skokie, IL, USA) and MedCalc http://med calc.med-ia.net/.InterventionThe handheld devices were able to receive literature updates on a regular basis, using customized software (IqSync; Infiniq Software, Mississauga, Ontario, Canada), which accessed an internet-based server using either a connection via desktop computer or infrared data transfer to a telephone modem (Fig. 1 ).", [["Intervention", "TREATMENT", 158, 170], ["The handheld devices", "TREATMENT", 170, 190], ["LLC", "ANATOMY", 96, 99]]], ["These updates, provided every 2-3 weeks, comprised brief reviews of relevant new literature including a short summary, a commentary and the article abstract.InterventionAll handheld devices were equipped with backup software that allowed the content to be rapidly restored in the event of a hardware failure (BackupBuddy VFS; Blue Nomad Software, Redwood City, CA, USA).", [["Intervention", "TREATMENT", 157, 169], ["All handheld devices", "TREATMENT", 169, 189], ["backup software", "TREATMENT", 209, 224], ["a hardware failure", "PROBLEM", 289, 307], ["hardware failure", "OBSERVATION", 291, 307]]], ["The devices were also equipped with software capable of generating a log of the applications used (AppUsage; Benc Software Production, Slavonski Brod, Croatia).InterventionBetween September and November 2002 the handheld devices were distributed to participating physicians, at which time they each received a 1-hour training session on the use of the handheld device and the internet link (Fig. 2) .", [["The devices", "TREATMENT", 0, 11], ["the applications", "TREATMENT", 76, 92], ["the handheld devices", "TREATMENT", 208, 228], ["a 1-hour training session", "TREATMENT", 308, 333], ["the handheld device", "TREATMENT", 348, 367]]], ["After training, the participants were able to utilize the devices in clinical practice for 12 months.", [["participants", "SPECIES", 20, 32], ["the devices", "TREATMENT", 54, 65]]], ["We provided 24-hour support by telephone and e-mail, with a website for independent review.Outcome measuresFeasibility Feasibility of the system was assessed by tracking physicians' use of the handheld device and tracking their access of the individual handheld applications during the study period.", [["the handheld device", "TREATMENT", 189, 208], ["the study", "TEST", 282, 291]]], ["A qualitative assessment of the system was achieved through surveys and focus group methodology.", [["A qualitative assessment of the system", "TEST", 0, 38]]], ["Participants completed surveys at baseline to identify their prior familiarity with handheld devices, and at the end of the study period to evaluate subjectively the handheld reference system and the individual handheld applications.", [["Participants", "SPECIES", 0, 12], ["handheld devices", "TREATMENT", 84, 100], ["the study", "TEST", 120, 129]]], ["Survey data were scored on a 7-point scale, in which 'poor' scored 1 and 'excellent' scored 7.", [["Survey data", "TEST", 0, 11]]], ["An independent company (The NRC+Picker Group, Markham, Canada) conducted the focus group evaluations at the end of the intervention period, to determine the perceived utility of the information system.", [["group evaluations", "TEST", 83, 100]]], ["Each hospital physician group participated in one focus group meeting.Information accessInformation sources that physicians accessed to make clinical decisions were evaluated during simulated patient care scenarios, completed in the physicians' own ICU utilizing a computerized patient simulator (SimMan; Laerdal Medical Corporation, Wappingers Falls, NY, USA).", [["patient", "ORGANISM", 192, 199], ["patient", "ORGANISM", 278, 285], ["patient", "SPECIES", 192, 199], ["patient", "SPECIES", 278, 285]]], ["Each physician completed one scenario before the handheld device was introduced (baseline scenario) and one at the end of the intervention period (final scenario), when the handheld device could be used (Fig. 2) .", [["the handheld device", "TREATMENT", 45, 64], ["the handheld device", "TREATMENT", 169, 188]]], ["A small pool of five scenarios with equivalent complexity was developed, such that physicians would likely need to access information sources in order to make management decisions.", [["A small pool of five scenarios", "PROBLEM", 0, 30], ["small", "OBSERVATION_MODIFIER", 2, 7], ["pool", "OBSERVATION_MODIFIER", 8, 12], ["equivalent", "OBSERVATION_MODIFIER", 36, 46], ["complexity", "OBSERVATION_MODIFIER", 47, 57]]], ["The scenarios involved unusual but important conditions, namely thyroid storm, myasthenia gravis, methanol toxicity, malaria and methemoglobinaemia.", [["thyroid", "ANATOMY", 64, 71], ["thyroid storm", "DISEASE", 64, 77], ["myasthenia gravis", "DISEASE", 79, 96], ["toxicity", "DISEASE", 107, 115], ["malaria", "DISEASE", 117, 124], ["methemoglobinaemia", "DISEASE", 129, 147], ["methanol", "CHEMICAL", 98, 106], ["thyroid", "ORGAN", 64, 71], ["methanol", "SIMPLE_CHEMICAL", 98, 106], ["thyroid storm", "PROBLEM", 64, 77], ["myasthenia gravis", "PROBLEM", 79, 96], ["methanol toxicity", "PROBLEM", 98, 115], ["malaria", "PROBLEM", 117, 124], ["methemoglobinaemia", "PROBLEM", 129, 147], ["thyroid", "ANATOMY", 64, 71], ["myasthenia gravis", "OBSERVATION", 79, 96]]], ["They were allocated to study participants in such a way as to avoid participants from the same site receiving the same scenario at the same time point, and to avoid repetition of scenarios among individual participants.", [["participants", "SPECIES", 29, 41], ["participants", "SPECIES", 68, 80], ["participants", "SPECIES", 206, 218]]], ["Each scenario concluded with the physician writing admission orders for the simulated patient.Information accessDuring the scenarios we tracked all medical reference sources utilized by the physicians, who were encouraged to use a 'think The internet-based data transfer system The internet-based data transfer system.", [["patient", "ORGANISM", 86, 93], ["patient", "SPECIES", 86, 93]]], ["Connection to the internet can take place via hardwire synchronization with a desktop computer or using infrared (IR) data transmission to a dial-up modem.", [["infrared (IR)", "TREATMENT", 104, 117]]], ["ISP, internet service provider.Figure 2The study time course The study time course. aloud' process [15] .", [["The study", "TEST", 39, 48], ["The study", "TEST", 61, 70]]], ["An audiovisual recording was made of the scenarios for later analysis, and when the handheld was used real-time screen capture was incorporated into the recording (Additional file 2).", [["An audiovisual recording", "TEST", 0, 24], ["later analysis", "TEST", 55, 69]]], ["The admission orders were assigned a score (range 0-100) by a critical care physician (SM) and critical care pharmacist (LB), who were blinded as to whether the physician used the handheld device.", [["a score", "TEST", 35, 42], ["the handheld device", "TREATMENT", 176, 195]]], ["The scenario-specific scoring system allocated points for all necessary diagnostic and therapeutic interventions, weighted according to relative importance.", [["therapeutic interventions", "TREATMENT", 87, 112]]], ["Negative points were given for potentially harmful orders.Data analysisData are presented as median and interquartile range (IQR), and permutation tests were used for comparisons because numbers were small and not normally distributed.", [["Data analysisData", "TEST", 58, 75], ["permutation tests", "TEST", 135, 152], ["numbers", "TEST", 187, 194], ["small", "OBSERVATION_MODIFIER", 200, 205], ["distributed", "OBSERVATION_MODIFIER", 223, 234]]], ["The differences between the final and baseline admission order scores and the time to completion of scenarios were calculated for each participant.", [["participant", "SPECIES", 135, 146]]], ["A two-sample permutation test was used to compare these differences between the group of physicians who chose to use the handheld in the final scenario and those who did not use the device.", [["A two-sample permutation test", "TEST", 0, 29], ["the device", "TREATMENT", 178, 188]]], ["Admission order scores obtained for each of the five scenarios were compared.", [["Admission order scores", "TEST", 0, 22]]], ["The SAS System for Window version 8.2 (SAS Institute, Inc., Cary, NC, USA) was used for all analyses.Data analysisFocus groups were recorded, transcribed verbatim and subsequently analyzed.", [["Window version", "TEST", 19, 33], ["NC, USA)", "TREATMENT", 66, 74], ["Data analysisFocus groups", "TEST", 101, 126]]], ["Themes were identified and unique perspectives on key issues noted [16] .FeasibilityThe handheld information system functioned well during the study period.", [["the study", "TEST", 139, 148]]], ["Tracking of the deployment of handhelds identified 10 regular users (59%), four physicians (23%) who used the system variably and three physicians (18%) who never used their handheld device.", [["their handheld device", "TREATMENT", 168, 189]]], ["The regular users accessed the personal information management applications more commonly (median 32.8 times/month, IQR 28.3-126.8) than the medical software (median 9/month, IQR 3.7-13.7; P = 0.028), although significant variation was noted (Table 1) .FeasibilityBaseline survey data identified that, of the 17 critical care physicians participating, 12 (71%) had previous experience with handheld devices (nine had used the Palm operating system, and three had used Windows CE) for a median duration of 1 year (range 1 month to 3.8 years).", [["IQR", "TEST", 116, 119], ["IQR", "TEST", 175, 178], ["significant variation", "PROBLEM", 210, 231], ["handheld devices", "TREATMENT", 390, 406]]], ["Seven participants (41%) reported using handhelds for accessing medical information before the study.", [["participants", "SPECIES", 6, 18], ["the study", "TEST", 91, 100]]], ["The handheld medical applications (Critical Care, What's New, Medcalc and PEPID) received similar ratings, with overall evaluation scores ranging from 4.1 to 5.3 on the 7-point scale.FeasibilityFour focus group meetings, involving a total of 13 participants (76%), identified the benefits and barriers to use of handhelds for information access, and made suggestions for improvement ( Table 2 ).", [["participants", "SPECIES", 245, 257], ["Medcalc and PEPID)", "TREATMENT", 62, 80], ["overall evaluation scores", "TEST", 112, 137]]], ["The overall impression of participants was that there is a role for handhelds for mobile information access, but that in situations away from the bedside other electronic media such as desktop computers were preferable.Information accessNot all study physicians were able to participate in the simulated clinical scenarios on the pre-assigned day.", [["participants", "SPECIES", 26, 38]]], ["Information sources utilized during the baseline scenarios included the internet (50% of participants; e.g. Medline searches and electronic textbooks), textbooks (43%), telephoning colleagues, the ICU pharmacist or Poison Control Centre (71%), and other sources such as pocket guides (21%).", [["participants", "SPECIES", 89, 101]]], ["In the final scenarios, the handheld device was used as the primary source of information by eight participants (62%; Table 3 ).", [["participants", "SPECIES", 99, 111], ["the handheld device", "TREATMENT", 24, 43]]], ["Of 14 information searches on the handheld device, 11 searches (79%) were successful and the median time to access information was 19 s (IQR 15-40 s).", [["the handheld device", "TREATMENT", 30, 49], ["IQR", "TEST", 137, 140]]], ["The information sources of those participants not using the handheld device were similar to those in the baseline surveys ( Fig. 3 ).", [["participants", "SPECIES", 33, 45], ["the handheld device", "TREATMENT", 56, 75]]], ["When scores recorded for each of the five clinical scenarios were compared, no significant difference was noted, reducing the likelihood that scenario assignment influenced outcomes.DiscussionThis study demonstrates the feasibility of using an electronic knowledge translation system to provide high quality, regularly updated medical reference information from a central academic centre to multiple peripheral users.", [["This study", "TEST", 192, 202]]], ["User acceptance of this technology was not uniform, with just over half of the participants using their handheld devices to access information on a regular basis.", [["participants", "SPECIES", 79, 91], ["their handheld devices", "TREATMENT", 98, 120]]], ["Nevertheless, the availability of point-ofcare access to information may have improved the quality of clinical decision-making.DiscussionAlthough mobile computing devices have potential beneficial roles to play in clinical medicine, few publications describe for- mal evaluation of this technology [13] .", [["mobile computing devices", "TREATMENT", 146, 170], ["mal evaluation", "TEST", 264, 278]]], ["Because the present study was an early hypothesis-generating evaluation of this technology, multiple quantitative and qualitative outcomes were measured.", [["the present study", "TEST", 8, 25], ["evaluation", "TEST", 61, 71], ["this technology", "TEST", 75, 90]]], ["We generated novel data on the use of handheld devices in a clinical situation, but the study has several limitations.", [["handheld devices", "TREATMENT", 38, 54], ["the study", "TEST", 84, 93]]], ["The number of physicians involved was relatively small, with a significant proportion not utilizing the technology.", [["small", "OBSERVATION_MODIFIER", 49, 54]]], ["However, the analysis performed compared participants who used the handheld with those who did not; because it was not known which participant would use the handheld at the time of allocation of scenarios, potential bias was minimized.", [["participants", "SPECIES", 41, 53], ["the analysis", "TEST", 9, 21]]], ["A confounding factor in the study was the outbreak of SARS (severe acute respiratory syndrome) from March to May 2003, which had a significant impact on the study ICUs [17] .", [["SARS", "DISEASE", 54, 58], ["acute respiratory syndrome", "DISEASE", 67, 93], ["A confounding factor", "PROBLEM", 0, 20], ["the study", "TEST", 24, 33], ["SARS (severe acute respiratory syndrome", "PROBLEM", 54, 93], ["severe", "OBSERVATION_MODIFIER", 60, 66], ["acute", "OBSERVATION_MODIFIER", 67, 72], ["respiratory syndrome", "OBSERVATION", 73, 93]]], ["Participants were advised to avoid using their handhelds during patient contact because of the potential to transmit infection, and this affected continuity of the study.", [["infection", "DISEASE", 117, 126], ["patient", "ORGANISM", 64, 71], ["Participants", "SPECIES", 0, 12], ["patient", "SPECIES", 64, 71], ["transmit infection", "PROBLEM", 108, 126], ["the study", "TEST", 160, 169], ["infection", "OBSERVATION", 117, 126]]], ["Had we not encountered this event, utilization might have been higher.DiscussionThe lack of universal acceptance of this technology is not surprising and may be due to a number of factors, including inadequate training and the lack of familiarity with the technology [18] .", [["inadequate training", "TREATMENT", 199, 218], ["higher", "OBSERVATION_MODIFIER", 63, 69]]], ["Training is essential when introducing handheld computing technology [19, 20] and, although all users underwent a training programme, the surveys and focus groups indicated a need for improvement.", [["a training programme", "TREATMENT", 112, 132]]], ["Familiarity with handhelds is increasing, with 33% of all Canadian physicians and 53% of under 35year-olds using these devices in 2003, but these levels of utilization remain relatively low when compared with use of the internet, at 88% [21] .", [["these devices", "TREATMENT", 113, 126], ["increasing", "OBSERVATION_MODIFIER", 30, 40]]], ["Other potential barriers to use of the handheld system may be addressed by the rapidly developing technology, including improved screen resolution, ease of data entry and wireless connectivity.", [["the handheld system", "TREATMENT", 35, 54]]], ["Acceptance may be increased through the devel- opment of an all-in-one package on the handheld, allowing additional functionality such as decision support, billing, electronic prescribing and communication.DiscussionThe study demonstrated the potential role of an updateable handheld information system for knowledge translation in critical care.", [["The study", "TEST", 216, 225], ["increased", "OBSERVATION_MODIFIER", 18, 27]]], ["Rapid access to current clinical guidelines may be a valuable component of a comprehensive solution to reducing error and improving efficiency.", [["a comprehensive solution", "TREATMENT", 75, 99], ["improving efficiency", "PROBLEM", 122, 142]]], ["In many situations other media, such as desktop or tablet computers, may be preferable for information access.DiscussionAlthough the study was carried out in a critical care environment, such a system is probably applicable to other specialties in which clinicians are mobile and may not have ready access to a desktop computer (for example, anaesthesia, emergency medicine, home care).", [["the study", "TEST", 129, 138]]], ["This study provides insight into the potential impact of this technology in improving health care outcomes [14] .", [["This study", "TEST", 0, 10], ["this technology", "TREATMENT", 57, 72]]], ["Nevertheless, further study that builds on our findings is essential to determine how these new technologies can best be incorporated into the patient care setting.ConclusionA handheld computer system is feasible as a means of providing point-of-care access to medical reference material in the ICU.", [["patient", "ORGANISM", 143, 150], ["patient", "SPECIES", 143, 150], ["further study", "TEST", 14, 27]]]], "19cc471df1363f275614ea22b2f4cc668ff8292a": [["IntroductionOn December 3, 2019, a new virus emerged, affecting 41 patients with a mysterious pneumonia, in the large seafood market area of Wuhan, China (Patrikar et al., 2020) .", [["pneumonia", "DISEASE", 94, 103], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["a new virus", "PROBLEM", 33, 44], ["a mysterious pneumonia", "PROBLEM", 81, 103], ["pneumonia", "OBSERVATION", 94, 103], ["large", "OBSERVATION_MODIFIER", 112, 117]]], ["Initially, this virus was called the SARS-CoV version 2; however, WHO named it COVID-19 and declared it as a global pandemic on March 11, 2020 (de Le\u00f3n et al., 2020).", [["SARS-CoV", "SPECIES", 37, 45], ["this virus", "PROBLEM", 11, 21]]], ["COVID-19 is an infectious disease caused by the severe acute respiratory syndrome-novel coronavirus-2 (SARS-CoV-2) (Khatua et al., 2020) .", [["COVID-19", "CHEMICAL", 0, 8], ["infectious disease", "DISEASE", 15, 33], ["acute respiratory syndrome", "DISEASE", 55, 81], ["SARS-CoV-2", "ORGANISM", 103, 113], ["novel coronavirus", "SPECIES", 82, 99], ["COVID-19", "SPECIES", 0, 8], ["severe acute respiratory syndrome-novel coronavirus", "SPECIES", 48, 99], ["SARS-CoV-2", "SPECIES", 103, 113], ["an infectious disease", "PROBLEM", 12, 33], ["the severe acute respiratory syndrome", "PROBLEM", 44, 81], ["novel coronavirus", "TEST", 82, 99], ["SARS-CoV", "TEST", 103, 111], ["infectious", "OBSERVATION", 15, 25], ["severe", "OBSERVATION_MODIFIER", 48, 54], ["acute", "OBSERVATION_MODIFIER", 55, 60], ["respiratory syndrome", "OBSERVATION", 61, 81]]], ["Currently, almost all parts of the world are exposed to this virus, and because the infectivity of this virus is high, an immense number of people have already become victims of it (Bhattacharyya et al., 2020) .", [["people", "ORGANISM", 140, 146], ["people", "SPECIES", 140, 146], ["this virus", "PROBLEM", 56, 66], ["this virus", "PROBLEM", 99, 109], ["high", "OBSERVATION_MODIFIER", 113, 117]]], ["The SARS-CoV-2 infection represents one of the greatest challenges for humanity.", [["SARS", "DISEASE", 4, 8], ["infection", "DISEASE", 15, 24], ["SARS-CoV-2", "ORGANISM", 4, 14], ["SARS-CoV-2", "SPECIES", 4, 14], ["The SARS-CoV-2 infection", "PROBLEM", 0, 24], ["SARS", "OBSERVATION", 4, 8], ["CoV", "OBSERVATION_MODIFIER", 9, 12], ["infection", "OBSERVATION", 15, 24], ["greatest", "OBSERVATION_MODIFIER", 47, 55]]], ["Figure 1 shows the COVID-19 scenario of the world until May 31, 2020 by considering confirmed, death, and recovered cases.", [["death", "DISEASE", 95, 100]]], ["Dhanwant and Ramanathan (2020) employed a susceptible-infected-recovered (SIR) approach to forecast the outbreak of COVID-19 cases in India using the SciPy platform.", [["COVID", "DISEASE", 116, 121]]], ["Rodrigues Figure 2 shows the COVID-19 scenario of India until May 31, 2020 by considering the confirmed, death, and recovered cases.Estimation of parameters of SIR model of India using an actual data setFor the epidemical mathematical model, basic models that are based on compartments, as shown in the following, were used:Estimation of parameters of SIR model of India using an actual data setIn 1927, Kermack and McKendrick first proposed a class of compartmental models that simplified the mathematical modeling of infectious disease transmission.", [["death", "DISEASE", 105, 110], ["infectious disease transmission", "DISEASE", 519, 550], ["an actual data", "TEST", 185, 199], ["the epidemical mathematical model", "TEST", 207, 240], ["infectious disease transmission", "PROBLEM", 519, 550], ["infectious", "OBSERVATION", 519, 529]]], ["The SIR model is a set of general equations that explain the dynamics of an infectious disease spreading through a susceptible population.", [["an infectious disease spreading", "PROBLEM", 73, 104], ["a susceptible population", "PROBLEM", 113, 137], ["infectious", "OBSERVATION", 76, 86]]], ["Figure 3 shows the schematic of division of population based on the SIR model.Estimation of parameters of SIR model of India using an actual data setEssentially, the standard SIR model is a set of differential equations that can be categorized as susceptible (if previously unexposed to the pandemic disease), infected (if currently colonized by the pandemic disease), and removed (either by death or recovery) as follows:Estimation of parameters of SIR model of India using an actual data set(1)Estimation of parameters of SIR model of India using an actual data setHere, N=S+I+R is independent of time t and denotes the total population size (Elhia et al. When there is no infection or I+R=0, then by substituting S\u2248N into Equation (2), we obtain the following equation:Estimation of parameters of SIR model of India using an actual data setThen, by integrating Equation (4), we obtained the following equation:Determination of \u03b2 and m valuesAt the onset of infection, almost all of the population is susceptible; i.e., S\u2248N. Therefore, I(t) first grows exponentially.Determination of \u03b2 and m valueswhere m=\u03b2-\u03b3 is a constant term that represents the difference between transmission and recovery rates.Determination of \u03b2 and m valuesThe m value can be estimated from the log-plot data and by using, for example, least squares to obtain the best-line fit.Determination of \u03b2 and m valuesIn this study, the dataset was taken from In this study, we assume that the governmental protocols of each lockdown measure are homogeneously implemented across the country.", [["death", "DISEASE", 392, 397], ["infection", "DISEASE", 675, 684], ["infection", "DISEASE", 960, 969], ["\u03b2", "GENE_OR_GENE_PRODUCT", 1086, 1087], ["=\u03b2-\u03b3", "PROTEIN", 1107, 1111], ["an actual data", "TEST", 131, 145], ["the pandemic disease", "PROBLEM", 287, 307], ["the pandemic disease", "PROBLEM", 346, 366], ["an actual data", "TEST", 549, 563], ["infection", "PROBLEM", 675, 684], ["infection", "PROBLEM", 960, 969], ["\u03b2 and m values", "TEST", 1219, 1233], ["The m value", "TEST", 1233, 1244], ["\u03b2 and m values", "TEST", 1371, 1385], ["this study", "TEST", 1388, 1398], ["this study", "TEST", 1430, 1440], ["size", "OBSERVATION_MODIFIER", 639, 643], ["no", "UNCERTAINTY", 672, 674], ["infection", "OBSERVATION", 675, 684], ["infection", "OBSERVATION", 960, 969], ["constant term", "OBSERVATION_MODIFIER", 1117, 1130], ["line fit", "OBSERVATION", 1345, 1353], ["homogeneously", "OBSERVATION_MODIFIER", 1513, 1526]]], ["However, because of significant differences in various socio-economic, demographic, cultural, and administrative level factors, actual transmission rates are bound to differ from region to region.", [["administrative level factors", "PROBLEM", 98, 126], ["actual transmission rates", "PROBLEM", 128, 153], ["significant", "OBSERVATION_MODIFIER", 20, 31], ["differences", "OBSERVATION_MODIFIER", 32, 43]]], ["Hence, the parameters estimated in our study are only valid for the overall prediction of cases in India, on an average, and they may fail to trace the dynamics of the epidemic in sub-regions; e.g., districts or states (Deo et al., 2020) .", [["the parameters", "TEST", 7, 21], ["our study", "TEST", 35, 44], ["epidemic", "OBSERVATION_MODIFIER", 168, 176], ["sub", "OBSERVATION_MODIFIER", 180, 183]]], ["The uncertainty in our predictions is large because of several unknown reasons arising from model assumptions, population demographics, the number of COVID-19 diagnostic tests administered per day, testing criteria, accuracy of the test results, and heterogeneity in implementation of different governmentinitiated interventions and community-level protective measures across the country.", [["COVID", "TEST", 150, 155], ["diagnostic tests", "TEST", 159, 175], ["testing criteria", "TEST", 198, 214], ["the test results", "TEST", 228, 244], ["different governmentinitiated interventions", "TREATMENT", 285, 328], ["community-level protective measures", "TREATMENT", 333, 368], ["large", "OBSERVATION_MODIFIER", 38, 43]]], ["We have neither accounted for the age structure, contact patterns, or spatial information to finesse our predictions nor considered the possibility of a latent number of true cases, only a fraction of which are ascertained and observed.", [["neither accounted for", "UNCERTAINTY", 8, 29], ["latent", "OBSERVATION_MODIFIER", 153, 159]]], ["The COVID-19 hotspots in India are not uniformly spread across the country, and state-level forecasts may be more meaningful for state-level policymaking.", [["COVID-19 hotspots", "DNA", 4, 21], ["The COVID", "TEST", 0, 9]]], ["Regardless of the caveats in our study, our analyses show the impact and necessity of lockdown and suppressed activity postlockdown in India.", [["our study", "TEST", 29, 38], ["our analyses", "TEST", 40, 52], ["lockdown", "TREATMENT", 86, 94]]], ["One ideological limitation of considering only the epidemiological perspective of controlling the COVID-19 transmission in our model is the inability to count the excess deaths due to other causes during this period, or the flexibility to factor in reduction in mortality/morbidity due to other infectious or flu-like illnesses, traffic accidents, or health benefits of reduced air pollution levels.", [["deaths", "DISEASE", 170, 176], ["flu-like illnesses", "DISEASE", 309, 327], ["traffic accidents", "DISEASE", 329, 346], ["the COVID", "TEST", 94, 103], ["the excess deaths", "PROBLEM", 159, 176], ["morbidity", "PROBLEM", 272, 281], ["flu", "PROBLEM", 309, 312], ["reduced air pollution levels", "PROBLEM", 370, 398], ["infectious", "OBSERVATION", 295, 305], ["air pollution", "OBSERVATION", 378, 391]]], ["A more expansive framework of a cost-benefit analysis is required to gather more data and build an integrated landscape of population attributable risks (Ray et al., 2020).", [["a cost-benefit analysis", "TEST", 30, 53], ["expansive", "OBSERVATION_MODIFIER", 7, 16]]], ["Figure 5 shows the time span of lockdowns in India during the COVID-19 pandemic situation.Determination of \u03b2 and m valuesUsing the COVID-19 dataset of India, we obtained the values presented in Table 1 .Determination of \u03b2 and m valuesHere, lockdown 4 exhibited the minimum value; this means that severe control measures were taken to control the spread of virus.Determination of \u03b3 valueSuppose I(t)=I 0 (constant), then we obtain the following equation:Determination of \u03b3 valueThen, by integrating Equation (9), we obtained the following equation:Determination of \u03b3 valueIf it takes t=T days to recover, then, R(T)=I 0 , or \u03b3T=1.Determination of \u03b3 valueThus, we obtained the following equation:Determination of \u03b3 valuewhere T is the recovery period.Determination of \u03b3 valueFrom Equation (3), for a change in time of dt=a, we obtained the following equation:Determination of \u03b3 value(12) or (13) By estimating directly from the dataset of India, we obtained the values presented in Table 2 .Determination of \u03b3 valueHere, lockdown 2 exhibited the maximum value; this means that the recovery rate of population in this period was better than those in other lockdown periods.Determination of I max and S infBy dividing Equation (2) by Equation (1), we obtained the following equation: This equation is valid for all times.", [["lockdown 4", "DNA", 240, 250], ["\u03b3 valueIf", "PROTEIN", 564, 573], ["\u03b3 valueHere", "PROTEIN", 1006, 1017], ["\u03b2 and m values", "TEST", 107, 121], ["\u03b2 and m values", "TEST", 220, 234], ["severe control measures", "TREATMENT", 296, 319], ["the spread of virus", "PROBLEM", 342, 361], ["This equation", "TEST", 1280, 1293]]], ["Generally, the I initially increases exponentially, reaches a peak, and then gradually decreases back to zero.", [["increases", "OBSERVATION_MODIFIER", 27, 36], ["exponentially", "OBSERVATION_MODIFIER", 37, 50], ["peak", "OBSERVATION_MODIFIER", 62, 66]]], ["We, now, need to find out the percentage of sick people at the peak of infection (I max ) and susceptible people remaining after the infection of COVID-19 virus has passed.", [["infection", "DISEASE", 71, 80], ["infection", "DISEASE", 133, 142], ["COVID-19 virus", "CHEMICAL", 146, 160], ["people", "ORGANISM", 49, 55], ["people", "ORGANISM", 106, 112], ["COVID-19 virus", "ORGANISM", 146, 160], ["people", "SPECIES", 49, 55], ["people", "SPECIES", 106, 112], ["COVID-19 virus", "SPECIES", 146, 160], ["infection", "PROBLEM", 71, 80], ["the infection of COVID-19 virus", "PROBLEM", 129, 160], ["infection", "OBSERVATION", 71, 80], ["infection", "OBSERVATION", 133, 142]]], ["The Equation (2) and (19) are the differential equation of infection rate and its solution respectively.Determination of I max and S infTo simplify, assume S=N s , I=N i , and R=N r .", [["infection", "DISEASE", 59, 68], ["N", "CHEMICAL", 158, 159], ["infection rate", "PROBLEM", 59, 73], ["infection", "OBSERVATION", 59, 68]]], ["Here, s, i, and r represent the fraction of total susceptible, infected, and recovery/removed populations.", [["total susceptible, infected", "PROBLEM", 44, 71], ["total", "OBSERVATION_MODIFIER", 44, 49], ["susceptible", "OBSERVATION_MODIFIER", 50, 61], ["infected", "OBSERVATION", 63, 71]]], ["Thus, we obtained the following equations:Determination of I max and S inf(20) and (21) During peak infection at di/dt=0, s is obtained by the following equation: (22) By substituting Equation (22) into Equation (21), we obtained the following equation: (23) From the dataset of India, we obtained the values presented in Table 3 .Determination of I max and S infThe percentage of sick people at the peak of infection drastically reduced in each lockdown period of India.", [["infection", "DISEASE", 100, 109], ["infection", "DISEASE", 408, 417], ["people", "ORGANISM", 386, 392], ["people", "SPECIES", 386, 392], ["I max and S inf", "TEST", 59, 74], ["peak infection", "PROBLEM", 95, 109], ["infection", "PROBLEM", 408, 417], ["infection", "OBSERVATION", 100, 109], ["percentage", "OBSERVATION_MODIFIER", 367, 377], ["peak", "OBSERVATION_MODIFIER", 400, 404], ["infection", "OBSERVATION", 408, 417], ["drastically", "OBSERVATION_MODIFIER", 418, 429], ["reduced", "OBSERVATION_MODIFIER", 430, 437]]], ["We, now, need to find out S inf = ; i.e., the percentage of susceptible people remaining after the infection has passed.", [["infection", "DISEASE", 99, 108], ["people", "ORGANISM", 72, 78], ["people", "SPECIES", 72, 78], ["the infection", "PROBLEM", 95, 108], ["infection", "OBSERVATION", 99, 108]]], ["We note that i=0 because t tends to infinity (\u221e) at the end of infection; thus, Equation (21) can be rewritten as follows: (24) Equation (24) can be solved numerically to obtain the s value.", [["infection", "DISEASE", 63, 72], ["infection", "PROBLEM", 63, 72], ["infection", "OBSERVATION", 63, 72]]], ["From the data set of India, we obtained the values of S inf for every lockdown stage, as shown in Table 4 .Determination of I max and S infThe percentage of sick people at the end of infection decreased because of the strict procedures of lockdown, and this can be further decreased in future lockdown implementations.Determination of R 0The basic reproduction number, R 0 , is the ratio of transmission and recovery rates.Determination of R 0and (27) From the dataset of India, we obtained the values presented in Table 5 .Determination of R 0The basic reproduction number decreased because of the strict procedures of lockdown, and this can be further decreased.", [["infection", "DISEASE", 183, 192], ["people", "ORGANISM", 162, 168], ["R 0", "GENE_OR_GENE_PRODUCT", 541, 544], ["people", "SPECIES", 162, 168], ["infection", "PROBLEM", 183, 192], ["lockdown", "TREATMENT", 239, 247], ["future lockdown implementations", "TREATMENT", 286, 317], ["lockdown", "TREATMENT", 620, 628], ["percentage", "OBSERVATION_MODIFIER", 143, 153], ["infection", "OBSERVATION", 183, 192], ["decreased", "OBSERVATION_MODIFIER", 193, 202], ["decreased", "OBSERVATION_MODIFIER", 574, 583], ["decreased", "OBSERVATION_MODIFIER", 654, 663]]], ["The simulation results of the Python code of SIR model, based on the India COVID-19 dataset, are shown in Figure 6 -11 for each lockdown case.ConclusionFrom the study of the SIR model for India, several points could be concluded, which are considered as the betterment of each lockdown measure that is to be incorporated.", [["the India COVID", "TEST", 65, 80], ["the study", "TEST", 157, 166]]], ["The recovery rate increased and the transmission rate decreased.", [["The recovery rate", "TEST", 0, 17], ["the transmission rate", "TEST", 32, 53], ["recovery", "OBSERVATION_MODIFIER", 4, 12], ["rate", "OBSERVATION_MODIFIER", 13, 17], ["increased", "OBSERVATION_MODIFIER", 18, 27], ["decreased", "OBSERVATION_MODIFIER", 54, 63]]], ["Thus, the value of basic reproduction number decreased, flattening the curve of epidemic spread of COVID-19.", [["COVID", "TEST", 99, 104], ["decreased", "OBSERVATION_MODIFIER", 45, 54], ["flattening", "OBSERVATION_MODIFIER", 56, 66], ["curve", "OBSERVATION_MODIFIER", 71, 76], ["epidemic", "OBSERVATION_MODIFIER", 80, 88], ["spread", "OBSERVATION_MODIFIER", 89, 95]]], ["Similarly, the percentage of susceptible people remaining after the infection had passed decreased, and it should be checked in the near future.", [["infection", "DISEASE", 68, 77], ["people", "ORGANISM", 41, 47], ["people", "SPECIES", 41, 47], ["the infection", "PROBLEM", 64, 77], ["percentage", "OBSERVATION_MODIFIER", 15, 25], ["susceptible", "OBSERVATION_MODIFIER", 29, 40], ["infection", "OBSERVATION", 68, 77], ["decreased", "OBSERVATION_MODIFIER", 89, 98]]], ["In addition, the peak percentage value of infectious people decreased and exhibited better values.", [["people", "ORGANISM", 53, 59], ["people", "SPECIES", 53, 59], ["the peak percentage value", "TEST", 13, 38], ["infectious people", "PROBLEM", 42, 59], ["peak", "OBSERVATION_MODIFIER", 17, 21], ["percentage", "OBSERVATION_MODIFIER", 22, 32], ["infectious", "OBSERVATION", 42, 52]]], ["In the case of India, further strict governmental interventions should be performed, and, of course, the pandemic cases can be drastically decreased by spreading awareness among the residing people.Conflict of InterestThe authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Author ContributionsMr.", [["people", "ORGANISM", 191, 197], ["people", "SPECIES", 191, 197], ["further strict governmental interventions", "TREATMENT", 22, 63]]], ["Dilip Kumar Bagal monitored the research works from starting to ending process, Ms. Arati Rath simulated the SIR model through Python code, Mr. Abhishek Barua and Dr. Dulu Patnaik both drafted the manuscript as per the requirements.FundingThere is no funding for this study.", [["this study", "TEST", 263, 273], ["no", "UNCERTAINTY", 248, 250], ["funding", "OBSERVATION", 251, 258]]]], "PMC7303697": [["Related Work ::: IntroductionThe most closely related work to CFG identification is by Imada and Nakamura [11].", [["CFG", "CANCER", 62, 65]]], ["They proposed a way to synthesize CFGs from positive and negative samples based on solving a Boolean satisfiability problem (SAT).", [["CFGs", "SIMPLE_CHEMICAL", 34, 38], ["SAT", "TISSUE", 125, 128], ["CFGs", "PROTEIN", 34, 38]]], ["They translated the learning problem for a CFG into a SAT, which is then solved by a SAT solver.", [["CFG", "DISEASE", 43, 46], ["SAT", "TISSUE", 54, 57], ["a SAT solver", "TREATMENT", 83, 95]]], ["The result of the SAT solver satisfying the SAT contains a minimal set of rules (it can be easily changed to a minimal set of variables) that derives all positive samples and no negative samples.Related Work ::: IntroductionThey used one derivation constraint and two main types of Boolean variables:Derivation variables.", [["samples", "ANATOMY", 163, 170], ["samples", "ANATOMY", 187, 194], ["SAT", "TISSUE", 18, 21], ["SAT", "PROTEIN", 44, 47], ["the SAT solver", "TEST", 14, 28], ["the SAT", "TEST", 40, 47], ["one derivation constraint", "TREATMENT", 234, 259], ["Derivation variables", "PROBLEM", 300, 320]]], ["A set of derivation variables represents a relation between nonterminal symbols and substrings (in other words, derivation or parse tree) of each (positive or negative) sample w as follows: for any substring x of w and", [["derivation variables", "PROBLEM", 9, 29]]]], "PMC7212535": [["IntroductionClustered regularly interspaced short palindromic repeats (CRISPR) are segments of nucleic acid containing short, repetitive base sequences that play an important role in prokaryotic defense and form the basis of a genome editing technology that allows permanent modification of genes known as CRISPR-Cas9, as well as CRISPR-Cas12a and CRISPR-13 [1\u20133].", [["nucleic acid", "CHEMICAL", 95, 107], ["CRISPR-Cas9", "GENE_OR_GENE_PRODUCT", 306, 317], ["CRISPR-Cas12a", "GENE_OR_GENE_PRODUCT", 330, 343], ["CRISPR-13", "GENE_OR_GENE_PRODUCT", 348, 357], ["Clustered regularly interspaced short palindromic repeats", "DNA", 12, 69], ["CRISPR", "DNA", 71, 77], ["short, repetitive base sequences", "DNA", 119, 151], ["CRISPR", "DNA", 306, 312], ["Cas9", "DNA", 313, 317], ["CRISPR", "DNA", 330, 336], ["Cas12a", "DNA", 337, 343], ["CRISPR", "DNA", 348, 354], ["IntroductionClustered regularly interspaced short palindromic repeats (CRISPR", "TREATMENT", 0, 77], ["nucleic acid containing short, repetitive base sequences", "PROBLEM", 95, 151], ["a genome editing technology", "PROBLEM", 225, 252], ["CRISPR", "TEST", 348, 354]]], ["While much has been written about how this novel methodology will contribute to scientific inquiry, no literature yet exists on how these advances will affect hospitalists \u2013 specialists in inpatient medicine \u2013 who care exclusively for hospitalized patients suffering from a variety of maladies [4\u20136].", [["patients", "ORGANISM", 248, 256], ["patients", "SPECIES", 248, 256]]], ["It concludes with a look at ethical issues and technical hurdles pertaining to the implementation of permanent gene modification in clinical practice.BackgroundThe CRISPR-Cas system evolved in microbes as an immune system in prokaryotes that confers resistance to foreign genetic elements such as those present within plasmids and phages [8,9].", [["immune system", "ANATOMY", 208, 221], ["plasmids", "ANATOMY", 318, 326], ["CRISPR-Cas", "GENE_OR_GENE_PRODUCT", 164, 174], ["Cas", "PROTEIN", 171, 174], ["foreign genetic elements", "DNA", 264, 288], ["plasmids", "DNA", 318, 326], ["permanent gene modification", "TREATMENT", 101, 128], ["foreign genetic elements", "PROBLEM", 264, 288]]], ["The Cas9 protein performs gene interrogation by unwinding foreign deoxyribonucleic acid (DNA) and determining whether the sequence is complementary to the 20-base pair spacer region of the guide ribonucleic acid (RNA) [10,11].", [["deoxyribonucleic acid", "CHEMICAL", 66, 87], ["ribonucleic acid", "CHEMICAL", 195, 211], ["Cas9", "GENE_OR_GENE_PRODUCT", 4, 8], ["DNA", "CELLULAR_COMPONENT", 89, 92], ["Cas9 protein", "PROTEIN", 4, 16], ["20-base pair spacer region", "DNA", 155, 181], ["guide ribonucleic acid", "RNA", 189, 211], ["The Cas9 protein", "TREATMENT", 0, 16], ["gene interrogation", "TEST", 26, 44], ["unwinding foreign deoxyribonucleic acid (DNA", "PROBLEM", 48, 92], ["the sequence", "TEST", 118, 130], ["ribonucleic acid", "OBSERVATION", 195, 211]]], ["The CRISPR-Cas9 system can be used to manipulate and excise stretches of DNA that have profound relevance for human health, ranging from aggressive malignancies to mitochondrial storage diseases, as well as potential applications in the prevention and treatment of infectious diseases such as human immunodeficiency virus, influenza virus, and malaria, among many others [12\u201316].", [["malignancies", "ANATOMY", 148, 160], ["mitochondrial", "ANATOMY", 164, 177], ["malignancies", "DISEASE", 148, 160], ["mitochondrial storage diseases", "DISEASE", 164, 194], ["infectious diseases", "DISEASE", 265, 284], ["human immunodeficiency virus", "DISEASE", 293, 321], ["influenza virus", "DISEASE", 323, 338], ["malaria", "DISEASE", 344, 351], ["CRISPR-Cas9", "GENE_OR_GENE_PRODUCT", 4, 15], ["DNA", "CELLULAR_COMPONENT", 73, 76], ["human", "ORGANISM", 110, 115], ["malignancies", "CANCER", 148, 160], ["mitochondrial", "CELLULAR_COMPONENT", 164, 177], ["human immunodeficiency virus", "ORGANISM", 293, 321], ["influenza virus", "ORGANISM", 323, 338], ["CRISPR", "DNA", 4, 10], ["human", "SPECIES", 110, 115], ["human immunodeficiency virus", "SPECIES", 293, 321], ["influenza virus", "SPECIES", 323, 338], ["human", "SPECIES", 110, 115], ["human immunodeficiency virus", "SPECIES", 293, 321], ["The CRISPR-Cas9 system", "TREATMENT", 0, 22], ["DNA", "TREATMENT", 73, 76], ["aggressive malignancies", "PROBLEM", 137, 160], ["mitochondrial storage diseases", "PROBLEM", 164, 194], ["treatment", "TREATMENT", 252, 261], ["infectious diseases", "PROBLEM", 265, 284], ["human immunodeficiency virus", "PROBLEM", 293, 321], ["influenza virus", "PROBLEM", 323, 338], ["malaria", "PROBLEM", 344, 351], ["infectious", "OBSERVATION", 265, 275]]], ["Other genetic modification systems exist, such as CRISPR-12a and CRISPR-13, but they are outside of the scope of this manuscript, which will focus on CRISPR-Cas9.BackgroundInitial applications of gene modification have dealt primarily with conditions that are treated by subspecialty providers (oncologists, rheumatologists, infectious disease specialists), but the CRISPR-Cas9 platform also has profound relevance for primary providers, including pediatricians, obstetricians/gynecologists, primary care physicians, and hospitalists, which will be the focus of this manuscript.BackgroundThe term \u2018hospitalist\u2019 was coined in 1996 by Watcher and Goldman and since that time, Hospital Medicine has emerged as the fastest growing subspecialty in the history of medicine [17].", [["infectious disease", "DISEASE", 325, 343], ["CRISPR-12a", "GENE_OR_GENE_PRODUCT", 50, 60], ["CRISPR-13", "GENE_OR_GENE_PRODUCT", 65, 74], ["CRISPR-Cas9", "GENE_OR_GENE_PRODUCT", 150, 161], ["CRISPR-Cas9", "GENE_OR_GENE_PRODUCT", 366, 377], ["CRISPR", "DNA", 50, 56], ["CRISPR-13", "DNA", 65, 74], ["CRISPR", "DNA", 150, 156], ["Cas9", "DNA", 157, 161], ["CRISPR", "DNA", 366, 372], ["CRISPR", "TEST", 50, 56], ["CRISPR", "TEST", 65, 71], ["gene modification", "TREATMENT", 196, 213]]], ["Hospitalists care for a broad array of medical maladies, ranging from blood clots to pneumonia, and emerging research suggests that many of the medical conditions under the hospitalist\u2019s purview could be influenced by advances in the CRISPR-Cas9 [19,20].", [["blood clots", "ANATOMY", 70, 81], ["blood clots", "DISEASE", 70, 81], ["pneumonia", "DISEASE", 85, 94], ["blood", "ORGANISM_SUBSTANCE", 70, 75], ["clots", "ORGANISM_SUBSTANCE", 76, 81], ["CRISPR-Cas9", "GENE_OR_GENE_PRODUCT", 234, 245], ["CRISPR", "DNA", 234, 240], ["medical maladies", "PROBLEM", 39, 55], ["blood clots", "PROBLEM", 70, 81], ["pneumonia", "PROBLEM", 85, 94], ["pneumonia", "OBSERVATION", 85, 94]]], ["Given the rapid evolution of this technology and the widespread appreciation of its potential to alter the treatment of disease, it is necessary for hospitalists to be familiar with the relevance of CRISPR-Cas9.", [["CRISPR-Cas9", "GENE_OR_GENE_PRODUCT", 199, 210], ["CRISPR", "DNA", 199, 205], ["Cas9", "DNA", 206, 210], ["disease", "PROBLEM", 120, 127], ["CRISPR-Cas9", "TREATMENT", 199, 210], ["disease", "OBSERVATION", 120, 127]]], ["An overview of the most common conditions cared for by hospitalists is provided below followed by an examination of how management of these diseases may change with advances in somatic and germline gene modification [21].Viruses ::: Infectious diseasesThe CRISPR-Cas9 systems evolved in microbes as a defense mechanism against viruses by cleaving nucleic acids from the invading bacteriophage [27,28].", [["Infectious diseases", "DISEASE", 233, 252], ["nucleic acids", "CHEMICAL", 347, 360], ["CRISPR-Cas9", "GENE_OR_GENE_PRODUCT", 256, 267], ["CRISPR", "DNA", 256, 262], ["an examination", "TEST", 98, 112], ["these diseases", "PROBLEM", 134, 148], ["somatic and germline gene modification", "TREATMENT", 177, 215], ["Cas9 systems", "TREATMENT", 263, 275], ["viruses", "PROBLEM", 327, 334], ["cleaving nucleic acids", "PROBLEM", 338, 360], ["the invading bacteriophage", "PROBLEM", 366, 392], ["diseases", "OBSERVATION", 140, 148]]], ["For purposes of pathogen detection, cleavage of a labeled sing-strand RNA or DNA probe generates a signal that can provide a fluorescent readout in a number of portable formats, including the use of disposable paper strips, enabling rapid detection of pathogenic viruses [29].", [["DNA", "CELLULAR_COMPONENT", 77, 80], ["labeled sing-strand RNA", "RNA", 50, 73], ["DNA probe", "DNA", 77, 86], ["pathogen detection", "TEST", 16, 34], ["a labeled sing-strand RNA", "TREATMENT", 48, 73], ["a fluorescent readout", "TEST", 123, 144], ["disposable paper strips", "TREATMENT", 199, 222], ["pathogenic viruses", "PROBLEM", 252, 270]]], ["CRISPR-based tests carry several advantages over traditional microbiological diagnostics such as polymerase chain reaction (PCR), which is generally considered to be the most sensitive and specific test available for viral detection.", [["CRISPR", "DNA", 0, 6], ["CRISPR-based tests", "TEST", 0, 18], ["traditional microbiological diagnostics", "TEST", 49, 88], ["polymerase chain reaction", "TEST", 97, 122], ["PCR", "TEST", 124, 127], ["specific test", "TEST", 189, 202], ["viral detection", "TEST", 217, 232]]], ["However, PCR require multiple steps to run the assay, including an upfront nucleic acid extraction and amplification steps, and require dedicated instrumentation [30\u201332].", [["nucleic acid", "CHEMICAL", 75, 87], ["PCR", "TEST", 9, 12], ["the assay", "TEST", 43, 52], ["an upfront nucleic acid extraction", "TREATMENT", 64, 98], ["dedicated instrumentation", "TREATMENT", 136, 161]]], ["By contrast, CRISPR-Cas-based assays can be run directly on primary clinical samples as a single reaction and performed using minimal equipment [33\u201336].", [["samples", "ANATOMY", 77, 84], ["CRISPR-Cas", "GENE_OR_GENE_PRODUCT", 13, 23], ["CRISPR", "DNA", 13, 19], ["Cas", "PROTEIN", 20, 23], ["a single reaction", "PROBLEM", 88, 105]]], ["This is especially relevant for detection of SARS-CoV-2, where testing has been limited in many places due to a lack of testing materials and personal protective equipment [37\u201339].Viruses ::: Infectious diseasesAs front-line healthcare providers, hospitalists are often the clinicians who must coordinate the work-up of a patient with a suspected infection.", [["SARS", "DISEASE", 45, 49], ["Infectious diseases", "DISEASE", 192, 211], ["infection", "DISEASE", 347, 356], ["SARS-CoV-2", "ORGANISM", 45, 55], ["patient", "ORGANISM", 322, 329], ["patient", "SPECIES", 322, 329], ["SARS-CoV", "SPECIES", 45, 53], ["SARS", "PROBLEM", 45, 49], ["CoV", "TEST", 50, 53], ["testing", "TEST", 63, 70], ["Infectious diseases", "PROBLEM", 192, 211], ["a suspected infection", "PROBLEM", 335, 356], ["infection", "OBSERVATION", 347, 356]]], ["Determining the appropriate tests is essential to patient care but also to medical education [40,41].", [["patient", "ORGANISM", 50, 57], ["patient", "SPECIES", 50, 57], ["the appropriate tests", "TEST", 12, 33]]], ["Hospitalists have emerged as the primary medical educators on the general medicine service at many academic medical centers and they must be familiar with emerging assays to ensure that patients receive proper treatment and that the next generation of clinicians is properly informed [42,43].", [["patients", "ORGANISM", 186, 194], ["patients", "SPECIES", 186, 194], ["proper treatment", "TREATMENT", 203, 219]]], ["This includes diagnostic tests for common and emerging viral pathogens.Viruses ::: Infectious diseasesThe SHERLOCK assay has been successfully used to detect both Zika virus and dengue virus directly from bodily fluids, including urine and respiratory samples, in less than two hours and enabled discrimination among viral serotypes [29,44].", [["bodily fluids", "ANATOMY", 205, 218], ["urine", "ANATOMY", 230, 235], ["respiratory samples", "ANATOMY", 240, 259], ["Infectious diseases", "DISEASE", 83, 102], ["dengue", "DISEASE", 178, 184], ["Zika virus", "ORGANISM", 163, 173], ["dengue virus", "ORGANISM", 178, 190], ["urine", "ORGANISM_SUBSTANCE", 230, 235], ["Zika virus and dengue virus", "SPECIES", 163, 190], ["Zika virus", "SPECIES", 163, 173], ["dengue virus", "SPECIES", 178, 190], ["diagnostic tests", "TEST", 14, 30], ["emerging viral pathogens", "PROBLEM", 46, 70], ["Infectious diseases", "PROBLEM", 83, 102], ["The SHERLOCK assay", "TEST", 102, 120], ["Zika virus", "PROBLEM", 163, 173], ["dengue virus", "PROBLEM", 178, 190], ["bodily fluids", "TEST", 205, 218], ["urine and respiratory samples", "TEST", 230, 259], ["viral serotypes", "PROBLEM", 317, 332], ["viral pathogens", "OBSERVATION", 55, 70], ["Zika virus", "OBSERVATION", 163, 173], ["respiratory", "ANATOMY", 240, 251]]], ["This approach may soon extend to serum samples, and has potential for the rapid diagnosis of human immunodeficiency virus (HIV) as well as hepatitis c virus (HCV) genotype in order to guide the choice of antiviral therapy, which may depend on the presence of single nucleotide polymorphisms [45\u201348].Viruses ::: Infectious diseasesOthers have used the CRISPR-based DETECTR assay to detect human papillomavirus (HPV) types 16 and 18, which are associated with invasive genital tumors, and highlights the potential use of CRISPR-Cas technologies from infectious diseases to other fields, such as cancer (which will be discussed later in this manuscript) [49,50].", [["serum samples", "ANATOMY", 33, 46], ["invasive genital tumors", "ANATOMY", 458, 481], ["cancer", "ANATOMY", 593, 599], ["human immunodeficiency virus (HIV)", "DISEASE", 93, 127], ["hepatitis c", "DISEASE", 139, 150], ["Infectious diseases", "DISEASE", 311, 330], ["human papillomavirus (HPV) types", "DISEASE", 388, 420], ["genital tumors", "DISEASE", 467, 481], ["infectious diseases", "DISEASE", 548, 567], ["cancer", "DISEASE", 593, 599], ["nucleotide", "CHEMICAL", 266, 276], ["serum samples", "ORGANISM_SUBSTANCE", 33, 46], ["human immunodeficiency virus", "ORGANISM", 93, 121], ["hepatitis c virus", "ORGANISM", 139, 156], ["HCV", "ORGANISM", 158, 161], ["human papillomavirus (HPV", "ORGANISM", 388, 413], ["genital tumors", "CANCER", 467, 481], ["CRISPR-Cas", "GENE_OR_GENE_PRODUCT", 519, 529], ["cancer", "CANCER", 593, 599], ["CRISPR", "DNA", 351, 357], ["human immunodeficiency virus", "SPECIES", 93, 121], ["hepatitis c virus", "SPECIES", 139, 156], ["human", "SPECIES", 388, 393], ["human immunodeficiency virus", "SPECIES", 93, 121], ["HIV", "SPECIES", 123, 126], ["hepatitis c virus", "SPECIES", 139, 156], ["HCV", "SPECIES", 158, 161], ["human papillomavirus", "SPECIES", 388, 408], ["HPV", "SPECIES", 410, 413], ["serum samples", "TEST", 33, 46], ["human immunodeficiency virus", "PROBLEM", 93, 121], ["HIV", "PROBLEM", 123, 126], ["hepatitis c virus (HCV) genotype", "PROBLEM", 139, 171], ["antiviral therapy", "TREATMENT", 204, 221], ["single nucleotide polymorphisms", "PROBLEM", 259, 290], ["the CRISPR", "TEST", 347, 357], ["DETECTR assay", "TEST", 364, 377], ["human papillomavirus", "PROBLEM", 388, 408], ["invasive genital tumors", "PROBLEM", 458, 481], ["CRISPR-Cas technologies", "TREATMENT", 519, 542], ["infectious diseases", "PROBLEM", 548, 567], ["cancer", "PROBLEM", 593, 599], ["associated with", "UNCERTAINTY", 442, 457], ["invasive", "OBSERVATION_MODIFIER", 458, 466], ["genital", "ANATOMY", 467, 474], ["tumors", "OBSERVATION", 475, 481], ["infectious", "OBSERVATION", 548, 558], ["cancer", "OBSERVATION", 593, 599]]], ["Although more work is necessary to standardize and validate this approach to diagnosis, CRISPR-Cas-based assays show tremendous potential for point-of-care diagnostic because of its ease of implementation, short turnaround time, direct detection from human samples, and colorimetric fluorescent readout [51\u201353].Bacteria ::: Infectious diseasesCRISPR-based platforms also have the potential to detect and alter bacterial pathogens, including those that exist as external threats as well those that live within us and comprise the microbiome [54].", [["samples", "ANATOMY", 257, 264], ["CRISPR-Cas", "GENE_OR_GENE_PRODUCT", 88, 98], ["human", "ORGANISM", 251, 256], ["CRISPR", "DNA", 88, 94], ["Cas", "PROTEIN", 95, 98], ["human", "SPECIES", 251, 256], ["human", "SPECIES", 251, 256], ["human samples", "TEST", 251, 264], ["colorimetric fluorescent readout", "TEST", 270, 302], ["alter bacterial pathogens", "PROBLEM", 404, 429]]], ["This platform also has tremendous potential to identify and eradicate bacterial resistance genes, which enable pathogens to evade or neutralize antibiotics [2].", [["bacterial resistance genes", "DNA", 70, 96], ["bacterial resistance genes", "PROBLEM", 70, 96], ["neutralize antibiotics", "TREATMENT", 133, 155]]], ["This approach has been shown to antibiotic resistance genes in saliva and serum and may soon replace multiplex PCR [56].", [["saliva", "ANATOMY", 63, 69], ["serum", "ANATOMY", 74, 79], ["saliva", "ORGANISM_SUBSTANCE", 63, 69], ["serum", "ORGANISM_SUBSTANCE", 74, 79], ["antibiotic resistance genes", "DNA", 32, 59], ["antibiotic resistance genes in saliva and serum", "PROBLEM", 32, 79], ["multiplex PCR", "TEST", 101, 114], ["antibiotic resistance", "OBSERVATION", 32, 53]]], ["However, significant hurdles remain.", [["significant", "OBSERVATION_MODIFIER", 9, 20], ["hurdles", "OBSERVATION", 21, 28]]], ["It is unclear how a CRISPR-based platform could remove all clinically-relevant resistance genes in a single bacterium or how this could be scaled up to remove these sequences from an entire population of pathogens.Bacteria ::: Infectious diseasesCRISPR-based methods have also been used to treat drug-resistant bacterial infections.", [["bacterial infections", "DISEASE", 311, 331], ["CRISPR", "DNA", 20, 26], ["resistance genes", "DNA", 79, 95], ["relevant resistance genes", "PROBLEM", 70, 95], ["a single bacterium", "PROBLEM", 99, 117], ["these sequences", "TEST", 159, 174], ["pathogens", "PROBLEM", 204, 213], ["Infectious diseasesCRISPR-based methods", "TREATMENT", 227, 266], ["drug-resistant bacterial infections", "PROBLEM", 296, 331], ["pathogens", "OBSERVATION", 204, 213], ["bacterial", "OBSERVATION_MODIFIER", 311, 320], ["infections", "OBSERVATION", 321, 331]]], ["In one example, a fifteen-year-old girl with cystic fibrosis with a disseminated Mycobacterium abscessus infection (which included her skin) was treated with a three-bacteriophage cocktail that had been manipulated using CRISPR [57].", [["cystic", "ANATOMY", 45, 51], ["skin", "ANATOMY", 135, 139], ["cystic fibrosis", "DISEASE", 45, 60], ["Mycobacterium abscessus infection", "DISEASE", 81, 114], ["girl", "ORGANISM", 35, 39], ["Mycobacterium abscessus", "ORGANISM", 81, 104], ["skin", "ORGAN", 135, 139], ["girl", "SPECIES", 35, 39], ["Mycobacterium abscessus", "SPECIES", 81, 104], ["Mycobacterium abscessus", "SPECIES", 81, 104], ["cystic fibrosis", "PROBLEM", 45, 60], ["a disseminated Mycobacterium abscessus infection", "PROBLEM", 66, 114], ["a three-bacteriophage cocktail", "TREATMENT", 158, 188], ["cystic", "OBSERVATION_MODIFIER", 45, 51], ["fibrosis", "OBSERVATION", 52, 60], ["disseminated", "OBSERVATION_MODIFIER", 68, 80], ["Mycobacterium", "OBSERVATION_MODIFIER", 81, 94], ["abscessus", "OBSERVATION_MODIFIER", 95, 104], ["infection", "OBSERVATION", 105, 114], ["skin", "ANATOMY", 135, 139]]], ["Bacteriophage treatment was associated with marked clinical improvement in this patient who had undergone bilateral lung transplantation and had previously been unable to clear her infection, suggesting that phage therapy may prove to be a useful treatment for drug-resistant bacterial infections for other patients, many of whom are now managed by hospitalists at medical centers around the world [12,58].Fungi ::: Infectious diseasesMycotic infections are broadly divided into those caused by yeasts, molds, and thermally-dimorphic fungi [59].", [["lung", "ANATOMY", 116, 120], ["infection", "DISEASE", 181, 190], ["bacterial infections", "DISEASE", 276, 296], ["Infectious diseasesMycotic infections", "DISEASE", 416, 453], ["patient", "ORGANISM", 80, 87], ["lung", "ORGAN", 116, 120], ["patients", "ORGANISM", 307, 315], ["patient", "SPECIES", 80, 87], ["patients", "SPECIES", 307, 315], ["Bacteriophage treatment", "TREATMENT", 0, 23], ["bilateral lung transplantation", "TREATMENT", 106, 136], ["her infection", "PROBLEM", 177, 190], ["phage therapy", "TREATMENT", 208, 221], ["a useful treatment", "TREATMENT", 238, 256], ["drug-resistant bacterial infections", "PROBLEM", 261, 296], ["Infectious diseasesMycotic infections", "PROBLEM", 416, 453], ["yeasts", "PROBLEM", 495, 501], ["molds", "PROBLEM", 503, 508], ["dimorphic fungi", "PROBLEM", 524, 539], ["marked", "OBSERVATION_MODIFIER", 44, 50], ["bilateral", "ANATOMY_MODIFIER", 106, 115], ["lung", "ANATOMY", 116, 120], ["transplantation", "OBSERVATION", 121, 136], ["infection", "OBSERVATION", 181, 190], ["infections", "OBSERVATION", 443, 453], ["dimorphic", "OBSERVATION_MODIFIER", 524, 533], ["fungi", "OBSERVATION", 534, 539]]], ["Many of these organisms are ubiquitous in our environment, and preferentially infect patients with immune impairment [60].", [["immune impairment", "DISEASE", 99, 116], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["these organisms", "PROBLEM", 8, 23], ["immune impairment", "PROBLEM", 99, 116], ["organisms", "OBSERVATION", 14, 23]]], ["These opportunistic pathogens are on the rise, due to advances in the treatment of cancer and autoimmune conditions, which have produced a variety of new drugs that alter the human immune system [61].", [["cancer", "ANATOMY", 83, 89], ["opportunistic pathogens", "DISEASE", 6, 29], ["cancer", "DISEASE", 83, 89], ["cancer", "CANCER", 83, 89], ["human", "ORGANISM", 175, 180], ["human", "SPECIES", 175, 180], ["human", "SPECIES", 175, 180], ["These opportunistic pathogens", "PROBLEM", 0, 29], ["cancer", "PROBLEM", 83, 89], ["autoimmune conditions", "PROBLEM", 94, 115], ["new drugs", "TREATMENT", 150, 159], ["opportunistic", "OBSERVATION_MODIFIER", 6, 19], ["pathogens", "OBSERVATION", 20, 29], ["cancer", "OBSERVATION", 83, 89]]], ["The arsenal of anti-fungal drugs is small \u2013 there are only three major classes of antifungal drugs \u2013 and novel treatment approaches are desperately needed.", [["anti-fungal drugs", "TREATMENT", 15, 32], ["antifungal drugs", "TREATMENT", 82, 98], ["novel treatment approaches", "TREATMENT", 105, 131], ["anti-fungal drugs", "OBSERVATION", 15, 32], ["small", "OBSERVATION_MODIFIER", 36, 41], ["antifungal drugs", "OBSERVATION", 82, 98]]], ["One such approach involves CRISPR.Fungi ::: Infectious diseasesKwon and colleagues provided the first comprehensive analysis and evaluation of different CRISPR approaches for the modification of molds [62].", [["Infectious diseases", "DISEASE", 44, 63], ["CRISPR", "DNA", 27, 33], ["the first comprehensive analysis", "TEST", 92, 124], ["evaluation", "TEST", 129, 139], ["different CRISPR approaches", "TREATMENT", 143, 170]]], ["Guide RNAs were created and CRISPR nucleases were delivered to the filamentous fungus Thermothelomyces thermophilus on plasmids.", [["plasmids", "ANATOMY", 119, 127], ["Thermothelomyces thermophilus", "ORGANISM", 86, 115], ["Guide RNAs", "RNA", 0, 10], ["CRISPR nucleases", "DNA", 28, 44], ["plasmids", "DNA", 119, 127], ["Thermothelomyces thermophilus", "SPECIES", 86, 115], ["Thermothelomyces thermophilus", "SPECIES", 86, 115], ["Guide RNAs", "TREATMENT", 0, 10], ["CRISPR nucleases", "PROBLEM", 28, 44], ["plasmids", "TREATMENT", 119, 127]]], ["The team was able to generated high numbers of positive transformants that could be useful for high-throughput assays to identify novel antifungal agents.", [["transformants", "ANATOMY", 56, 69], ["transformants", "CELL", 56, 69], ["positive transformants", "PROBLEM", 47, 69], ["novel antifungal agents", "TREATMENT", 130, 153]]], ["This approach will likely extend to other fungi, and may yield insights into drug resistance associated with mycotic infection, which have emerged as an important cause of morbidity and mortality in immunocompromised patients.Parasites ::: Infectious diseasesParasites encompass a variety of human pathogens [63].", [["mycotic infection", "DISEASE", 109, 126], ["Infectious diseasesParasites", "DISEASE", 240, 268], ["patients", "ORGANISM", 217, 225], ["human", "ORGANISM", 292, 297], ["patients", "SPECIES", 217, 225], ["human", "SPECIES", 292, 297], ["human", "SPECIES", 292, 297], ["This approach", "TREATMENT", 0, 13], ["other fungi", "PROBLEM", 36, 47], ["drug resistance", "PROBLEM", 77, 92], ["mycotic infection", "PROBLEM", 109, 126], ["morbidity", "PROBLEM", 172, 181], ["Infectious diseasesParasites", "PROBLEM", 240, 268], ["human pathogens", "PROBLEM", 292, 307], ["mycotic", "OBSERVATION_MODIFIER", 109, 116], ["infection", "OBSERVATION", 117, 126], ["morbidity", "OBSERVATION", 172, 181], ["Infectious", "OBSERVATION", 240, 250], ["variety", "OBSERVATION_MODIFIER", 281, 288]]], ["Parasitic worms, such as roundworms and flatworms, are amongst the most complex representing the sixth leading cause of morbidity worldwide and treatment options are limited [64].", [["worms", "ANATOMY", 10, 15], ["roundworms", "ANATOMY", 25, 35], ["Parasitic worms", "DISEASE", 0, 15], ["worms", "SPECIES", 10, 15], ["Parasitic worms", "PROBLEM", 0, 15], ["flatworms", "PROBLEM", 40, 49], ["morbidity", "PROBLEM", 120, 129], ["treatment options", "TREATMENT", 144, 161], ["worms", "OBSERVATION", 10, 15], ["morbidity", "OBSERVATION", 120, 129]]], ["Several investigators have employed CRISPR to interrupt essential genes in parasitic worms.", [["CRISPR", "DNA", 36, 42], ["worms", "SPECIES", 85, 90], ["essential genes in parasitic worms", "PROBLEM", 56, 90], ["parasitic worms", "OBSERVATION", 75, 90]]], ["For example, in the flatworm Opisthorchis viverrini, CRISPR-induced mutations were introduced into the Ov-grn-1 transcript and protein levels were reduced within 48 h of transfection [65,66].", [["flatworm", "ORGANISM", 20, 28], ["Opisthorchis viverrini", "ORGANISM", 29, 51], ["CRISPR", "GENE_OR_GENE_PRODUCT", 53, 59], ["Ov-grn-1", "GENE_OR_GENE_PRODUCT", 103, 111], ["CRISPR", "DNA", 53, 59], ["Ov-grn", "PROTEIN", 103, 109], ["Opisthorchis viverrini", "SPECIES", 29, 51], ["Opisthorchis viverrini", "SPECIES", 29, 51], ["the flatworm Opisthorchis viverrini", "PROBLEM", 16, 51], ["CRISPR-induced mutations", "TREATMENT", 53, 77], ["protein levels", "TEST", 127, 141], ["transfection", "TEST", 170, 182], ["flatworm", "OBSERVATION_MODIFIER", 20, 28], ["Opisthorchis", "OBSERVATION", 29, 41]]], ["The livers of animals infected with modified worms were less swollen, and their biliary ducts had less scarring compared to the those of animals harboring unmodified worms, suggesting that this CRISPR-based method may serve as an approach to attenuate the pathogenicity of a devastating pathogen that affects humans around the world [67,68].CancerThe use of CRISPR holds tremendous promise for the treatment of infectious diseases, but many of those assays and therapies are years away.", [["livers", "ANATOMY", 4, 10], ["biliary ducts", "ANATOMY", 80, 93], ["worms", "ANATOMY", 166, 171], ["Cancer", "ANATOMY", 341, 347], ["scarring", "DISEASE", 103, 111], ["Cancer", "DISEASE", 341, 347], ["infectious diseases", "DISEASE", 411, 430], ["livers", "ORGAN", 4, 10], ["animals", "ORGANISM", 14, 21], ["worms", "ORGANISM", 45, 50], ["biliary ducts", "MULTI-TISSUE_STRUCTURE", 80, 93], ["humans", "ORGANISM", 309, 315], ["Cancer", "CANCER", 341, 347], ["CRISPR", "DNA", 194, 200], ["CRISPR", "DNA", 358, 364], ["worms", "SPECIES", 45, 50], ["worms", "SPECIES", 166, 171], ["humans", "SPECIES", 309, 315], ["humans", "SPECIES", 309, 315], ["Cancer", "SPECIES", 341, 347], ["modified worms", "PROBLEM", 36, 50], ["less swollen", "PROBLEM", 56, 68], ["less scarring", "PROBLEM", 98, 111], ["this CRISPR", "TEST", 189, 200], ["a devastating pathogen", "PROBLEM", 273, 295], ["Cancer", "PROBLEM", 341, 347], ["CRISPR", "TREATMENT", 358, 364], ["infectious diseases", "PROBLEM", 411, 430], ["livers", "ANATOMY", 4, 10], ["animals", "OBSERVATION_MODIFIER", 14, 21], ["infected", "OBSERVATION", 22, 30], ["less", "OBSERVATION_MODIFIER", 56, 60], ["swollen", "OBSERVATION", 61, 68], ["biliary ducts", "ANATOMY", 80, 93], ["less", "OBSERVATION_MODIFIER", 98, 102], ["scarring", "OBSERVATION", 103, 111], ["devastating", "OBSERVATION_MODIFIER", 275, 286], ["pathogen", "OBSERVATION", 287, 295], ["infectious", "OBSERVATION", 411, 421]]], ["For cancer treatment, CRISPR-based therapies have already arrived [47].", [["cancer", "ANATOMY", 4, 10], ["cancer", "DISEASE", 4, 10], ["cancer", "CANCER", 4, 10], ["CRISPR", "DNA", 22, 28], ["cancer treatment", "TREATMENT", 4, 20], ["CRISPR-based therapies", "TREATMENT", 22, 44], ["cancer", "OBSERVATION", 4, 10]]], ["In fact, preliminary results of the first phase-one study using CRISPR to treat cancer were recently revealed.", [["cancer", "ANATOMY", 80, 86], ["cancer", "DISEASE", 80, 86], ["cancer", "CANCER", 80, 86], ["CRISPR", "DNA", 64, 70], ["one study", "TEST", 48, 57], ["CRISPR to treat cancer", "PROBLEM", 64, 86], ["cancer", "OBSERVATION", 80, 86]]], ["In that study, T-cells from the blood of three patients (two with multiple myeloma and one with sarcoma) and used CRISPR-Cas9 to remove three genes from the cells, including two T-cell receptors as well as programmed cell death-1 (PD-1) [69].", [["T-cells", "ANATOMY", 15, 22], ["blood", "ANATOMY", 32, 37], ["myeloma", "ANATOMY", 75, 82], ["sarcoma", "ANATOMY", 96, 103], ["cells", "ANATOMY", 157, 162], ["T-cell", "ANATOMY", 178, 184], ["multiple myeloma", "DISEASE", 66, 82], ["sarcoma", "DISEASE", 96, 103], ["T-cells", "CELL", 15, 22], ["blood", "ORGANISM_SUBSTANCE", 32, 37], ["patients", "ORGANISM", 47, 55], ["myeloma", "CANCER", 75, 82], ["sarcoma", "CANCER", 96, 103], ["CRISPR-Cas9", "GENE_OR_GENE_PRODUCT", 114, 125], ["cells", "CELL", 157, 162], ["T-cell receptors", "GENE_OR_GENE_PRODUCT", 178, 194], ["programmed cell death-1", "GENE_OR_GENE_PRODUCT", 206, 229], ["PD-1", "GENE_OR_GENE_PRODUCT", 231, 235], ["T-cells", "CELL_TYPE", 15, 22], ["CRISPR", "DNA", 114, 120], ["Cas9", "DNA", 121, 125], ["T-cell receptors", "PROTEIN", 178, 194], ["patients", "SPECIES", 47, 55], ["that study", "TEST", 3, 13], ["multiple myeloma", "PROBLEM", 66, 82], ["sarcoma", "PROBLEM", 96, 103], ["CRISPR-Cas9", "TREATMENT", 114, 125], ["two T-cell receptors", "TREATMENT", 174, 194], ["programmed cell death", "TEST", 206, 227], ["PD", "TEST", 231, 233], ["multiple", "OBSERVATION_MODIFIER", 66, 74], ["myeloma", "OBSERVATION", 75, 82], ["sarcoma", "OBSERVATION", 96, 103]]], ["The patients received modified cells after chemotherapy and the CRISPR-edited cells proliferated in all of the patients while no serious treatment-related adverse events were noted.", [["cells", "ANATOMY", 31, 36], ["cells", "ANATOMY", 78, 83], ["patients", "ORGANISM", 4, 12], ["cells", "CELL", 31, 36], ["cells", "CELL", 78, 83], ["patients", "ORGANISM", 111, 119], ["CRISPR-edited cells", "CELL_LINE", 64, 83], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 111, 119], ["modified cells", "TREATMENT", 22, 36], ["chemotherapy", "TREATMENT", 43, 55], ["the CRISPR", "TEST", 60, 70], ["serious treatment", "TREATMENT", 129, 146], ["adverse events", "PROBLEM", 155, 169]]], ["This proof-of-principle study shows that CRISPR-based treatments for cancer are both safe and feasible and will serve as the basis for phase two studies, which will likely begin in the near future [69\u201372].", [["cancer", "ANATOMY", 69, 75], ["cancer", "DISEASE", 69, 75], ["cancer", "CANCER", 69, 75], ["CRISPR", "DNA", 41, 47], ["principle study", "TEST", 14, 29], ["CRISPR-based treatments", "TREATMENT", 41, 64], ["cancer", "PROBLEM", 69, 75], ["phase two studies", "TEST", 135, 152], ["cancer", "OBSERVATION", 69, 75]]], ["It is not yet known how these malignancies evade immune surveillance or how removal of these genes affected the efficacy of T-cells against cancer.CancerAnother CRISPR-based approach to the treatment of cancer is based on the production of next-generation chimeric antigen receptor (CAR) T-cells, which are created to express cancer-targeting receptors [73,74].", [["malignancies", "ANATOMY", 30, 42], ["T-cells", "ANATOMY", 124, 131], ["cancer", "ANATOMY", 140, 146], ["cancer", "ANATOMY", 203, 209], ["CAR) T-cells", "ANATOMY", 283, 295], ["cancer", "ANATOMY", 326, 332], ["malignancies", "DISEASE", 30, 42], ["cancer", "DISEASE", 140, 146], ["cancer", "DISEASE", 203, 209], ["cancer", "DISEASE", 326, 332], ["malignancies", "CANCER", 30, 42], ["T-cells", "CELL", 124, 131], ["cancer", "CANCER", 140, 146], ["cancer", "CANCER", 203, 209], ["chimeric antigen receptor", "GENE_OR_GENE_PRODUCT", 256, 281], ["cancer", "CANCER", 326, 332], ["T-cells", "CELL_TYPE", 124, 131], ["chimeric antigen receptor (CAR) T-cells", "CELL_TYPE", 256, 295], ["cancer-targeting receptors", "PROTEIN", 326, 352], ["these malignancies", "PROBLEM", 24, 42], ["immune surveillance", "TREATMENT", 49, 68], ["cancer", "PROBLEM", 140, 146], ["CancerAnother CRISPR", "TREATMENT", 147, 167], ["cancer", "PROBLEM", 203, 209], ["not yet", "UNCERTAINTY", 6, 13], ["malignancies", "OBSERVATION", 30, 42], ["cancer", "OBSERVATION", 203, 209], ["cancer", "OBSERVATION", 326, 332]]], ["CAR T-cell therapy targeting the CD19 antigen has been the most studied and successful due to its specific expression in various forms of leukemia.", [["T-cell", "ANATOMY", 4, 10], ["leukemia", "ANATOMY", 138, 146], ["leukemia", "DISEASE", 138, 146], ["CAR", "GENE_OR_GENE_PRODUCT", 0, 3], ["CD19 antigen", "GENE_OR_GENE_PRODUCT", 33, 45], ["leukemia", "CANCER", 138, 146], ["CD19 antigen", "PROTEIN", 33, 45], ["CAR T-cell therapy", "TREATMENT", 0, 18], ["the CD19 antigen", "TREATMENT", 29, 45], ["leukemia", "PROBLEM", 138, 146], ["leukemia", "OBSERVATION", 138, 146]]], ["Recently, investigators treated a patient with aggressive lung cancer with T-cells edited by CRISPR [75].", [["lung cancer", "ANATOMY", 58, 69], ["T-cells", "ANATOMY", 75, 82], ["aggressive lung cancer", "DISEASE", 47, 69], ["patient", "ORGANISM", 34, 41], ["lung cancer", "CANCER", 58, 69], ["T-cells", "CELL", 75, 82], ["T-cells", "CELL_TYPE", 75, 82], ["patient", "SPECIES", 34, 41], ["aggressive lung cancer", "PROBLEM", 47, 69], ["aggressive", "OBSERVATION_MODIFIER", 47, 57], ["lung", "ANATOMY", 58, 62], ["cancer", "OBSERVATION", 63, 69]]], ["Clinical trials the safety and efficacy of CAR T-cell immunotherapy for leukemia and lymphoma are ongoing and may soon expand to solid organ malignancies [74,76,77].Heart diseaseHeart disease comes in many forms [78,79].", [["T-cell", "ANATOMY", 47, 53], ["leukemia", "ANATOMY", 72, 80], ["lymphoma", "ANATOMY", 85, 93], ["solid organ malignancies", "ANATOMY", 129, 153], ["Heart", "ANATOMY", 165, 170], ["leukemia and lymphoma", "DISEASE", 72, 93], ["organ malignancies", "DISEASE", 135, 153], ["Heart diseaseHeart disease", "DISEASE", 165, 191], ["CAR T-cell", "CELL", 43, 53], ["leukemia", "CANCER", 72, 80], ["lymphoma", "CANCER", 85, 93], ["solid organ malignancies", "CANCER", 129, 153], ["Heart", "ORGAN", 165, 170], ["CAR T-cell immunotherapy", "TREATMENT", 43, 67], ["leukemia", "PROBLEM", 72, 80], ["lymphoma", "PROBLEM", 85, 93], ["solid organ malignancies", "PROBLEM", 129, 153], ["Heart diseaseHeart disease", "PROBLEM", 165, 191], ["lymphoma", "OBSERVATION", 85, 93], ["diseaseHeart", "OBSERVATION", 171, 183]]], ["So too, do the treatment options.", [["the treatment options", "TREATMENT", 11, 32]]], ["Recently, CRISPR has been presented as a potential method to remove monogenic cardiovascular disorders from the offspring and subsequent generations of affected families [80].", [["cardiovascular", "ANATOMY", 78, 92], ["monogenic cardiovascular disorders", "DISEASE", 68, 102], ["cardiovascular", "ANATOMICAL_SYSTEM", 78, 92], ["CRISPR", "DNA", 10, 16], ["monogenic cardiovascular disorders", "PROBLEM", 68, 102]]], ["Heritable cardiomyopathies, such as dilated cardiomyopathy, hypertrophic cardiomyopathy, and Duchenne muscular dystrophy, vasculopathies such as Marfan\u2019s syndrome, and infiltrative diseases such as amyloidosis, serve potential candidates for clinical applications of CRISPR-based germline genome editing techniques [81,82].", [["Duchenne muscular dystrophy", "ANATOMY", 93, 120], ["cardiomyopathies", "DISEASE", 10, 26], ["dilated cardiomyopathy", "DISEASE", 36, 58], ["hypertrophic cardiomyopathy", "DISEASE", 60, 87], ["Duchenne muscular dystrophy", "DISEASE", 93, 120], ["vasculopathies", "DISEASE", 122, 136], ["Marfan\u2019s syndrome", "DISEASE", 145, 162], ["amyloidosis", "DISEASE", 198, 209], ["CRISPR", "DNA", 267, 273], ["germline genome", "DNA", 280, 295], ["Heritable cardiomyopathies", "PROBLEM", 0, 26], ["dilated cardiomyopathy", "PROBLEM", 36, 58], ["hypertrophic cardiomyopathy", "PROBLEM", 60, 87], ["Duchenne muscular dystrophy", "PROBLEM", 93, 120], ["vasculopathies", "PROBLEM", 122, 136], ["Marfan\u2019s syndrome", "PROBLEM", 145, 162], ["infiltrative diseases", "PROBLEM", 168, 189], ["amyloidosis", "PROBLEM", 198, 209], ["clinical applications of CRISPR", "TREATMENT", 242, 273], ["cardiomyopathies", "OBSERVATION", 10, 26], ["dilated", "OBSERVATION_MODIFIER", 36, 43], ["cardiomyopathy", "OBSERVATION", 44, 58], ["hypertrophic", "OBSERVATION_MODIFIER", 60, 72], ["cardiomyopathy", "OBSERVATION", 73, 87], ["Duchenne muscular dystrophy", "OBSERVATION", 93, 120], ["infiltrative", "OBSERVATION_MODIFIER", 168, 180], ["amyloidosis", "OBSERVATION", 198, 209], ["germline genome", "OBSERVATION", 280, 295]]], ["Permanently editing the germline will affect unborn children who are unable to consent to such a procedure and its use is currently prohibited [83\u201385].", [["children", "ORGANISM", 52, 60], ["germline", "DNA", 24, 32], ["children", "SPECIES", 52, 60], ["a procedure", "TREATMENT", 95, 106]]], ["But that may soon change.Heart diseaseAs the technology advances, CRISPR-based treatments for heart disease may expand beyond heritable cardiomyopathies.", [["Heart", "ANATOMY", 25, 30], ["heart", "ANATOMY", 94, 99], ["Heart diseaseAs", "DISEASE", 25, 40], ["heart disease", "DISEASE", 94, 107], ["cardiomyopathies", "DISEASE", 136, 152], ["Heart", "ORGAN", 25, 30], ["heart", "ORGAN", 94, 99], ["Heart diseaseAs", "PROBLEM", 25, 40], ["CRISPR-based treatments", "TREATMENT", 66, 89], ["heart disease", "PROBLEM", 94, 107], ["heritable cardiomyopathies", "PROBLEM", 126, 152], ["diseaseAs", "OBSERVATION", 31, 40], ["heart", "ANATOMY", 94, 99], ["disease", "OBSERVATION", 100, 107], ["heritable", "OBSERVATION_MODIFIER", 126, 135], ["cardiomyopathies", "OBSERVATION", 136, 152]]], ["It is easy to foresee how gene-editing may be useful for polygenetic syndromes, including hypercholesterolemia, hypertension, and diabetes, among others [80,86,87].", [["hypercholesterolemia", "DISEASE", 90, 110], ["hypertension", "DISEASE", 112, 124], ["diabetes", "DISEASE", 130, 138], ["polygenetic syndromes", "PROBLEM", 57, 78], ["hypercholesterolemia", "PROBLEM", 90, 110], ["hypertension", "PROBLEM", 112, 124], ["diabetes", "PROBLEM", 130, 138], ["hypercholesterolemia", "OBSERVATION", 90, 110], ["hypertension", "OBSERVATION", 112, 124], ["diabetes", "OBSERVATION", 130, 138]]], ["For example, one group used CRISPR-Cas9 genome editing to target genes linked to insulin production, SPRY2, and the functional consequences of SPRY2 knockout and overexpression subsequently assessed using glucose uptake and lipid assays [88].", [["glucose", "CHEMICAL", 205, 212], ["glucose", "CHEMICAL", 205, 212], ["CRISPR-Cas9", "GENE_OR_GENE_PRODUCT", 28, 39], ["insulin", "GENE_OR_GENE_PRODUCT", 81, 88], ["SPRY2", "GENE_OR_GENE_PRODUCT", 101, 106], ["SPRY2", "GENE_OR_GENE_PRODUCT", 143, 148], ["glucose", "SIMPLE_CHEMICAL", 205, 212], ["CRISPR", "DNA", 28, 34], ["SPRY2", "PROTEIN", 101, 106], ["SPRY2", "PROTEIN", 143, 148], ["SPRY2", "TREATMENT", 101, 106], ["SPRY2 knockout", "TEST", 143, 157], ["glucose uptake", "TEST", 205, 219], ["lipid assays", "TEST", 224, 236]]], ["This work implicates a novel mechanism in the development of glucose intolerance and has profound implications for the treatment of diabetes, which is known to be an important risk factor for heart disease.", [["heart", "ANATOMY", 192, 197], ["glucose intolerance", "DISEASE", 61, 80], ["diabetes", "DISEASE", 132, 140], ["heart disease", "DISEASE", 192, 205], ["glucose", "CHEMICAL", 61, 68], ["glucose", "SIMPLE_CHEMICAL", 61, 68], ["heart", "ORGAN", 192, 197], ["glucose intolerance", "PROBLEM", 61, 80], ["diabetes", "PROBLEM", 132, 140], ["heart disease", "PROBLEM", 192, 205], ["glucose intolerance", "OBSERVATION", 61, 80], ["diabetes", "OBSERVATION", 132, 140], ["heart", "ANATOMY", 192, 197], ["disease", "OBSERVATION", 198, 205]]], ["Research in this area is ongoing [82].ConclusionsCRISPR-based platforms have been described as the greatest scientific discovery of the twentieth century.", [["ConclusionsCRISPR-based platforms", "TEST", 38, 71], ["greatest", "OBSERVATION_MODIFIER", 99, 107]]], ["It is incumbent upon clinicians to familiarize themselves with CRISPR to both understand how it may benefit patients and to help identify future areas of inquiry [89].", [["patients", "ORGANISM", 108, 116], ["CRISPR", "DNA", 63, 69], ["patients", "SPECIES", 108, 116]]], ["As technical and ethical questions regarding the use of CRISPR in humans continue to mount, hospitalists must take a more active role in the discussions to ensure that relevant stakeholders have a say in determining how this technology is implemented.", [["humans", "ORGANISM", 66, 72], ["CRISPR", "DNA", 56, 62], ["humans", "SPECIES", 66, 72], ["humans", "SPECIES", 66, 72], ["CRISPR in humans", "TREATMENT", 56, 72]]], ["CRISPR provides tremendous potential but also comes with serious pitfalls, and the next decade will be an important period to determine how best to harness this platform to advance the field of hospital medicine.Expert opinionCRISPR-based platforms have profoundly altered molecular biology and are poised to redefine the practice of medicine [48,90\u201392].", [["CRISPR", "DNA", 0, 6], ["hospital medicine", "TREATMENT", 194, 211]]], ["This paper reviews some of the most promising developments in diagnostics and therapeutics that have pertinence to hospitalists \u2013 specialists in inpatient medicine \u2013 who care for patients with a wide variety of maladies, ranging from infectious diseases to cancer to heart disease [93,94].", [["cancer", "ANATOMY", 257, 263], ["heart", "ANATOMY", 267, 272], ["infectious diseases", "DISEASE", 234, 253], ["cancer", "DISEASE", 257, 263], ["heart disease", "DISEASE", 267, 280], ["patients", "ORGANISM", 179, 187], ["cancer", "CANCER", 257, 263], ["heart", "ORGAN", 267, 272], ["patients", "SPECIES", 179, 187], ["infectious diseases", "PROBLEM", 234, 253], ["cancer to heart disease", "PROBLEM", 257, 280], ["heart", "ANATOMY", 267, 272]]], ["It is important for hospitalists to understand this emerging new technology both to ensure that it is used properly and to identify areas where it might be further deployed.Expert opinionThis has become especially relevant with the emergence of the novel coronavirus, SARS-CoV-2.", [["coronavirus", "DISEASE", 255, 266], ["SARS", "DISEASE", 268, 272], ["coronavirus", "ORGANISM", 255, 266], ["SARS-CoV-2", "ORGANISM", 268, 278], ["SARS-CoV", "SPECIES", 268, 276]]], ["In many medical centers, hospitalists have been the primary physicians responsible for the care of patients with this infection.", [["infection", "DISEASE", 118, 127], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["this infection", "PROBLEM", 113, 127], ["infection", "OBSERVATION", 118, 127]]], ["Diagnostic and therapeutic options have been limited, and hospitalists on the front lines have been forced to make treatment decisions with little or no data.", [["front lines", "ANATOMY", 78, 89], ["front lines", "CELL", 78, 89]]], ["This experience has reinforced the crucial role of the hospitalist in the care of patients with novel infections and it further strengthens the argument that hospitalists must be a part of the future research involving emerging pathogens.", [["infections", "DISEASE", 102, 112], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["novel infections", "PROBLEM", 96, 112], ["emerging pathogens", "PROBLEM", 219, 237], ["infections", "OBSERVATION", 102, 112]]], ["Frontline clinicians have a better understanding of the questions pertinent to patient care and can help formulate research projects that will address knowledge gaps.", [["patient", "ORGANISM", 79, 86], ["patient", "SPECIES", 79, 86]]], ["One area that has not yet been full explored is the role of CRISPR-Cas9 in the battle against SARS-CoV-2.", [["SARS", "DISEASE", 94, 98], ["CRISPR-Cas9", "GENE_OR_GENE_PRODUCT", 60, 71], ["SARS-CoV-2", "ORGANISM", 94, 104], ["CRISPR", "DNA", 60, 66], ["Cas9", "DNA", 67, 71], ["SARS-CoV", "SPECIES", 94, 102]]], ["Permanent nucleic acid modification may provide unique insights into a pandemic that has already infected more than two million people.Expert opinionBut this area of research comes with certain risks and important caveats [95].", [["nucleic acid", "CHEMICAL", 10, 22], ["people", "ORGANISM", 128, 134], ["people", "SPECIES", 128, 134], ["Permanent nucleic acid modification", "TREATMENT", 0, 35], ["a pandemic", "PROBLEM", 69, 79], ["nucleic acid", "OBSERVATION", 10, 22]]], ["CRISPR-based human genome editing comes in two forms: heritable germline editing, and non-heritable somatic modifications [36,89].", [["human", "ORGANISM", 13, 18], ["CRISPR", "DNA", 0, 6], ["germline", "DNA", 64, 72], ["human", "SPECIES", 13, 18], ["human", "SPECIES", 13, 18], ["heritable germline editing", "PROBLEM", 54, 80], ["genome editing", "OBSERVATION", 19, 33], ["germline editing", "OBSERVATION", 64, 80]]], ["The former results in genetic changes that are passed on to future generations and is currently prohibited to clinical researchers [21,96].", [["genetic changes", "PROBLEM", 22, 37]]], ["In 2019, the World Health Organization recommended against any clinical research on human germline editing until all technical and ethical considerations have been properly vetted and this policy is unlikely to change in the foreseeable future [97\u201399].Expert opinionIn fact, some expert now believe that the most relevant hospital applications of CRISPR-Cas9 involve no editing of human DNA.", [["human", "ORGANISM", 84, 89], ["CRISPR-Cas9", "GENE_OR_GENE_PRODUCT", 347, 358], ["human", "ORGANISM", 381, 386], ["DNA", "CELLULAR_COMPONENT", 387, 390], ["germline", "DNA", 90, 98], ["CRISPR", "DNA", 347, 353], ["Cas9", "DNA", 354, 358], ["human DNA", "DNA", 381, 390], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 381, 386], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 381, 386], ["human germline editing", "TREATMENT", 84, 106], ["CRISPR-Cas9", "TREATMENT", 347, 358], ["human DNA", "PROBLEM", 381, 390]]], ["Rather, they see the editing of the microbiota as a far more promising approach, as it would be non-heritable and non-somatic.", [["non-somatic", "PROBLEM", 114, 125]]], ["DNA manipulation may extend to a variety of human pathogens, and may include deletion of viral DNA and cancer DNA to hamper proliferation of malignant cells.", [["cancer", "ANATOMY", 103, 109], ["malignant cells", "ANATOMY", 141, 156], ["cancer", "DISEASE", 103, 109], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["human", "ORGANISM", 44, 49], ["DNA", "CELLULAR_COMPONENT", 95, 98], ["cancer", "ORGANISM_SUBSTANCE", 103, 109], ["DNA", "CELLULAR_COMPONENT", 110, 113], ["malignant cells", "CELL", 141, 156], ["viral DNA", "DNA", 89, 98], ["malignant cells", "CELL_TYPE", 141, 156], ["human", "SPECIES", 44, 49], ["human", "SPECIES", 44, 49], ["DNA manipulation", "TREATMENT", 0, 16], ["human pathogens", "PROBLEM", 44, 59], ["viral DNA", "PROBLEM", 89, 98], ["cancer DNA", "PROBLEM", 103, 113], ["malignant cells", "PROBLEM", 141, 156], ["pathogens", "OBSERVATION", 50, 59], ["viral DNA", "OBSERVATION", 89, 98], ["proliferation", "OBSERVATION_MODIFIER", 124, 137], ["malignant cells", "OBSERVATION", 141, 156]]], ["As mentioned above, CRISPR-based diagnosis may hasten detection of emerging viral pathogens, such as SARS-CoV-2.Expert opinionFor now, CRISPR-based clinical research will focus on the identification and alteration of infectious pathogens as well as novel treatment options for a variety of diseases ranging from infections to heart disease and cancer [45,100\u2013103].Expert opinionRecent research indicates that CRISPR has tremendous potential to improve the care of hematologic diseases, such as sickle cell disease and other heritable hemoglobinopathies, as well as autoimmune conditions, such as lupus [35,47,103\u2013105].", [["heart", "ANATOMY", 326, 331], ["cancer", "ANATOMY", 344, 350], ["hematologic", "ANATOMY", 464, 475], ["sickle cell", "ANATOMY", 494, 505], ["viral pathogens", "DISEASE", 76, 91], ["SARS", "DISEASE", 101, 105], ["infections", "DISEASE", 312, 322], ["heart disease", "DISEASE", 326, 339], ["cancer", "DISEASE", 344, 350], ["hematologic diseases", "DISEASE", 464, 484], ["sickle cell disease", "DISEASE", 494, 513], ["hemoglobinopathies", "DISEASE", 534, 552], ["autoimmune conditions", "DISEASE", 565, 586], ["lupus", "DISEASE", 596, 601], ["SARS-CoV-2", "ORGANISM", 101, 111], ["heart", "ORGAN", 326, 331], ["cancer", "CANCER", 344, 350], ["hematologic", "CANCER", 464, 475], ["sickle cell", "CELL", 494, 505], ["CRISPR", "DNA", 20, 26], ["CRISPR", "DNA", 409, 415], ["SARS-CoV", "SPECIES", 101, 109], ["emerging viral pathogens", "PROBLEM", 67, 91], ["the identification", "TEST", 180, 198], ["infectious pathogens", "PROBLEM", 217, 237], ["novel treatment options", "TREATMENT", 249, 272], ["diseases", "PROBLEM", 290, 298], ["infections", "PROBLEM", 312, 322], ["heart disease", "PROBLEM", 326, 339], ["cancer", "PROBLEM", 344, 350], ["hematologic diseases", "PROBLEM", 464, 484], ["sickle cell disease", "PROBLEM", 494, 513], ["other heritable hemoglobinopathies", "PROBLEM", 518, 552], ["autoimmune conditions", "PROBLEM", 565, 586], ["lupus", "PROBLEM", 596, 601], ["infectious", "OBSERVATION", 217, 227], ["heart", "ANATOMY", 326, 331], ["disease", "OBSERVATION", 332, 339], ["sickle cell disease", "OBSERVATION", 494, 513], ["heritable", "OBSERVATION_MODIFIER", 524, 533], ["hemoglobinopathies", "OBSERVATION", 534, 552], ["lupus", "OBSERVATION", 596, 601]]], ["CRISRP-based platforms have the potential to alter microbiota, which can be associated with adverse health events [106,107].", [["CRISRP", "PROTEIN", 0, 6], ["adverse health events", "PROBLEM", 92, 113]]], ["It will be crucial for hospitalists, who often care for these patients, to take a more involved role in this aspect of clinical research as CRISPR-based approaches will undoubtedly affect many of their patients in the years to come.", [["patients", "ORGANISM", 62, 70], ["patients", "ORGANISM", 202, 210], ["patients", "SPECIES", 62, 70], ["patients", "SPECIES", 202, 210]]]], "PMC7334121": [["IntroductionIt is understood that SARS-CoV-2 is a respiratory virus and it is mainly transmitted between people through \u201crespiratory droplets\u201d when symptomatic people sneeze or cough (Rothan and Biareddy 2020).", [["SARS", "DISEASE", 34, 38], ["respiratory virus", "DISEASE", 50, 67], ["sneeze", "DISEASE", 167, 173], ["cough", "DISEASE", 177, 182], ["SARS-CoV-2", "ORGANISM", 34, 44], ["people", "ORGANISM", 105, 111], ["people", "ORGANISM", 160, 166], ["people", "SPECIES", 105, 111], ["people", "SPECIES", 160, 166], ["SARS-CoV-2", "SPECIES", 34, 44], ["SARS", "PROBLEM", 34, 38], ["a respiratory virus", "PROBLEM", 48, 67], ["symptomatic people sneeze", "PROBLEM", 148, 173], ["cough", "PROBLEM", 177, 182], ["respiratory virus", "OBSERVATION", 50, 67]]], ["But like influenza, this virus appears to spread both through large droplets and droplets smaller than five micrometers (aerosols) that infected people might release, especially while coughing.", [["influenza", "DISEASE", 9, 18], ["people", "ORGANISM", 145, 151], ["people", "SPECIES", 145, 151], ["influenza", "PROBLEM", 9, 18], ["this virus", "PROBLEM", 20, 30], ["coughing", "PROBLEM", 184, 192], ["influenza", "OBSERVATION", 9, 18], ["large", "OBSERVATION_MODIFIER", 62, 67], ["droplets", "OBSERVATION", 68, 76], ["droplets", "OBSERVATION_MODIFIER", 81, 89], ["smaller", "OBSERVATION_MODIFIER", 90, 97]]], ["Through these aerosols, one\u2019s dress and shoes as well as the article one carries get contaminated during exposure in public places.", [["these aerosols", "TREATMENT", 8, 22], ["one\u2019s dress and shoes", "TREATMENT", 24, 45], ["aerosols", "OBSERVATION", 14, 22]]], ["If the virus is already on one\u2019s body or clothes, it is likely to pass on to other surfaces which come in contact.", [["body", "ANATOMY", 33, 37], ["body", "ORGANISM_SUBDIVISION", 33, 37], ["the virus", "PROBLEM", 3, 12], ["virus", "OBSERVATION", 7, 12]]], ["Other people might touch these surfaces accidentally.", [["people", "ORGANISM", 6, 12], ["people", "SPECIES", 6, 12]]], ["So, any form of eliminating such kind of transfers should be welcomed.IntroductionThere has been a section of health experts and epidemiologists who advocate herd immunity as a possible solution to coronavirus pandemic (Kwok et al. 2020).", [["coronavirus pandemic", "DISEASE", 198, 218], ["coronavirus", "ORGANISM", 198, 209]]], ["Vaccine, more when than if found, will bring the same effect on the population.", [["Vaccine", "TREATMENT", 0, 7]]], ["Since most patients of COVID-19 are either asymptomatic or have mild illness, health economy strategists have been of the view that herd immunity combined with targeted medical care of serious patients is the best way to deal with coronavirus pandemic.", [["coronavirus pandemic", "DISEASE", 231, 251], ["patients", "ORGANISM", 11, 19], ["patients", "ORGANISM", 193, 201], ["coronavirus", "ORGANISM", 231, 242], ["patients", "SPECIES", 11, 19], ["patients", "SPECIES", 193, 201], ["asymptomatic", "PROBLEM", 43, 55], ["mild illness", "PROBLEM", 64, 76], ["coronavirus pandemic", "PROBLEM", 231, 251], ["mild", "OBSERVATION_MODIFIER", 64, 68], ["illness", "OBSERVATION", 69, 76]]], ["Preparing for herd immunity involves the controlled exposure of the population to the disease, with control over the extent of exposure to the viral load.", [["herd immunity", "TREATMENT", 14, 27], ["the disease", "PROBLEM", 82, 93], ["the viral load", "PROBLEM", 139, 153], ["viral load", "OBSERVATION", 143, 153]]], ["This calls for all efforts towards bringing down the level of bioburden one gets exposed to so that the exposure becomes subclinical.IntroductionIt was in this background, along with many other proposals to address the COVID-19 management by providing solutions which are easily replicated across the country using locally available resources, a disinfection gateway for reducing the viral load from people entering public places was proposed and developed.MethodologyChitra Disinfection Gateway is built as a walkthrough which can be installed in public places and passages.", [["people", "ORGANISM", 400, 406], ["people", "SPECIES", 400, 406], ["the COVID-19 management", "TREATMENT", 215, 238], ["a disinfection gateway", "TREATMENT", 344, 366], ["the viral load", "PROBLEM", 380, 394], ["MethodologyChitra Disinfection", "TREATMENT", 457, 487], ["viral load", "OBSERVATION", 384, 394]]], ["The structure is 4 m \u00d7 1.5 m \u00d7 2 m in dimension (Fig. 1).", [["structure", "OBSERVATION_MODIFIER", 4, 13], ["4 m", "OBSERVATION_MODIFIER", 17, 20]]], ["There are two tanks which are fitted on either side of the chamber which contain the hydrogen peroxide mix for the disinfection process.", [["hydrogen peroxide", "CHEMICAL", 85, 102], ["hydrogen peroxide", "CHEMICAL", 85, 102], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 85, 102], ["the hydrogen peroxide mix", "TREATMENT", 81, 106], ["the disinfection process", "PROBLEM", 111, 135], ["two", "OBSERVATION_MODIFIER", 10, 13], ["tanks", "OBSERVATION", 14, 19], ["chamber", "ANATOMY_MODIFIER", 59, 66], ["disinfection", "OBSERVATION", 115, 127]]], ["There are two outlets inside the chamber through which atomized hydrogen peroxide is being blown in from the side tanks.", [["hydrogen peroxide", "CHEMICAL", 64, 81], ["hydrogen peroxide", "CHEMICAL", 64, 81], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 64, 81], ["hydrogen peroxide", "TREATMENT", 64, 81], ["two", "OBSERVATION_MODIFIER", 10, 13], ["outlets", "OBSERVATION_MODIFIER", 14, 21], ["chamber", "ANATOMY_MODIFIER", 33, 40], ["hydrogen peroxide", "OBSERVATION", 64, 81], ["blown", "OBSERVATION_MODIFIER", 91, 96]]], ["The atomization process is done using ultrasonic vibrators which convert the liquid in the tanks to very fine atomized mist with a droplet size of 2\u201310 microm diameter and this mist is being blown inside the chamber using blower fans.", [["The atomization process", "TREATMENT", 0, 23], ["ultrasonic vibrators", "TREATMENT", 38, 58], ["the liquid in the tanks", "TREATMENT", 73, 96], ["a droplet size of 2\u201310 microm diameter", "TREATMENT", 129, 167], ["size", "OBSERVATION_MODIFIER", 139, 143]]], ["Along with the mist generator, a set of UV lamps are used for disinfection of the system.", [["the mist generator", "TREATMENT", 11, 29], ["UV lamps", "TREATMENT", 40, 48], ["disinfection of the system", "TREATMENT", 62, 88], ["UV lamps", "OBSERVATION", 40, 48], ["system", "ANATOMY", 82, 88]]], ["UV type C sources are well proven for microbial disinfection.", [["UV type C sources", "PROBLEM", 0, 17], ["microbial disinfection", "PROBLEM", 38, 60]]], ["The UV lamp is meant for bioburden reduction inside the chamber after each passage of a person.MethodologyFigure 2 shows the system level and component level breakup of the disinfection gateway.MethodologyThe control console provided has sensors for detecting the entry and exit of a person and a microcontroller which coordinates the timing sequences and the mist generation process.", [["person", "SPECIES", 88, 94], ["person", "SPECIES", 284, 290], ["The UV lamp", "TREATMENT", 0, 11], ["bioburden reduction", "TREATMENT", 25, 44], ["MethodologyThe control console", "TREATMENT", 194, 224], ["a microcontroller", "TREATMENT", 295, 312], ["UV lamp", "OBSERVATION", 4, 11], ["chamber", "OBSERVATION_MODIFIER", 56, 63], ["component", "OBSERVATION_MODIFIER", 142, 151], ["level", "OBSERVATION_MODIFIER", 152, 157], ["breakup", "OBSERVATION_MODIFIER", 158, 165]]], ["There are indicators placed at the entry, one red and one green, which tell the person in the queue whether he can enter or not.", [["person", "SPECIES", 80, 86]]], ["Once the green light in the front of the gateway is ON a person can enter and he needs to be inside the chamber till the green light inside the chamber is ON.", [["person", "SPECIES", 57, 63], ["chamber", "OBSERVATION", 144, 151]]], ["After the exit, which is sensed by the exit sensor, the UV lamp is switched ON for a predefined time.MethodologyThe UV ray is used only for disinfecting the gateway, when there are no people inside the gateway and hence does not pose any health or safety hazard.", [["people", "ORGANISM", 184, 190], ["people", "SPECIES", 184, 190], ["the UV lamp", "TREATMENT", 52, 63]]], ["Occupational Health and Safety Officials (OSHA) had provided guidance for ultraviolet radiation exposure (Institute and for Occupational Safety and Health 1972).", [["ultraviolet radiation exposure", "TREATMENT", 74, 104]]], ["Overexposure to UVC may lead to photo-conjunctivitis and skin irritation.", [["skin", "ANATOMY", 57, 61], ["UVC", "CHEMICAL", 16, 19], ["conjunctivitis", "DISEASE", 38, 52], ["skin irritation", "DISEASE", 57, 72], ["skin", "ORGAN", 57, 61], ["UVC", "TREATMENT", 16, 19], ["photo", "TREATMENT", 32, 37], ["conjunctivitis", "PROBLEM", 38, 52], ["skin irritation", "PROBLEM", 57, 72], ["UVC", "OBSERVATION", 16, 19], ["may lead to", "UNCERTAINTY", 20, 31], ["conjunctivitis", "OBSERVATION", 38, 52], ["skin", "ANATOMY", 57, 61], ["irritation", "OBSERVATION", 62, 72]]], ["So, eye and skin exposure time limits the practical usage of ultraviolet germicidal irradiation during human occupancy of design spaces.", [["eye", "ANATOMY", 4, 7], ["skin", "ANATOMY", 12, 16], ["ultraviolet germicidal", "CHEMICAL", 61, 83], ["eye", "ORGAN", 4, 7], ["skin", "ORGAN", 12, 16], ["human", "ORGANISM", 103, 108], ["human", "SPECIES", 103, 108], ["human", "SPECIES", 103, 108], ["ultraviolet germicidal irradiation", "TREATMENT", 61, 95], ["eye", "ANATOMY", 4, 7], ["skin", "ANATOMY", 12, 16], ["germicidal irradiation", "OBSERVATION", 73, 95]]], ["The threshold limit value (TLV) recommended by the American Conference of Governmental Industrial Hygienists (ACGIH) for 253.7 nm UVC is 6 mJ/cm2 for any 8-h period.MethodologyThe risk mitigation strategies adopted during the UVC disinfection during gateway design were.The TLV values must be less than 6mJ/cm2 for an 8-h period.", [["UVC", "CHEMICAL", 226, 229], ["nm UVC", "TREATMENT", 127, 133], ["The risk mitigation strategies", "TREATMENT", 176, 206], ["the UVC disinfection", "TREATMENT", 222, 242], ["The TLV values", "TEST", 270, 284], ["UVC disinfection", "OBSERVATION", 226, 242], ["TLV", "OBSERVATION", 274, 277]]], ["First, the system was designed in such a way that there is no direct exposure of human beings to UVC.", [["UVC", "CHEMICAL", 97, 100], ["human", "ORGANISM", 81, 86], ["human", "SPECIES", 81, 86], ["human", "SPECIES", 81, 86], ["UVC", "TREATMENT", 97, 100], ["no", "UNCERTAINTY", 59, 61], ["UVC", "OBSERVATION", 97, 100]]], ["The UVC light is switched ON only if the IR/ultrasonic sensors detect that there is no human being inside.", [["UVC", "CHEMICAL", 4, 7], ["human", "ORGANISM", 87, 92], ["human", "SPECIES", 87, 92], ["human", "SPECIES", 87, 92], ["The UVC light", "TREATMENT", 0, 13], ["the IR/ultrasonic sensors", "TEST", 37, 62], ["UVC light", "OBSERVATION", 4, 13]]], ["Second, the time of operation of UVC light is 10 seconds or lesser.", [["UVC", "CHEMICAL", 33, 36], ["operation of UVC light", "TREATMENT", 20, 42], ["UVC", "ANATOMY", 33, 36], ["lesser", "OBSERVATION_MODIFIER", 60, 66]]], ["Hence, a sufficient safety margin is provided.It should be noted that UVC germicidal process is effective at the line of sight.", [["UVC", "CHEMICAL", 70, 73], ["UVC germicidal process", "TREATMENT", 70, 92], ["UVC", "OBSERVATION", 70, 73], ["germicidal process", "OBSERVATION", 74, 92]]], ["Sufficient shielding has been provided by the walls of the gateway to ensure that there is no UVC leakage in the line of sight.A warning message has been provided on the device, as a part of the risk management plan and instructions for use: Exposure to germicidal UVC can cause injury to the eyes and skin.Efficacy of Hydrogen Peroxide as a DisinfectantChitra Disinfection Gateway employs 0.5% hydrogen peroxide solution to generate mist using an ultrasonic atomizer.", [["eyes", "ANATOMY", 293, 297], ["skin", "ANATOMY", 302, 306], ["UVC", "CHEMICAL", 94, 97], ["UVC", "CHEMICAL", 265, 268], ["injury to the eyes and skin", "DISEASE", 279, 306], ["Hydrogen Peroxide", "CHEMICAL", 319, 336], ["hydrogen peroxide", "CHEMICAL", 395, 412], ["Hydrogen Peroxide", "CHEMICAL", 319, 336], ["hydrogen peroxide", "CHEMICAL", 395, 412], ["eyes", "ORGAN", 293, 297], ["skin", "ORGAN", 302, 306], ["Hydrogen Peroxide", "SIMPLE_CHEMICAL", 319, 336], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 395, 412], ["UVC leakage", "PROBLEM", 94, 105], ["the device", "TREATMENT", 166, 176], ["germicidal UVC", "TREATMENT", 254, 268], ["injury to the eyes and skin", "PROBLEM", 279, 306], ["Hydrogen Peroxide", "TREATMENT", 319, 336], ["a DisinfectantChitra Disinfection", "TREATMENT", 340, 373], ["0.5% hydrogen peroxide solution", "TREATMENT", 390, 421], ["an ultrasonic atomizer", "TREATMENT", 445, 467], ["shielding", "OBSERVATION", 11, 20], ["no", "UNCERTAINTY", 91, 93], ["UVC leakage", "OBSERVATION", 94, 105], ["injury", "OBSERVATION", 279, 285], ["eyes", "ANATOMY", 293, 297], ["skin", "ANATOMY", 302, 306]]], ["As per the Centre for Disease Control (CDC), USA guidelines (Centers for disease control and prevention 2002), this concentration of hydrogen peroxide has demonstrated bactericidal and virucidal activity in 1 min and mycobactericidal and fungicidal activities in 5 min.", [["hydrogen peroxide", "CHEMICAL", 133, 150], ["hydrogen peroxide", "CHEMICAL", 133, 150], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 133, 150], ["disease control", "TREATMENT", 73, 88], ["this concentration of hydrogen peroxide", "TREATMENT", 111, 150], ["bactericidal", "PROBLEM", 168, 180], ["virucidal activity", "TREATMENT", 185, 203], ["mycobactericidal", "TREATMENT", 217, 233], ["bactericidal", "OBSERVATION_MODIFIER", 168, 180], ["virucidal activity", "OBSERVATION", 185, 203], ["fungicidal activities", "OBSERVATION", 238, 259]]], ["Viruses are more fragile and unstable than bacteria and are easier to destroy.", [["Viruses", "PROBLEM", 0, 7], ["bacteria", "PROBLEM", 43, 51], ["more", "OBSERVATION_MODIFIER", 12, 16], ["fragile", "OBSERVATION_MODIFIER", 17, 24], ["unstable", "OBSERVATION_MODIFIER", 29, 37]]], ["The hydrogen peroxide mist from the Chitra Disinfection Gateway gets deposited on the clothing when one person walks through it.", [["hydrogen peroxide", "CHEMICAL", 4, 21], ["hydrogen peroxide", "CHEMICAL", 4, 21], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 4, 21], ["person", "SPECIES", 104, 110], ["The hydrogen peroxide mist", "TREATMENT", 0, 26], ["the Chitra Disinfection", "TREATMENT", 32, 55], ["hydrogen peroxide", "OBSERVATION", 4, 21]]], ["The droplet size of atomized hydrogen peroxide is in the range of 2\u201310 microns.", [["hydrogen peroxide", "CHEMICAL", 29, 46], ["hydrogen peroxide", "CHEMICAL", 29, 46], ["atomized hydrogen peroxide", "SIMPLE_CHEMICAL", 20, 46], ["atomized hydrogen peroxide", "TREATMENT", 20, 46], ["droplet", "OBSERVATION_MODIFIER", 4, 11], ["size", "OBSERVATION_MODIFIER", 12, 16], ["hydrogen peroxide", "OBSERVATION", 29, 46]]], ["In this size, the droplets from the mist will deposit over the person\u2019s clothes and body in the process of walking through the gateway, and subsequently, the disinfection happens.", [["body", "ANATOMY", 84, 88], ["body", "ORGANISM_SUBDIVISION", 84, 88], ["person", "SPECIES", 63, 69], ["size", "OBSERVATION_MODIFIER", 8, 12], ["droplets", "OBSERVATION_MODIFIER", 18, 26]]], ["Since the droplet size is too small, the person will not have the feeling of being drenched.", [["person", "SPECIES", 41, 47], ["droplet", "OBSERVATION_MODIFIER", 10, 17], ["size", "OBSERVATION_MODIFIER", 18, 22], ["too small", "OBSERVATION_MODIFIER", 26, 35]]], ["Within the next few minutes, this mist reduces the virus load from the surface of the clothing, even after he has moved out of the gateway.Efficacy of Hydrogen Peroxide as a DisinfectantThere is ample scientific evidence to the fact that this type of disinfection process provides 3\u20134 log reduction (reduction by 1000\u201310,000-fold) of the viruses (Pottage et al. 2010; Tuladhar et al. 2012).Safety Considerations of Hydrogen PeroxideHydrogen peroxide (at 3% concentration) is a mild disinfectant used on the skin to prevent infection of minor cuts, scrapes, and burns.", [["surface", "ANATOMY", 71, 78], ["skin", "ANATOMY", 507, 511], ["scrapes", "ANATOMY", 548, 555], ["Hydrogen Peroxide", "CHEMICAL", 151, 168], ["Hydrogen PeroxideHydrogen peroxide", "CHEMICAL", 415, 449], ["infection", "DISEASE", 523, 532], ["burns", "DISEASE", 561, 566], ["Hydrogen Peroxide", "CHEMICAL", 151, 168], ["Hydrogen PeroxideHydrogen peroxide", "CHEMICAL", 415, 449], ["Hydrogen Peroxide", "SIMPLE_CHEMICAL", 151, 168], ["Hydrogen PeroxideHydrogen peroxide", "SIMPLE_CHEMICAL", 415, 449], ["skin", "ORGAN", 507, 511], ["the virus load", "PROBLEM", 47, 61], ["Hydrogen Peroxide", "TREATMENT", 151, 168], ["disinfection process", "TREATMENT", 251, 271], ["log reduction (reduction", "TREATMENT", 285, 309], ["Hydrogen PeroxideHydrogen peroxide", "TREATMENT", 415, 449], ["a mild disinfectant", "TREATMENT", 475, 494], ["infection of minor cuts", "PROBLEM", 523, 546], ["scrapes", "PROBLEM", 548, 555], ["burns", "PROBLEM", 561, 566], ["virus", "OBSERVATION", 51, 56], ["surface", "OBSERVATION_MODIFIER", 71, 78], ["clothing", "OBSERVATION", 86, 94], ["Hydrogen Peroxide", "OBSERVATION", 151, 168], ["mild", "OBSERVATION_MODIFIER", 477, 481], ["disinfectant", "OBSERVATION", 482, 494], ["skin", "ANATOMY", 507, 511], ["infection", "OBSERVATION", 523, 532], ["burns", "OBSERVATION", 561, 566]]], ["It may also be used as a mouth rinse to help remove mucus or to relieve minor mouth irritation (e.g., due to canker/cold sores, gingivitis).", [["mouth", "ANATOMY", 25, 30], ["mucus", "ANATOMY", 52, 57], ["mouth", "ANATOMY", 78, 83], ["canker", "ANATOMY", 109, 115], ["mouth irritation", "DISEASE", 78, 94], ["canker/cold sores", "DISEASE", 109, 126], ["gingivitis", "DISEASE", 128, 138], ["mucus", "ORGANISM_SUBSTANCE", 52, 57], ["mouth", "ORGANISM_SUBDIVISION", 78, 83], ["canker", "ORGANISM_SUBDIVISION", 109, 115], ["a mouth rinse", "TREATMENT", 23, 36], ["mucus", "PROBLEM", 52, 57], ["minor mouth irritation", "PROBLEM", 72, 94], ["canker/cold sores", "PROBLEM", 109, 126], ["gingivitis", "PROBLEM", 128, 138], ["mouth", "ANATOMY", 78, 83], ["irritation", "OBSERVATION", 84, 94]]], ["Hydrogen peroxide breaks down into water and oxygen, and does not have any environmental issues.Safety Considerations of Hydrogen PeroxideAs per the guidelines of the Occupational Safety and Health Administration (OSHA 1992), USA, the safe Time Weighted Average (TWA) concentration of hydrogen peroxide in air is 1.4 mg/m3 of air (which corresponds to 1 ppm) for an 8-h shift duration (The National Institute for Occupational Safety and Health 1994).", [["Hydrogen peroxide", "CHEMICAL", 0, 17], ["oxygen", "CHEMICAL", 45, 51], ["Hydrogen PeroxideAs", "CHEMICAL", 121, 140], ["hydrogen peroxide", "CHEMICAL", 285, 302], ["Hydrogen peroxide", "CHEMICAL", 0, 17], ["oxygen", "CHEMICAL", 45, 51], ["Hydrogen", "CHEMICAL", 121, 129], ["hydrogen peroxide", "CHEMICAL", 285, 302], ["Hydrogen peroxide", "SIMPLE_CHEMICAL", 0, 17], ["water", "SIMPLE_CHEMICAL", 35, 40], ["oxygen", "SIMPLE_CHEMICAL", 45, 51], ["Hydrogen PeroxideAs", "SIMPLE_CHEMICAL", 121, 140], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 285, 302], ["Hydrogen peroxide breaks", "TREATMENT", 0, 24], ["oxygen", "TREATMENT", 45, 51], ["Hydrogen PeroxideAs", "TREATMENT", 121, 140], ["hydrogen peroxide in air", "TREATMENT", 285, 309], ["peroxide breaks", "OBSERVATION", 9, 24]]], ["In the case of Chitra Disinfection Gateway, the exposure duration is between 5 and 10 s and the concentration of hydrogen peroxide in the zone is 1.5 ppm (2.1 mg/m3).Safety Considerations of Hydrogen PeroxideAs per the pocket guide on chemical hazards for hydrogen peroxide published by National Institute for Occupational Safety and Health (NIOSH), the safe inhalation limit is 75 ppm and the Chitra Disinfection Gateway has 1.5 ppm design limits, providing a very good safety margin (The National Institute for Occupational Safety and Health 1973).Hydrogen Peroxide vs. Other DisinfectantsDisinfectants are created with one purpose: to kill microbes and pathogens.", [["hydrogen peroxide", "CHEMICAL", 113, 130], ["Hydrogen PeroxideAs", "CHEMICAL", 191, 210], ["hydrogen peroxide", "CHEMICAL", 256, 273], ["Hydrogen Peroxide", "CHEMICAL", 550, 567], ["hydrogen peroxide", "CHEMICAL", 113, 130], ["Hydrogen", "CHEMICAL", 191, 199], ["hydrogen peroxide", "CHEMICAL", 256, 273], ["Hydrogen Peroxide", "CHEMICAL", 550, 567], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 113, 130], ["Hydrogen PeroxideAs", "SIMPLE_CHEMICAL", 191, 210], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 256, 273], ["Hydrogen Peroxide", "SIMPLE_CHEMICAL", 550, 567], ["Chitra Disinfection", "TREATMENT", 15, 34], ["the exposure duration", "TEST", 44, 65], ["the concentration of hydrogen peroxide", "TREATMENT", 92, 130], ["Hydrogen PeroxideAs", "TREATMENT", 191, 210], ["hydrogen peroxide", "TREATMENT", 256, 273], ["the safe inhalation limit", "TREATMENT", 350, 375], ["the Chitra Disinfection", "TREATMENT", 390, 413], ["Hydrogen Peroxide", "TREATMENT", 550, 567], ["Other DisinfectantsDisinfectants", "TREATMENT", 572, 604], ["pathogens", "PROBLEM", 656, 665], ["zone", "ANATOMY_MODIFIER", 138, 142], ["Hydrogen PeroxideAs", "OBSERVATION", 191, 210]]], ["In other words, by definition, disinfectants are destructive to cells, which means none are completely harmless.", [["cells", "ANATOMY", 64, 69], ["cells", "CELL", 64, 69], ["destructive to cells", "PROBLEM", 49, 69], ["destructive", "OBSERVATION_MODIFIER", 49, 60]]], ["However, some active ingredients are safer for human health and the environment than others.", [["human", "ORGANISM", 47, 52], ["human", "SPECIES", 47, 52], ["human", "SPECIES", 47, 52], ["some", "OBSERVATION_MODIFIER", 9, 13], ["active", "OBSERVATION_MODIFIER", 14, 20], ["ingredients", "OBSERVATION", 21, 32]]], ["The most widely used active ingredients in disinfectants include sodium hypochlorite (bleaching powder), quaternary ammonium compounds (QAC) and hydrogen peroxide.", [["sodium hypochlorite", "CHEMICAL", 65, 84], ["quaternary ammonium", "CHEMICAL", 105, 124], ["QAC", "CHEMICAL", 136, 139], ["hydrogen peroxide", "CHEMICAL", 145, 162], ["sodium hypochlorite", "CHEMICAL", 65, 84], ["quaternary ammonium", "CHEMICAL", 105, 124], ["hydrogen peroxide", "CHEMICAL", 145, 162], ["sodium hypochlorite", "SIMPLE_CHEMICAL", 65, 84], ["quaternary ammonium compounds", "SIMPLE_CHEMICAL", 105, 134], ["QAC", "SIMPLE_CHEMICAL", 136, 139], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 145, 162], ["disinfectants", "TREATMENT", 43, 56], ["sodium hypochlorite (bleaching powder", "TREATMENT", 65, 102], ["quaternary ammonium compounds", "TREATMENT", 105, 134], ["hydrogen peroxide", "TREATMENT", 145, 162], ["most widely", "OBSERVATION_MODIFIER", 4, 15], ["active", "OBSERVATION_MODIFIER", 21, 27], ["ingredients", "OBSERVATION", 28, 39]]], ["A comparison of the basic safety and efficacy of these basic ingredients is provided in (Table 1) (Neighbour and Newberry 1994).Experimental ValidationThough the safety and efficacy of hydrogen peroxide are well established, the Institute chose to confirm the suitability of the materials through a series of safety and efficacy studies.", [["hydrogen peroxide", "CHEMICAL", 185, 202], ["hydrogen peroxide", "CHEMICAL", 185, 202], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 185, 202], ["Experimental Validation", "TREATMENT", 128, 151], ["hydrogen peroxide", "TREATMENT", 185, 202], ["efficacy studies", "TEST", 320, 336]]], ["These studies were carried out in laboratories practicing quality management systems conforming to ISO/IEC 17,025:2017-General requirements for the competence of testing and calibration laboratories and accredited by the Le Comit\u00e9 Fran\u00e7ais d\u2019Accr\u00e9ditation (COFRAC), the national accreditation agency of France.", [["ISO", "CHEMICAL", 99, 102], ["These studies", "TEST", 0, 13], ["ISO/IEC", "TEST", 99, 106], ["testing", "TEST", 162, 169], ["calibration laboratories", "TEST", 174, 198]]], ["The following studies were planned as part of the experimental validation.Antimicrobial activity of 0.5% hydrogen peroxide solutionReduction in bioburden levels on clothing of person walking through the gatewayReduction in bioburden levels on the hands of person walking through the gatewayISO 10,993\u201310: Biological evaluation of medical devices\u2014Part 10: tests for irritation and skin sensitizationAntimicrobial Activity of Hydrogen PeroxideThe bactericidal property of 0.5\u20133% concentrations of hydrogen peroxide was tested for different exposure time periods.", [["skin", "ANATOMY", 380, 384], ["hydrogen peroxide", "CHEMICAL", 105, 122], ["Hydrogen Peroxide", "CHEMICAL", 424, 441], ["hydrogen peroxide", "CHEMICAL", 495, 512], ["hydrogen peroxide", "CHEMICAL", 105, 122], ["Hydrogen Peroxide", "CHEMICAL", 424, 441], ["hydrogen peroxide", "CHEMICAL", 495, 512], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 105, 122], ["skin", "ORGAN", 380, 384], ["Hydrogen Peroxide", "SIMPLE_CHEMICAL", 424, 441], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 495, 512], ["person", "SPECIES", 176, 182], ["person", "SPECIES", 256, 262], ["The following studies", "TEST", 0, 21], ["the experimental validation", "TEST", 46, 73], ["Antimicrobial activity", "TREATMENT", 74, 96], ["0.5% hydrogen peroxide solutionReduction", "TREATMENT", 100, 140], ["Biological evaluation", "TEST", 305, 326], ["medical devices", "TREATMENT", 330, 345], ["tests", "TEST", 355, 360], ["irritation", "PROBLEM", 365, 375], ["skin sensitizationAntimicrobial", "TREATMENT", 380, 411], ["Hydrogen Peroxide", "TREATMENT", 424, 441], ["The bactericidal property", "TREATMENT", 441, 466], ["hydrogen peroxide", "TREATMENT", 495, 512], ["skin", "ANATOMY", 380, 384]]], ["H2O2 even at 0.5% concentration and exposure of five minutes was found to be bactericidal for Gram-positive S. aureus ATCC 25923, S. aures ATCC 700698 (MRSA), Gram-negative E. coli ATCC25922 and Pseudomonas aeruginosa ATCC 9027.Reduction in Bioburden Levels on Clothing of Person Walking Through the Gateway100 sq.cm of sterilized shirting material was used in triplicate for the study.", [["ATCC 25923", "ANATOMY", 118, 128], ["H2O2", "CHEMICAL", 0, 4], ["S. aures ATCC 700698", "CHEMICAL", 130, 150], ["MRSA", "CHEMICAL", 152, 156], ["H2O2", "CHEMICAL", 0, 4], ["H2O2", "SIMPLE_CHEMICAL", 0, 4], ["S. aureus ATCC 25923", "ORGANISM", 108, 128], ["S. aures ATCC 700698", "ORGANISM", 130, 150], ["E. coli", "ORGANISM", 173, 180], ["ATCC25922", "ORGANISM", 181, 190], ["Pseudomonas aeruginosa ATCC 9027", "CELL", 195, 227], ["S. aureus", "SPECIES", 108, 117], ["S. aures", "SPECIES", 130, 138], ["MRSA", "SPECIES", 152, 156], ["E. coli", "SPECIES", 173, 180], ["Pseudomonas aeruginosa", "SPECIES", 195, 217], ["S. aureus ATCC 25923", "SPECIES", 108, 128], ["S. aures ATCC 700698", "SPECIES", 130, 150], ["MRSA", "SPECIES", 152, 156], ["E. coli", "SPECIES", 173, 180], ["Pseudomonas aeruginosa ATCC 9027", "SPECIES", 195, 227], ["H2O2", "TREATMENT", 0, 4], ["bactericidal", "TEST", 77, 89], ["Gram-positive S. aureus ATCC", "PROBLEM", 94, 122], ["S. aures ATCC", "TEST", 130, 143], ["MRSA", "PROBLEM", 152, 156], ["Gram-negative E. coli", "TEST", 159, 180], ["Pseudomonas aeruginosa ATCC", "PROBLEM", 195, 222], ["Bioburden Levels", "TEST", 241, 257], ["sterilized shirting material", "TREATMENT", 320, 348], ["the study", "TEST", 376, 385], ["Bioburden", "OBSERVATION_MODIFIER", 241, 250], ["Levels", "OBSERVATION_MODIFIER", 251, 257]]], ["The samples were loaded with 106 cfu/cm2 of Bacillus subtilis ATCC 6633.", [["samples", "ANATOMY", 4, 11], ["Bacillus subtilis ATCC 6633", "ORGANISM", 44, 71], ["Bacillus subtilis ATCC", "SPECIES", 44, 66], ["Bacillus subtilis ATCC 6633", "SPECIES", 44, 71], ["The samples", "TEST", 0, 11], ["Bacillus subtilis ATCC", "TREATMENT", 44, 66]]], ["Before and after the exposure of the test material to the Chitra Disinfectant Gateway, the bacterial load was assessed.", [["the test material", "TEST", 33, 50], ["the bacterial load", "TEST", 87, 105], ["bacterial load", "OBSERVATION", 91, 105]]], ["Before the exposure, the bacterial load recovered was on average 7.3 \u00d7 105 cfu/cm2.", [["the bacterial load", "TEST", 21, 39], ["bacterial load", "OBSERVATION", 25, 39]]], ["After exposure to the disinfectant gateway, no bacteria were recovered from the test samples.Reduction in Bioburden Levels on the Arm of Person Walking Through the GatewayThe microbial load on an individual was assayed before entering the Chitra Disinfection Gateway and after walking through the gateway.", [["samples", "ANATOMY", 85, 92], ["bacteria", "PROBLEM", 47, 55], ["the test samples", "TEST", 76, 92], ["Bioburden Levels", "TEST", 106, 122], ["Bioburden", "OBSERVATION", 106, 115], ["Levels", "OBSERVATION_MODIFIER", 116, 122]]], ["One forearm of the personnel was swabbed using swab soaked in physiological saline before entering the gateway, and after entering the gateway, the other arm was swabbed.Reduction in Bioburden Levels on the Arm of Person Walking Through the GatewayThe microbial load on the forearm was 16 cfu/cm2 before entering the Chitra Disinfectant Gateway.", [["forearm", "ANATOMY", 4, 11], ["swab", "ANATOMY", 47, 51], ["forearm", "ANATOMY", 274, 281], ["forearm", "ORGANISM_SUBDIVISION", 4, 11], ["forearm", "ORGANISM_SUBDIVISION", 274, 281], ["swab", "TREATMENT", 47, 51], ["physiological saline", "TREATMENT", 62, 82], ["Bioburden Levels", "TEST", 183, 199], ["forearm", "ANATOMY", 4, 11], ["arm", "ANATOMY", 154, 157], ["swabbed", "OBSERVATION", 162, 169], ["Bioburden", "OBSERVATION", 183, 192], ["Levels", "OBSERVATION_MODIFIER", 193, 199], ["forearm", "ANATOMY", 274, 281]]], ["After passing through the gateway, the bioburden load was reduced to 0.75 cfu/cm2.ISO 10993-10: Tests for Irritation and Skin SensitizationThe study was designed to evaluate the animal irritation response of 0.5% hydrogen peroxide solution intended to be used as a disinfectant in Chitra Disinfectant Gateway.", [["Skin", "ANATOMY", 121, 125], ["ISO 10993-10", "CHEMICAL", 82, 94], ["hydrogen peroxide", "CHEMICAL", 213, 230], ["ISO 10993-10", "CHEMICAL", 82, 94], ["hydrogen peroxide", "CHEMICAL", 213, 230], ["Skin", "ORGAN", 121, 125], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 213, 230], ["the bioburden load", "TEST", 35, 53], ["ISO", "TEST", 82, 85], ["Tests", "TEST", 96, 101], ["Irritation", "PROBLEM", 106, 116], ["Skin Sensitization", "TEST", 121, 139], ["The study", "TEST", 139, 148], ["the animal irritation response", "PROBLEM", 174, 204], ["0.5% hydrogen peroxide solution", "TREATMENT", 208, 239], ["Skin", "ANATOMY", 121, 125]]], ["The study was conducted to meet the requirements of ISO 10993-10:2010: Biological evaluation of medical devices\u2014Part 10: test for irritation and skin sensitization (Pottage et al. 2010b; Medina-Cordoba et al. 2018)ISO 10993-10: Tests for Irritation and Skin SensitizationThe test sample (0.5% hydrogen peroxide) and control (physiological saline) were soaked in absorbent gauze piece and applied topically on the clipped skin of the New Zealand white rabbits.", [["skin", "ANATOMY", 145, 149], ["Skin", "ANATOMY", 253, 257], ["skin", "ANATOMY", 421, 425], ["ISO 10993-10:2010", "CHEMICAL", 52, 69], ["skin sensitization", "DISEASE", 145, 163], ["hydrogen peroxide", "CHEMICAL", 293, 310], ["hydrogen peroxide", "CHEMICAL", 293, 310], ["skin", "ORGAN", 145, 149], ["Skin", "ORGAN", 253, 257], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 293, 310], ["skin", "ORGAN", 421, 425], ["rabbits", "ORGANISM", 451, 458], ["rabbits", "SPECIES", 451, 458], ["Zealand white rabbits", "SPECIES", 437, 458], ["The study", "TEST", 0, 9], ["Biological evaluation", "TEST", 71, 92], ["medical devices", "TREATMENT", 96, 111], ["irritation", "PROBLEM", 130, 140], ["skin sensitization", "TEST", 145, 163], ["ISO", "TEST", 214, 217], ["Tests", "TEST", 228, 233], ["Irritation", "PROBLEM", 238, 248], ["Skin Sensitization", "TREATMENT", 253, 271], ["The test sample", "TEST", 271, 286], ["0.5% hydrogen peroxide", "TREATMENT", 288, 310], ["control (physiological saline)", "TREATMENT", 316, 346], ["absorbent gauze piece", "TREATMENT", 362, 383], ["skin", "ANATOMY", 145, 149], ["Skin", "ANATOMY", 253, 257], ["skin", "ANATOMY", 421, 425]]], ["Application sites were covered with occlusive bandage for 4 h.", [["sites", "ANATOMY", 12, 17], ["Application sites", "TREATMENT", 0, 17], ["occlusive bandage", "TREATMENT", 36, 53], ["occlusive", "OBSERVATION_MODIFIER", 36, 45], ["bandage", "OBSERVATION", 46, 53]]], ["The application sites were observed for any tissue reactions at 1 h, 24 h, 48 h and 72 h after removal of patches.", [["tissue", "ANATOMY", 44, 50], ["tissue", "TISSUE", 44, 50], ["The application sites", "TREATMENT", 0, 21], ["any tissue reactions", "PROBLEM", 40, 60], ["removal of patches", "TREATMENT", 95, 113]]], ["The test material did not produce any irritation following dermal application and confirmed that 0.5% hydrogen peroxide is non-irritant.Summary of TestsThe prime focus of the validation of the disinfection gateway was to prove the safety and efficacy.", [["dermal", "ANATOMY", 59, 65], ["hydrogen peroxide", "CHEMICAL", 102, 119], ["hydrogen peroxide", "CHEMICAL", 102, 119], ["dermal", "TISSUE", 59, 65], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 102, 119], ["The test material", "TEST", 0, 17], ["any irritation", "PROBLEM", 34, 48], ["dermal application", "TREATMENT", 59, 77], ["0.5% hydrogen peroxide", "TREATMENT", 97, 119], ["the disinfection gateway", "TREATMENT", 189, 213], ["irritation", "OBSERVATION", 38, 48]]], ["The safety experiments were carried out in rabbits and the results showed that the concentration of 0.5% which we are using for mist regeneration does not cause any harm or irritation or sensitization.", [["rabbits", "ORGANISM", 43, 50], ["rabbits", "SPECIES", 43, 50], ["rabbits", "SPECIES", 43, 50], ["The safety experiments", "TEST", 0, 22], ["mist regeneration", "TREATMENT", 128, 145], ["irritation", "PROBLEM", 173, 183], ["sensitization", "PROBLEM", 187, 200], ["irritation", "OBSERVATION", 173, 183]]], ["The tests were in accordance with ISO 10993.", [["ISO 10993", "CHEMICAL", 34, 43], ["The tests", "TEST", 0, 9]]], ["The microbiology experiments proved the efficacy of the gateway that it reduces the bioburden load on things that are passing through it.", [["The microbiology experiments", "TEST", 0, 28], ["the bioburden load", "PROBLEM", 80, 98], ["bioburden load", "OBSERVATION", 84, 98]]], ["All the experiments proved the disinfection gateway can act as a good tool in COVID management by reducing the bioburden and thereby assisting in the fight against COVID 19 spread.ConclusionsFrom design considerations and based on the experimental validation studies, it can be concluded that the Chitra Disinfection Gateway is designed by taking all precautions of chemical safety aspects and is providing a very good safety margin considering the exposure limits for hydrogen peroxide.", [["COVID", "DISEASE", 164, 169], ["hydrogen peroxide", "CHEMICAL", 469, 486], ["hydrogen peroxide", "CHEMICAL", 469, 486], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 469, 486], ["COVID management", "TREATMENT", 78, 94], ["the bioburden", "TREATMENT", 107, 120], ["the experimental validation studies", "TEST", 231, 266], ["the Chitra Disinfection", "TREATMENT", 293, 316], ["hydrogen peroxide", "TREATMENT", 469, 486]]], ["Hence, the device does not pose any safety hazards for the people who use it.ConclusionsThe CDG is devised to reduce the viral bioburden a person carries when one enters a private space (which is relatively less contaminated) from a public zone (like streets, public transport, markets, railway stations, bus stations), thereby achieving the control of the bioburden in the private space.", [["CDG", "DISEASE", 92, 95], ["people", "ORGANISM", 59, 65], ["bus stations", "MULTI-TISSUE_STRUCTURE", 305, 317], ["people", "SPECIES", 59, 65], ["person", "SPECIES", 139, 145], ["the device", "TREATMENT", 7, 17], ["viral bioburden", "OBSERVATION", 121, 136], ["bioburden", "OBSERVATION", 357, 366]]], ["These private spaces could be entities like offices, banks, laboratories, and educational institutions,. where a person is likely to spend more time than one spends in public space.", [["person", "SPECIES", 113, 119]]], ["This minimizes the risk of communal spread of the disease when the lockdown conditions are getting released.", [["the disease", "PROBLEM", 46, 57], ["the lockdown conditions", "PROBLEM", 63, 86], ["communal", "OBSERVATION_MODIFIER", 27, 35], ["spread", "OBSERVATION_MODIFIER", 36, 42], ["disease", "OBSERVATION", 50, 57]]]], "3fdc7c236b854cbc809e10b2cc1628102f5c7e6c": [["IntroductionMiddle East respiratory syndrome (MERS)-coronavirus (MERS-CoV), an emerging zoonotic virus, is the causative agent of MERS.", [["Middle East respiratory syndrome (MERS)-coronavirus", "DISEASE", 12, 63], ["zoonotic virus", "DISEASE", 88, 102], ["MERS", "DISEASE", 130, 134], ["Middle East respiratory syndrome (MERS)-coronavirus", "ORGANISM", 12, 63], ["MERS-CoV", "ORGANISM", 65, 73], ["-coronavirus", "SPECIES", 51, 63], ["Middle East respiratory syndrome (MERS)-coronavirus", "SPECIES", 12, 63], ["MERS-CoV", "SPECIES", 65, 73], ["Middle East respiratory syndrome", "PROBLEM", 12, 44], ["coronavirus", "PROBLEM", 52, 63], ["an emerging zoonotic virus", "PROBLEM", 76, 102], ["Middle", "ANATOMY_MODIFIER", 12, 18], ["respiratory syndrome", "OBSERVATION", 24, 44], ["zoonotic virus", "OBSERVATION", 88, 102]]], ["MERS-CoV was first identified in Saudi Arabia in 2012 and MERS cases have been reported in 27 countries since then [1, 2] .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["MERS-CoV", "SPECIES", 0, 8]]], ["As of February 10, 2017, 1905 laboratory-confirmed cases, including 677 deaths related to MERS-CoV, had been reported to WHO ($36% mortality).", [["deaths", "DISEASE", 72, 78], ["MERS-CoV", "SPECIES", 90, 98]]], ["Several family clusters and nosocomial clusters cases have been reported, revealing the human-to-human transmissibility of MERS-CoV, and raising the concern of a MERS-CoV global pandemic [3] [4] [5] .", [["human", "ORGANISM", 88, 93], ["human", "ORGANISM", 97, 102], ["MERS-CoV", "ORGANISM", 123, 131], ["MERS-CoV", "ORGANISM", 162, 170], ["human", "SPECIES", 88, 93], ["human", "SPECIES", 97, 102], ["human", "SPECIES", 88, 93], ["human", "SPECIES", 97, 102], ["MERS-CoV", "SPECIES", 123, 131], ["MERS-CoV", "SPECIES", 162, 170], ["a MERS", "PROBLEM", 160, 166]]], ["Currently, no licensed therapeutic or vaccine is available, which highlights the need for efficient vaccines against MERS-CoV.IntroductionTo date, several vaccine candidates have been developed, such as viral vector-based recombinants [6] [7] [8] [9] [10] [11] , subunit vaccines [12] [13] [14] [15] [16] [17] [18] [19] , DNA vaccines [20] , DNA prime/protein-boost vaccines [21] and a reverse genetics-constructed recombinant coronavirus vaccine [22] .", [["[6] [7] [8] [9] [10] [11] , subunit vaccines [12] [13] [14] [15] [16] [17] [18] [19]", "CHEMICAL", 235, 319], ["MERS-CoV", "ORGANISM", 117, 125], ["[6] [7] [8] [9] [10] [11]", "SIMPLE_CHEMICAL", 235, 260], ["[12] [13] [14] [15] [16] [17] [18] [19]", "SIMPLE_CHEMICAL", 280, 319], ["DNA", "CELLULAR_COMPONENT", 322, 325], ["DNA", "CELLULAR_COMPONENT", 342, 345], ["coronavirus", "ORGANISM", 427, 438], ["coronavirus", "SPECIES", 427, 438], ["MERS-CoV", "SPECIES", 117, 125], ["vaccine", "TREATMENT", 38, 45], ["efficient vaccines", "TREATMENT", 90, 108], ["MERS", "PROBLEM", 117, 121], ["CoV", "PROBLEM", 122, 125], ["several vaccine candidates", "TREATMENT", 147, 173], ["viral vector", "TEST", 203, 215], ["subunit vaccines", "TEST", 263, 279], ["DNA vaccines", "TEST", 322, 334], ["DNA prime/protein-boost vaccines", "TREATMENT", 342, 374], ["a reverse genetics", "TREATMENT", 384, 402], ["constructed recombinant coronavirus vaccine", "TREATMENT", 403, 446], ["no", "UNCERTAINTY", 11, 13]]], ["Among them, DNA vaccines present a range of unique advantages such as proper antigen protein folding, rapid design and production, cost-effectiveness, and stability at nonrefrigerated temperatures for convenient storage and shipping [23] .", [["DNA", "CELLULAR_COMPONENT", 12, 15], ["DNA vaccines", "TREATMENT", 12, 24], ["unique advantages", "TREATMENT", 44, 61], ["proper antigen protein folding", "TREATMENT", 70, 100]]], ["Furthermore, it has been reported that DNA vaccines can induce both humoral and cellular immune responses against MERS-CoV and SARS-CoV infection [20, 24, 25] .IntroductionMERS-CoV is the first lineage of Betacoronavirus known to infect humans [26] .", [["cellular", "ANATOMY", 80, 88], ["SARS-CoV infection", "DISEASE", 127, 145], ["DNA", "CELLULAR_COMPONENT", 39, 42], ["cellular", "CELL", 80, 88], ["MERS-CoV", "ORGANISM", 114, 122], ["SARS-CoV", "ORGANISM", 127, 135], ["IntroductionMERS-CoV", "GENE_OR_GENE_PRODUCT", 160, 180], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 205, 220], ["humans", "ORGANISM", 237, 243], ["SARS-CoV", "SPECIES", 127, 135], ["humans", "SPECIES", 237, 243], ["MERS-CoV", "SPECIES", 114, 122], ["SARS-CoV", "SPECIES", 127, 135], ["humans", "SPECIES", 237, 243], ["DNA vaccines", "TREATMENT", 39, 51], ["MERS", "PROBLEM", 114, 118], ["CoV", "PROBLEM", 119, 122], ["SARS", "PROBLEM", 127, 131], ["CoV infection", "PROBLEM", 132, 145], ["cellular immune", "OBSERVATION", 80, 95]]], ["The genome of MERS-CoV encodes four structural proteins -spike (S), envelope (E), membrane (M) and nucleocapsid (N) [27] .", [["membrane", "ANATOMY", 82, 90], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 14, 22], ["membrane", "CELLULAR_COMPONENT", 82, 90], ["MERS-CoV", "DNA", 14, 22], ["structural proteins", "PROTEIN", 36, 55], ["spike (S), envelope (E), membrane (M)", "PROTEIN", 57, 94], ["MERS-CoV", "SPECIES", 14, 22], ["structural proteins", "TEST", 36, 55]]], ["The S protein, a class I fusion protein forming protruding spikes on the virus surface, is composed of an N-terminal S1 subunit and a C-terminal S2 subunit [28] .", [["surface", "ANATOMY", 79, 86], ["N-", "CHEMICAL", 106, 108], ["C", "CHEMICAL", 134, 135], ["S protein", "PROTEIN", 4, 13], ["class I fusion protein", "PROTEIN", 17, 39], ["N-terminal S1 subunit", "PROTEIN", 106, 127], ["C-terminal S2 subunit", "PROTEIN", 134, 155], ["The S protein", "TEST", 0, 13], ["a class I fusion protein", "TREATMENT", 15, 39], ["protruding spikes", "PROBLEM", 48, 65], ["the virus surface", "PROBLEM", 69, 86], ["an N-terminal S1 subunit", "PROBLEM", 103, 127], ["a C-terminal S2 subunit", "TREATMENT", 132, 155], ["protruding spikes", "OBSERVATION", 48, 65]]], ["It has been reported that MERS-CoV binds to host cell receptor dipeptidyl peptidase 4 (DPP4) through an independently folded receptor binding domain (RBD) localized within the S1 subunit [29, 30] .", [["cell", "ANATOMY", 49, 53], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 26, 34], ["host cell receptor dipeptidyl peptidase 4", "GENE_OR_GENE_PRODUCT", 44, 85], ["DPP4", "GENE_OR_GENE_PRODUCT", 87, 91], ["MERS-CoV", "PROTEIN", 26, 34], ["host cell receptor dipeptidyl peptidase 4", "PROTEIN", 44, 85], ["DPP4", "PROTEIN", 87, 91], ["folded receptor binding domain", "PROTEIN", 118, 148], ["RBD", "PROTEIN", 150, 153], ["S1 subunit", "PROTEIN", 176, 186], ["MERS-CoV", "SPECIES", 26, 34], ["CoV binds", "PROBLEM", 31, 40], ["host cell receptor dipeptidyl peptidase 4 (DPP4)", "TREATMENT", 44, 92], ["an independently folded receptor binding domain (RBD)", "PROBLEM", 101, 154]]], ["Moreover, S protein has been identified as the most immunogenic antigen of MERS-CoV.", [["S protein", "GENE_OR_GENE_PRODUCT", 10, 19], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 75, 83], ["S protein", "PROTEIN", 10, 19], ["MERS-CoV", "PROTEIN", 75, 83], ["MERS-CoV", "SPECIES", 75, 83], ["S protein", "TEST", 10, 19]]], ["It plays an important role in the induction of neutralizing antibody and anti-viral T-cell responses [28] the major target for current vaccines development to protect against MERS [8, 10, 28] .", [["T-cell", "ANATOMY", 84, 90], ["T-cell", "CELL", 84, 90], ["neutralizing antibody", "PROTEIN", 47, 68], ["neutralizing antibody", "TREATMENT", 47, 68], ["anti-viral T-cell responses", "TREATMENT", 73, 100], ["current vaccines", "TREATMENT", 127, 143]]], ["However, previous studies have demonstrated that vaccines based on full-length S potentially induce harmful side effects caused by non-neutralizing epitopes [27, 31] .", [["non-neutralizing epitopes", "PROTEIN", 131, 156], ["previous studies", "TEST", 9, 25], ["vaccines", "TREATMENT", 49, 57], ["harmful side effects", "PROBLEM", 100, 120], ["non-neutralizing epitopes", "PROBLEM", 131, 156]]], ["In contrast, RBD protein-based subunit vaccines are able to induce both neutralizing antibody and anti-viral T-cell responses against MERS-CoV infection, with the additional superiority of safety [28] .", [["T-cell", "ANATOMY", 109, 115], ["MERS-CoV infection", "DISEASE", 134, 152], ["RBD", "GENE_OR_GENE_PRODUCT", 13, 16], ["T-cell", "CELL", 109, 115], ["MERS-CoV", "ORGANISM", 134, 142], ["RBD protein", "PROTEIN", 13, 24], ["MERS-CoV", "SPECIES", 134, 142], ["RBD protein", "TEST", 13, 24], ["subunit vaccines", "TREATMENT", 31, 47], ["neutralizing antibody", "TEST", 72, 93], ["anti-viral T", "TEST", 98, 110], ["MERS", "PROBLEM", 134, 138], ["CoV infection", "PROBLEM", 139, 152], ["infection", "OBSERVATION", 143, 152]]], ["Nevertheless, to improve the immunogenicity of these subunit vaccines, it has been found necessary to use an appropriate adjuvant or even adjuvant combinations, or immune enhancers (e.g., human IgG Fc), and optimized delivery routes and doses [12] [13] [14] [15] [16] [17] .", [["human", "ORGANISM", 188, 193], ["IgG Fc", "GENE_OR_GENE_PRODUCT", 194, 200], ["[12] [13] [14] [15] [16] [17]", "SIMPLE_CHEMICAL", 243, 272], ["immune enhancers", "DNA", 164, 180], ["human IgG Fc", "PROTEIN", 188, 200], ["human", "SPECIES", 188, 193], ["human", "SPECIES", 188, 193], ["these subunit vaccines", "TREATMENT", 47, 69], ["an appropriate adjuvant", "TREATMENT", 106, 129], ["adjuvant combinations", "TREATMENT", 138, 159], ["immune enhancers", "TREATMENT", 164, 180]]], ["An ideal MERS vaccine should induce potent neutralizing antibody response without inducing harmful immune effects such as virus-enhancing antibody or immunopathology [28, 32] .", [["immunopathology", "DISEASE", 150, 165], ["An ideal MERS vaccine", "TREATMENT", 0, 21], ["potent neutralizing antibody response", "PROBLEM", 36, 73], ["harmful immune effects", "PROBLEM", 91, 113], ["virus", "PROBLEM", 122, 127], ["enhancing antibody", "PROBLEM", 128, 146], ["immunopathology", "PROBLEM", 150, 165]]], ["Based on the established background and our previous research results, we selected S1 protein as the target for our DNA vaccine development.IntroductionIn the present study, we designed and constructed a DNA vaccine encoding the S1 subunit of MERS-CoV (pcDNA3.1-S1), and evaluated antigen-specific humoral and cellular immune responses induced by this DNA vaccine in mice.", [["cellular", "ANATOMY", 310, 318], ["DNA", "CELLULAR_COMPONENT", 116, 119], ["DNA", "CELLULAR_COMPONENT", 204, 207], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 243, 251], ["pcDNA3.1-S1", "GENE_OR_GENE_PRODUCT", 253, 264], ["cellular", "CELL", 310, 318], ["DNA", "CELLULAR_COMPONENT", 352, 355], ["mice", "ORGANISM", 367, 371], ["S1 protein", "PROTEIN", 83, 93], ["S1 subunit", "PROTEIN", 229, 239], ["MERS", "PROTEIN", 243, 247], ["pcDNA3.1", "PROTEIN", 253, 261], ["S1", "PROTEIN", 262, 264], ["mice", "SPECIES", 367, 371], ["MERS-CoV", "SPECIES", 243, 251], ["mice", "SPECIES", 367, 371], ["S1 protein", "TREATMENT", 83, 93], ["our DNA vaccine development", "TREATMENT", 112, 139], ["the present study", "TEST", 155, 172], ["a DNA vaccine", "TREATMENT", 202, 215], ["antigen", "TEST", 281, 288], ["this DNA vaccine", "TREATMENT", 347, 363], ["cellular immune", "OBSERVATION", 310, 325]]], ["Further, we investigated the protective efficacy of pcDNA3.1-S1 DNA vaccine in an Ad5-hDPP4transduced mouse model following MERS-CoV challenge.", [["pcDNA3.1-S1", "GENE_OR_GENE_PRODUCT", 52, 63], ["DNA", "CELLULAR_COMPONENT", 64, 67], ["Ad5", "ORGANISM", 82, 85], ["mouse", "ORGANISM", 102, 107], ["MERS-CoV", "ORGANISM", 124, 132], ["mouse", "SPECIES", 102, 107], ["Ad5", "SPECIES", 82, 85], ["mouse", "SPECIES", 102, 107], ["MERS-CoV", "SPECIES", 124, 132], ["pcDNA3.1-S1 DNA vaccine", "TREATMENT", 52, 75], ["an Ad5", "TREATMENT", 79, 85], ["CoV challenge", "TREATMENT", 129, 142]]], ["Vaccinated mice and mice receiving immune serum before infection were found to have significantly decreased virus loads in their lungs.Mice, virus and cellsSix-to eight-week-old specific pathogen-free female BALB/c mice were purchased from the Changchun Institute of Biological Products Co.Construction of the recombinant plasmids expressing MERS-CoV spike proteinThe gene sequence encoding amino acid 1-1353 (S) of the spike protein of the Al-Hasa_15_2013 strain of MERS-CoV (GenBank accession No.", [["immune serum", "ANATOMY", 35, 47], ["lungs", "ANATOMY", 129, 134], ["cells", "ANATOMY", 151, 156], ["plasmids", "ANATOMY", 322, 330], ["infection", "DISEASE", 55, 64], ["amino acid 1-1353", "CHEMICAL", 391, 408], ["amino acid", "CHEMICAL", 391, 401], ["mice", "ORGANISM", 11, 15], ["mice", "ORGANISM", 20, 24], ["serum", "ORGANISM_SUBSTANCE", 42, 47], ["lungs", "ORGAN", 129, 134], ["Mice", "ORGANISM", 135, 139], ["cells", "CELL", 151, 156], ["pathogen", "ORGANISM", 187, 195], ["BALB/c mice", "ORGANISM", 208, 219], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 342, 350], ["amino acid", "AMINO_ACID", 391, 401], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 467, 475], ["recombinant plasmids", "DNA", 310, 330], ["MERS-CoV spike protein", "PROTEIN", 342, 364], ["spike protein", "PROTEIN", 420, 433], ["MERS-CoV", "DNA", 467, 475], ["mice", "SPECIES", 11, 15], ["mice", "SPECIES", 20, 24], ["Mice", "SPECIES", 135, 139], ["mice", "SPECIES", 215, 219], ["mice", "SPECIES", 11, 15], ["mice", "SPECIES", 20, 24], ["mice", "SPECIES", 215, 219], ["MERS-CoV", "SPECIES", 342, 350], ["MERS-CoV", "SPECIES", 467, 475], ["immune serum", "TEST", 35, 47], ["infection", "PROBLEM", 55, 64], ["significantly decreased virus loads in their lungs", "PROBLEM", 84, 134], ["Mice, virus and cells", "PROBLEM", 135, 156], ["the recombinant plasmids", "TREATMENT", 306, 330], ["CoV spike protein", "PROBLEM", 347, 364], ["The gene sequence encoding amino acid", "TEST", 364, 401], ["the spike protein", "TEST", 416, 433], ["decreased virus loads", "OBSERVATION", 98, 119], ["lungs", "ANATOMY", 129, 134], ["virus", "OBSERVATION", 141, 146], ["cells", "OBSERVATION", 151, 156]]], ["KF600645.1) was synthesized by Sangon Biotech Company (Shanghai, China).", [["KF600645.1", "CHEMICAL", 0, 10], ["KF600645.1", "CHEMICAL", 0, 10], ["KF600645.1", "SIMPLE_CHEMICAL", 0, 10]]], ["The synthetic full-length S, SDCD (S without the entire cytoplasmic domain), and S1 fragment were respectively subcloned into the mammalian expression vector pcDNA3.1 (+) (Invitrogen, San Diego, CA, USA) to generate recombinant plasmid pcDNA3.1-S, pcDNA3.1-SDCD, and pcDNA3.1-S1 (Fig. 1A) .", [["cytoplasmic", "ANATOMY", 56, 67], ["plasmid", "ANATOMY", 228, 235], ["cytoplasmic", "ORGANISM_SUBSTANCE", 56, 67], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 158, 166], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 236, 242], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 248, 254], ["pcDNA3.1-S1", "GENE_OR_GENE_PRODUCT", 267, 278], ["synthetic full-length S, SDCD (S without the entire cytoplasmic domain", "DNA", 4, 74], ["S1 fragment", "DNA", 81, 92], ["recombinant plasmid pcDNA3", "DNA", 216, 242], ["1-S, pcDNA3", "DNA", 243, 254], ["pcDNA3.1", "DNA", 267, 275], ["SDCD (S", "PROBLEM", 29, 36], ["S1 fragment", "PROBLEM", 81, 92], ["recombinant plasmid pcDNA3", "TREATMENT", 216, 242], ["pcDNA3", "TREATMENT", 248, 254], ["S1", "ANATOMY", 81, 83], ["fragment", "OBSERVATION", 84, 92], ["S1", "ANATOMY", 276, 278]]], ["The recombinant plasmid was then amplified in Escherichia coli HST08 (TaKaRa, Dalian, China) and purified using the Endo-Free Plasmid Maxi Kit (QIAGEN GmbH, Shanghai, China).", [["plasmid", "ANATOMY", 16, 23], ["Escherichia coli", "ORGANISM", 46, 62], ["HST08", "ORGANISM", 63, 68], ["recombinant plasmid", "DNA", 4, 23], ["Escherichia coli", "SPECIES", 46, 62], ["Escherichia coli", "SPECIES", 46, 62], ["The recombinant plasmid", "TREATMENT", 0, 23], ["Escherichia coli HST08", "TREATMENT", 46, 68], ["the Endo", "TREATMENT", 112, 120], ["Free Plasmid Maxi Kit", "TREATMENT", 121, 142], ["Escherichia coli", "OBSERVATION", 46, 62]]], ["The recombinant plasmid was dissolved in PBS at a final concentration of 1 lg/lL for in vitro transfection and in vivo animal immunization.Western blot analysis of spike protein expression in vitroA 6-well plate was seeded with 293T cells which were grown to 80-90% confluence.", [["plasmid", "ANATOMY", 16, 23], ["293T cells", "ANATOMY", 228, 238], ["PBS", "SIMPLE_CHEMICAL", 41, 44], ["293T cells", "CELL", 228, 238], ["recombinant plasmid", "DNA", 4, 23], ["293T cells", "CELL_LINE", 228, 238], ["The recombinant plasmid", "TREATMENT", 0, 23], ["vitro transfection", "TREATMENT", 88, 106], ["vivo animal immunization", "TREATMENT", 114, 138], ["blot analysis", "TEST", 147, 160], ["spike protein expression", "PROBLEM", 164, 188], ["vitroA", "TEST", 192, 198], ["293T cells", "TREATMENT", 228, 238], ["293T cells", "OBSERVATION", 228, 238]]], ["Cells were respectively transfected with the recombinant plasmids and pcDNA3.1 empty vector using Lipofectamine 3000 Transfection Reagent (Invitrogen, San Diego, CA, USA) according to the manufacturer's instructions.", [["Cells", "ANATOMY", 0, 5], ["plasmids", "ANATOMY", 57, 65], ["Cells", "CELL", 0, 5], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 70, 78], ["recombinant plasmids", "DNA", 45, 65], ["Cells", "TEST", 0, 5], ["the recombinant plasmids", "TREATMENT", 41, 65], ["Lipofectamine", "TREATMENT", 98, 111]]], ["Cells were harvested at 48 h post-transfection.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5]]], ["Cell lysates were prepared using RIPA Lysis buffer (Solarbio LIFE SCIENCES, Beijing, China) according to the manufacturer's instructions, then separated on an 12% polyacrylamide gel and transferred onto a 0.45 lm nitrocellulose blotting membrane (GE Healthcare Life Sciences, Freiburg, Germany) for Western blotting analysis using mouse anti-MERS-S1 mono- clonal antibodies (Sino biologicals, Beijing, China) and mouse antib-tubulin monoclonal antibodies (Ray antibody biotech, Beijing, China).Animal immunizationsMice were randomly divided into two groups.", [["Cell lysates", "ANATOMY", 0, 12], ["polyacrylamide", "CHEMICAL", 163, 177], ["nitrocellulose", "CHEMICAL", 213, 227], ["Cell lysates", "ORGANISM_SUBSTANCE", 0, 12], ["mouse", "ORGANISM", 331, 336], ["mouse", "ORGANISM", 413, 418], ["antib-tubulin", "GENE_OR_GENE_PRODUCT", 419, 432], ["Mice", "ORGANISM", 514, 518], ["mouse anti-MERS-S1 mono- clonal antibodies", "PROTEIN", 331, 373], ["mouse antib-tubulin monoclonal antibodies", "PROTEIN", 413, 454], ["Ray antibody", "PROTEIN", 456, 468], ["mouse", "SPECIES", 331, 336], ["mouse", "SPECIES", 413, 418], ["Mice", "SPECIES", 514, 518], ["mouse", "SPECIES", 331, 336], ["mouse", "SPECIES", 413, 418], ["Cell lysates", "TREATMENT", 0, 12], ["RIPA Lysis buffer", "TREATMENT", 33, 50], ["an 12% polyacrylamide gel", "TREATMENT", 156, 181], ["a 0.45 lm nitrocellulose blotting membrane", "TREATMENT", 203, 245], ["Western blotting analysis", "TEST", 299, 324], ["mouse anti-MERS", "TEST", 331, 346], ["clonal antibodies", "PROBLEM", 356, 373], ["Sino biologicals", "TREATMENT", 375, 391], ["mouse antib", "TREATMENT", 413, 424], ["tubulin monoclonal antibodies", "TREATMENT", 425, 454], ["Animal immunizations", "TREATMENT", 494, 514]]], ["Mice in the experimental group were injected intramuscularly (i.m.) in the quadriceps muscle with 100 lg recombinant plasmid in 100 lL PBS on week 0, 3, 6 ( Fig. 1C) .", [["quadriceps muscle", "ANATOMY", 75, 92], ["plasmid", "ANATOMY", 117, 124], ["Mice", "ORGANISM", 0, 4], ["quadriceps muscle", "TISSUE", 75, 92], ["Mice", "SPECIES", 0, 4], ["lg recombinant plasmid", "TREATMENT", 102, 124], ["quadriceps muscle", "ANATOMY", 75, 92]]], ["Mice in the control group received either the same volume of PBS or pcDNA3.1 empty vector at the same time points.ELISA measurement of MERS-CoV S-specific IgGAt weeks 1, 2, 4, 5, 7 and 8 following the primary immunization, 6 mice from each group were randomly selected for collection of serum.", [["serum", "ANATOMY", 287, 292], ["Mice", "ORGANISM", 0, 4], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 68, 76], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 135, 143], ["mice", "ORGANISM", 225, 229], ["serum", "ORGANISM_SUBSTANCE", 287, 292], ["Mice", "SPECIES", 0, 4], ["mice", "SPECIES", 225, 229], ["MERS-CoV", "SPECIES", 135, 143], ["mice", "SPECIES", 225, 229], ["the same volume of PBS", "TREATMENT", 42, 64], ["pcDNA3.1 empty vector", "TREATMENT", 68, 89], ["ELISA measurement", "TEST", 114, 131], ["MERS", "TEST", 135, 139], ["the primary immunization", "TREATMENT", 197, 221], ["collection of serum", "TEST", 273, 292]]], ["Blood samples were collected by retro-orbital plexus puncture.", [["Blood samples", "ANATOMY", 0, 13], ["retro-orbital plexus", "ANATOMY", 32, 52], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["retro-orbital plexus", "MULTI-TISSUE_STRUCTURE", 32, 52], ["Blood samples", "TEST", 0, 13], ["retro-orbital plexus puncture", "TEST", 32, 61], ["retro-orbital plexus", "ANATOMY", 32, 52]]], ["Anti-MERS-S antibody levels in serum were measured by indirect ELISA using purified RBD protein (10 lg/mL) as the coating antigen as previously described [19] .", [["serum", "ANATOMY", 31, 36], ["Anti-MERS-S antibody", "GENE_OR_GENE_PRODUCT", 0, 20], ["serum", "ORGANISM_SUBSTANCE", 31, 36], ["RBD", "GENE_OR_GENE_PRODUCT", 84, 87], ["Anti-MERS-S antibody", "PROTEIN", 0, 20], ["RBD protein", "PROTEIN", 84, 95], ["Anti-MERS-S antibody levels", "TEST", 0, 27], ["serum", "TEST", 31, 36], ["indirect ELISA", "TEST", 54, 68], ["purified RBD protein", "TEST", 75, 95], ["the coating antigen", "TEST", 110, 129]]], ["Values 2-fold higher than the control group were considered positive.Plaque reduction neutralizing testOne week following the third immunization, serum samples were harvested and were 4-fold serially diluted in DMEM (Gibco, San Diego, CA, USA) and mixed 1:1 with 80 PFU MERS-CoV EMC/2012.", [["Plaque", "ANATOMY", 69, 75], ["serum samples", "ANATOMY", 146, 159], ["serum samples", "ORGANISM_SUBSTANCE", 146, 159], ["Values", "TEST", 0, 6], ["positive", "PROBLEM", 60, 68], ["Plaque reduction", "TREATMENT", 69, 85], ["neutralizing test", "TEST", 86, 103], ["the third immunization", "TREATMENT", 122, 144], ["serum samples", "TEST", 146, 159], ["reduction", "OBSERVATION_MODIFIER", 76, 85], ["neutralizing", "OBSERVATION", 86, 98]]], ["After a 1 h incubation at 37\u00b0C, the mixture was added to Vero 81 cells for an additional 1 h to permit absorption.", [["Vero 81 cells", "ANATOMY", 57, 70], ["Vero 81 cells", "CELL", 57, 70], ["Vero 81 cells", "CELL_LINE", 57, 70], ["the mixture", "TREATMENT", 32, 43], ["Vero 81 cells", "TREATMENT", 57, 70]]], ["Cells were then overlaid with 1.2% agarose (containing 2% FBS, DMEM).", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["agarose", "SIMPLE_CHEMICAL", 35, 42], ["FBS", "ORGANISM_SUBSTANCE", 58, 61], ["1.2% agarose", "TREATMENT", 30, 42], ["2% FBS", "TREATMENT", 55, 61]]], ["After a further incubation of 3 days, agarose plugs were removed for collection of virus.", [["agarose", "SIMPLE_CHEMICAL", 38, 45], ["a further incubation", "TREATMENT", 6, 26], ["agarose plugs", "TREATMENT", 38, 51], ["collection of virus", "PROBLEM", 69, 88], ["virus", "OBSERVATION", 83, 88]]], ["The remaining plaques were visualized by 0.1% crystal violet staining.IFN-c and IL-4 ELISpot assaysTwo weeks following the second immunization, 3 mice from each group were randomly selected and euthanized.", [["plaques", "ANATOMY", 14, 21], ["plaques", "PATHOLOGICAL_FORMATION", 14, 21], ["IFN-c", "GENE_OR_GENE_PRODUCT", 70, 75], ["IL-4", "GENE_OR_GENE_PRODUCT", 80, 84], ["mice", "ORGANISM", 146, 150], ["IFN", "PROTEIN", 70, 73], ["mice", "SPECIES", 146, 150], ["mice", "SPECIES", 146, 150], ["The remaining plaques", "PROBLEM", 0, 21], ["IFN", "TEST", 70, 73], ["IL", "TEST", 80, 82], ["ELISpot assays", "TEST", 85, 99], ["the second immunization", "TREATMENT", 119, 142], ["remaining", "OBSERVATION_MODIFIER", 4, 13], ["plaques", "OBSERVATION", 14, 21], ["violet staining", "OBSERVATION", 54, 69]]], ["Spleens were harvested into a tissue culture dish and teased apart into singlecell suspensions by pressing through a 3 ml syringe.", [["Spleens", "ANATOMY", 0, 7], ["tissue culture dish", "ANATOMY", 30, 49], ["Spleens", "ORGAN", 0, 7], ["tissue", "TISSUE", 30, 36], ["a tissue culture dish", "PROBLEM", 28, 49], ["singlecell suspensions", "TREATMENT", 72, 94], ["a 3 ml syringe", "TREATMENT", 115, 129], ["harvested", "OBSERVATION", 13, 22], ["tissue", "ANATOMY", 30, 36], ["culture dish", "OBSERVATION", 37, 49]]], ["Cells were cultured in RPMI 1640 medium (Gibco, San Diego, CA, USA) containing 10% FBS (Gibco, San Diego, CA, USA), then stimulated with or without recombinant MERS-CoV RBD (10 lg/mL).", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["FBS", "ORGANISM_SUBSTANCE", 83, 86], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 160, 168], ["recombinant MERS-CoV RBD", "PROTEIN", 148, 172], ["MERS-CoV", "SPECIES", 160, 168], ["Cells", "TEST", 0, 5], ["RPMI", "TEST", 23, 27]]], ["The protein was prokaryotically expressed and purified by Ni-NTA affinity chromatography (Thermo, USA).", [["Ni-NTA", "CHEMICAL", 58, 64], ["Ni-NTA", "CHEMICAL", 58, 64], ["Ni-NTA", "SIMPLE_CHEMICAL", 58, 64], ["The protein", "TEST", 0, 11]]], ["After passing through a endotoxin removal spinning column, the endotoxin level was measured to be less than 0.04 EU/ml using a gel-clot limulus amebocyte lysate assay.", [["endotoxin", "CHEMICAL", 63, 72], ["endotoxin", "SIMPLE_CHEMICAL", 24, 33], ["endotoxin", "SIMPLE_CHEMICAL", 63, 72], ["clot", "ORGANISM_SUBSTANCE", 131, 135], ["endotoxin", "PROTEIN", 63, 72], ["a endotoxin removal spinning column", "TREATMENT", 22, 57], ["the endotoxin level", "TEST", 59, 78], ["a gel-clot limulus amebocyte lysate assay", "TEST", 125, 166], ["clot", "OBSERVATION", 131, 135]]], ["Following incubation at 37\u00b0C in 5% CO 2 for 24 h, splenocytes producing IFN-c and IL-4 were measured using mouse enzymelinked immunospot (ELISpot) kits (Mabtech AB, Stockholm, Sweden) according to the manufacturer's instructions.", [["splenocytes", "ANATOMY", 50, 61], ["CO 2", "CHEMICAL", 35, 39], ["splenocytes", "CELL", 50, 61], ["IFN-c", "GENE_OR_GENE_PRODUCT", 72, 77], ["IL-4", "GENE_OR_GENE_PRODUCT", 82, 86], ["mouse", "ORGANISM", 107, 112], ["splenocytes", "CELL_TYPE", 50, 61], ["IFN-c and IL-4", "PROTEIN", 72, 86], ["mouse", "SPECIES", 107, 112], ["mouse", "SPECIES", 107, 112], ["incubation", "TREATMENT", 10, 20], ["splenocytes", "TEST", 50, 61], ["IFN", "TEST", 72, 75], ["IL", "TEST", 82, 84], ["mouse enzymelinked immunospot", "TEST", 107, 136], ["splenocytes", "ANATOMY", 50, 61]]], ["Spot-forming cells (SFCs) were enumerated by an automated ELISpot reader (AID ELISPOT reader-iSpot, AID GmbH, GER).Intracellular cytokine stainingTwo weeks following the second immunization, splenocytes from 3 mice of each group were isolated, cultured (1 \u00c2 10 6 cells/ mL) and stimulated at 37\u00b0C in 5% CO 2 for 6 h, as described above, in the presence of protein transport inhibitor containing monensin (BD Biosciences, Franklin, VA, USA).", [["Spot-forming cells", "ANATOMY", 0, 18], ["SFCs", "ANATOMY", 20, 24], ["Intracellular", "ANATOMY", 115, 128], ["splenocytes", "ANATOMY", 191, 202], ["cells", "ANATOMY", 263, 268], ["monensin", "CHEMICAL", 395, 403], ["CO 2", "CHEMICAL", 303, 307], ["monensin", "CHEMICAL", 395, 403], ["Spot-forming cells", "CELL", 0, 18], ["SFCs", "CELL", 20, 24], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 115, 128], ["splenocytes", "CELL", 191, 202], ["mice", "ORGANISM", 210, 214], ["monensin", "SIMPLE_CHEMICAL", 395, 403], ["Spot-forming cells", "CELL_TYPE", 0, 18], ["SFCs", "CELL_TYPE", 20, 24], ["iSpot", "PROTEIN", 93, 98], ["AID", "PROTEIN", 100, 103], ["cytokine", "PROTEIN", 129, 137], ["splenocytes", "CELL_TYPE", 191, 202], ["mice", "SPECIES", 210, 214], ["mice", "SPECIES", 210, 214], ["Intracellular cytokine staining", "PROBLEM", 115, 146], ["the second immunization", "TREATMENT", 166, 189], ["splenocytes", "TREATMENT", 191, 202], ["protein transport inhibitor", "TREATMENT", 356, 383], ["monensin", "TREATMENT", 395, 403], ["cytokine staining", "OBSERVATION", 129, 146]]], ["Cells were then labelled with equal volumes of 1:250 dilutions of anti-CD4-FITC (Clone #RM4-5) and anti-CD8-PE (Clone #53-6.7) monoclonal antibodies (BD Biosciences, Franklin, VA, USA), then fixed and permeabilized byELISA measurement of cytokinesTwo weeks following the second immunization, splenocytes from 3 mice of each group were isolated, cultured (1 \u00c2 10 6 cells/ mL) and stimulated as described above, then incubated at 37\u00b0C in 5% CO 2 .", [["Cells", "ANATOMY", 0, 5], ["splenocytes", "ANATOMY", 292, 303], ["cells", "ANATOMY", 364, 369], ["FITC", "CHEMICAL", 75, 79], ["CO 2", "CHEMICAL", 439, 443], ["Cells", "CELL", 0, 5], ["anti-CD4-FITC", "SIMPLE_CHEMICAL", 66, 79], ["anti-CD8-PE", "SIMPLE_CHEMICAL", 99, 110], ["splenocytes", "CELL", 292, 303], ["mice", "ORGANISM", 311, 315], ["cells", "CELL", 364, 369], ["anti-CD4", "PROTEIN", 66, 74], ["FITC", "PROTEIN", 75, 79], ["RM4", "PROTEIN", 88, 91], ["anti-CD8", "PROTEIN", 99, 107], ["monoclonal antibodies", "PROTEIN", 127, 148], ["BD", "PROTEIN", 150, 152], ["cytokines", "PROTEIN", 238, 247], ["splenocytes", "CELL_TYPE", 292, 303], ["mice", "SPECIES", 311, 315], ["mice", "SPECIES", 311, 315], ["anti-CD4", "TEST", 66, 74], ["FITC", "TEST", 75, 79], ["RM4", "TEST", 88, 91], ["anti-CD8", "TEST", 99, 107], ["PE", "PROBLEM", 108, 110], ["Clone", "TEST", 112, 117], ["monoclonal antibodies", "TEST", 127, 148], ["BD Biosciences", "TEST", 150, 164], ["cytokines", "TREATMENT", 238, 247], ["the second immunization", "TREATMENT", 267, 290], ["splenocytes", "TREATMENT", 292, 303], ["PE", "OBSERVATION", 108, 110]]], ["After 48 h, cell-free culture supernatants were harvested.", [["cell", "ANATOMY", 12, 16], ["supernatants", "ANATOMY", 30, 42], ["cell", "CELL", 12, 16], ["cell-free culture supernatants", "TREATMENT", 12, 42]]], ["Levels of IL-2, IL-4, IL-10 and IFN-c were measured using mouse enzyme-linked immunosorbent assays (ELISA) development kits (Mabtech AB, Stockholm, Sweden) according to the manufacturer's instructions.MERS-CoV infection of miceMice were sensitized to MERS-CoV infection after prior transduction with adenovirus 5 expressing human DPP4 (Ad5-hDPP4) as previously described [33] .", [["infection", "DISEASE", 210, 219], ["infection", "DISEASE", 260, 269], ["IL-2", "GENE_OR_GENE_PRODUCT", 10, 14], ["IL-4", "GENE_OR_GENE_PRODUCT", 16, 20], ["IL-10", "GENE_OR_GENE_PRODUCT", 22, 27], ["IFN-c", "GENE_OR_GENE_PRODUCT", 32, 37], ["mouse", "ORGANISM", 58, 63], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 201, 209], ["miceMice", "ORGANISM", 223, 231], ["MERS-CoV", "ORGANISM", 251, 259], ["adenovirus 5", "ORGANISM", 300, 312], ["human", "ORGANISM", 324, 329], ["DPP4", "GENE_OR_GENE_PRODUCT", 330, 334], ["Ad5-hDPP4", "GENE_OR_GENE_PRODUCT", 336, 345], ["IFN-c", "PROTEIN", 32, 37], ["human DPP4", "PROTEIN", 324, 334], ["Ad5", "PROTEIN", 336, 339], ["hDPP4", "PROTEIN", 340, 345], ["mouse", "SPECIES", 58, 63], ["human", "SPECIES", 324, 329], ["mouse", "SPECIES", 58, 63], ["MERS-CoV", "SPECIES", 201, 209], ["MERS-CoV", "SPECIES", 251, 259], ["human", "SPECIES", 324, 329], ["Levels", "TEST", 0, 6], ["IL", "TEST", 10, 12], ["IL", "TEST", 16, 18], ["IL", "TEST", 22, 24], ["IFN", "TEST", 32, 35], ["mouse enzyme", "TEST", 58, 70], ["immunosorbent assays", "TEST", 78, 98], ["CoV infection of miceMice", "PROBLEM", 206, 231], ["CoV infection", "PROBLEM", 256, 269], ["prior transduction with adenovirus", "TREATMENT", 276, 310], ["CoV", "OBSERVATION_MODIFIER", 206, 209], ["infection", "OBSERVATION", 210, 219]]], ["One week following the third immunization, DNA vaccine immunized mice or mice given 200 lL immune serum (harvested 1 week following the third immunization) were transduced with Ad5-hDPP4 5 days before intranasal challenge with 1 \u00c2 10 5 PFU MERS-CoV.", [["serum", "ANATOMY", 98, 103], ["Ad5-hDPP4", "CHEMICAL", 177, 186], ["DNA", "CELLULAR_COMPONENT", 43, 46], ["mice", "ORGANISM", 65, 69], ["mice", "ORGANISM", 73, 77], ["serum", "ORGANISM_SUBSTANCE", 98, 103], ["Ad5", "ORGANISM", 177, 180], ["MERS-CoV", "ORGANISM", 240, 248], ["mice", "SPECIES", 65, 69], ["mice", "SPECIES", 73, 77], ["mice", "SPECIES", 65, 69], ["mice", "SPECIES", 73, 77], ["Ad5", "SPECIES", 177, 180], ["MERS-CoV", "SPECIES", 240, 248], ["the third immunization", "TREATMENT", 19, 41], ["DNA vaccine", "TREATMENT", 43, 54], ["the third immunization", "TREATMENT", 132, 154], ["Ad5-hDPP4", "TREATMENT", 177, 186], ["intranasal challenge", "TREATMENT", 201, 221]]], ["Lungs from 3 mice of each group were removed into PBS at days 3 and 5 post-infection and manually homogenized.", [["Lungs", "ANATOMY", 0, 5], ["infection", "DISEASE", 75, 84], ["Lungs", "ORGAN", 0, 5], ["mice", "ORGANISM", 13, 17], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 13, 17], ["infection", "PROBLEM", 75, 84], ["infection", "OBSERVATION", 75, 84]]], ["Virus titers of clarified supernatants were assayed in Vero 81 cells and expressed as PFU/g tissue.Construction and verification of DNA vaccineRecombinant plasmids expressing the different fragments (fulllength S, SDCD and S1) of MERS-CoV were obtained and verified by restriction enzyme digestion and sequencing.", [["supernatants", "ANATOMY", 26, 38], ["Vero 81 cells", "ANATOMY", 55, 68], ["g tissue", "ANATOMY", 90, 98], ["fragments", "ANATOMY", 189, 198], ["Virus", "ORGANISM", 0, 5], ["Vero 81 cells", "CELL", 55, 68], ["tissue", "TISSUE", 92, 98], ["DNA", "CELLULAR_COMPONENT", 132, 135], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 230, 238], ["Vero 81 cells", "CELL_LINE", 55, 68], ["DNA vaccineRecombinant plasmids", "DNA", 132, 163], ["fulllength S", "DNA", 200, 212], ["SDCD", "DNA", 214, 218], ["S1", "DNA", 223, 225], ["MERS-CoV", "DNA", 230, 238], ["Vero 81", "SPECIES", 55, 62], ["MERS-CoV", "SPECIES", 230, 238], ["Virus titers", "TEST", 0, 12], ["DNA vaccineRecombinant plasmids", "TREATMENT", 132, 163], ["the different fragments", "PROBLEM", 175, 198], ["sequencing", "TEST", 302, 312], ["g tissue", "OBSERVATION_MODIFIER", 90, 98], ["S1", "ANATOMY", 223, 225]]], ["Expression of MERS-CoV spike protein in 293T cells respectively transfected with the above recombinant plasmids was confirmed by Western blot (Fig. 1B) .", [["293T cells", "ANATOMY", 40, 50], ["plasmids", "ANATOMY", 103, 111], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 14, 22], ["293T cells", "CELL", 40, 50], ["MERS-CoV spike protein", "PROTEIN", 14, 36], ["293T cells", "CELL_LINE", 40, 50], ["recombinant plasmids", "DNA", 91, 111], ["MERS-CoV", "SPECIES", 14, 22], ["MERS", "PROBLEM", 14, 18], ["CoV spike protein in 293T cells", "PROBLEM", 19, 50], ["the above recombinant plasmids", "TREATMENT", 81, 111]]], ["The expression level of S1 protein was significantly higher than S and SDCD.", [["S1", "GENE_OR_GENE_PRODUCT", 24, 26], ["S1 protein", "PROTEIN", 24, 34], ["S1 protein", "TEST", 24, 34]]], ["We considered that the differences in expression level had an influence on the immune response to the various constructs.DNA vaccine-induced neutralizing antibody against MERS-CoVAntibody responses to MERS-CoV were evaluated by indirect ELISA, and shown as end-point dilution titers.", [["DNA", "CELLULAR_COMPONENT", 121, 124], ["MERS-CoVAntibody", "ORGANISM", 171, 187], ["MERS-CoV", "ORGANISM", 201, 209], ["MERS", "PROTEIN", 171, 175], ["MERS-CoV", "SPECIES", 201, 209], ["the differences in expression level", "PROBLEM", 19, 54], ["DNA vaccine", "TREATMENT", 121, 132], ["neutralizing antibody", "TEST", 141, 162], ["MERS", "PROBLEM", 171, 175], ["CoV", "PROBLEM", 206, 209], ["indirect ELISA", "TEST", 228, 242]]], ["Of the three DNA vaccines constructed, pcDNA3.1-S1 DNA vaccine elicited the highest antibody titer in immunized mice ( Fig. 2A) and thus was selected for further experiments.", [["DNA", "CELLULAR_COMPONENT", 13, 16], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 39, 45], ["DNA", "CELLULAR_COMPONENT", 51, 54], ["mice", "ORGANISM", 112, 116], ["pcDNA3", "DNA", 39, 45], ["mice", "SPECIES", 112, 116], ["mice", "SPECIES", 112, 116], ["the three DNA vaccines", "TREATMENT", 3, 25], ["pcDNA3", "TREATMENT", 39, 45], ["S1 DNA vaccine", "TREATMENT", 48, 62], ["the highest antibody titer", "TEST", 72, 98]]], ["The sera from pcDNA3.1-S1 immunized mice strongly reacted with MERS-CoV RBD protein after receiving the second and third immunizations, reaching endpoint titers up to 1:1280 (Fig. 2B) .", [["sera", "ANATOMY", 4, 8], ["sera", "ORGANISM_SUBSTANCE", 4, 8], ["pcDNA3.1", "ORGANISM", 14, 22], ["mice", "ORGANISM", 36, 40], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 63, 71], ["MERS-CoV RBD protein", "PROTEIN", 63, 83], ["mice", "SPECIES", 36, 40], ["mice", "SPECIES", 36, 40], ["MERS-CoV", "SPECIES", 63, 71], ["The sera", "TEST", 0, 8], ["pcDNA3", "TEST", 14, 20], ["CoV RBD protein", "PROBLEM", 68, 83], ["the second and third immunizations", "TREATMENT", 100, 134], ["endpoint titers", "TEST", 145, 160]]], ["As shown in Fig. 2B , no significant differences were observed between samples harvested 1 week and 2 weeks post the third immunization, indicating that the antibody response reached the plateau.", [["samples", "ANATOMY", 71, 78], ["significant differences", "PROBLEM", 25, 48], ["the third immunization", "TREATMENT", 113, 135], ["the antibody response", "TEST", 153, 174], ["no", "UNCERTAINTY", 22, 24], ["significant", "OBSERVATION_MODIFIER", 25, 36], ["plateau", "ANATOMY", 187, 194]]], ["To determine if the antibodies in the immune serum could neutralize MERS-CoV infection in vitro, a plaque reduction neutralizing assay was performed using serially diluted serum samples.", [["immune serum", "ANATOMY", 38, 50], ["plaque", "ANATOMY", 99, 105], ["serum samples", "ANATOMY", 172, 185], ["infection", "DISEASE", 77, 86], ["serum", "ORGANISM_SUBSTANCE", 45, 50], ["MERS-CoV", "ORGANISM", 68, 76], ["plaque", "PATHOLOGICAL_FORMATION", 99, 105], ["serum samples", "ORGANISM_SUBSTANCE", 172, 185], ["antibodies", "PROTEIN", 20, 30], ["MERS-CoV", "SPECIES", 68, 76], ["the antibodies", "TEST", 16, 30], ["the immune serum", "TEST", 34, 50], ["CoV infection", "PROBLEM", 73, 86], ["a plaque reduction neutralizing assay", "TREATMENT", 97, 134], ["serially diluted serum samples", "TEST", 155, 185], ["infection", "OBSERVATION", 77, 86], ["plaque", "OBSERVATION", 99, 105]]], ["The serum samples efficiently neutralized MERS-CoV infection in vitro even after 1: 10 4 dilution (Fig. 2C) .", [["serum samples", "ANATOMY", 4, 17], ["infection", "DISEASE", 51, 60], ["serum samples", "ORGANISM_SUBSTANCE", 4, 17], ["MERS-CoV", "ORGANISM", 42, 50], ["MERS-CoV", "SPECIES", 42, 50], ["The serum samples", "TEST", 0, 17], ["CoV infection", "PROBLEM", 47, 60]]], ["These results demonstrate that DNA vaccine encoding MERS-CoV S1 gene induced a potent neutralizing antibody response.DNA vaccine-induced antigen-specific cellular immune responsesAfter confirming that pcDNA3.1-S1 successfully induced antibody responses in mice, antigen-specific cellular immune responses were evaluated by ELISpot assays and intracellular cytokine staining (ICS) assays.", [["cellular", "ANATOMY", 154, 162], ["cellular", "ANATOMY", 279, 287], ["intracellular", "ANATOMY", 342, 355], ["DNA", "CELLULAR_COMPONENT", 31, 34], ["MERS-CoV S1", "GENE_OR_GENE_PRODUCT", 52, 63], ["DNA", "CELLULAR_COMPONENT", 117, 120], ["cellular", "CELL", 154, 162], ["pcDNA3.1-S1", "GENE_OR_GENE_PRODUCT", 201, 212], ["mice", "ORGANISM", 256, 260], ["antigen", "GENE_OR_GENE_PRODUCT", 262, 269], ["cellular", "CELL", 279, 287], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 342, 355], ["MERS-CoV S1 gene", "DNA", 52, 68], ["pcDNA3.1-S1", "DNA", 201, 212], ["mice", "SPECIES", 256, 260], ["MERS-CoV", "SPECIES", 52, 60], ["mice", "SPECIES", 256, 260], ["DNA vaccine", "TREATMENT", 31, 42], ["a potent neutralizing antibody response", "PROBLEM", 77, 116], ["DNA vaccine", "TEST", 117, 128], ["induced antigen", "PROBLEM", 129, 144], ["pcDNA3", "TREATMENT", 201, 207], ["antibody responses", "TEST", 234, 252], ["antigen", "TEST", 262, 269], ["ELISpot assays", "TEST", 323, 337], ["intracellular cytokine staining", "TEST", 342, 373], ["cellular immune", "OBSERVATION", 154, 169]]], ["Splenocytes were harvested at two weeks post the second immunization.", [["Splenocytes", "ANATOMY", 0, 11], ["Splenocytes", "CELL", 0, 11], ["Splenocytes", "CELL_TYPE", 0, 11], ["the second immunization", "TREATMENT", 45, 68], ["harvested", "OBSERVATION", 17, 26]]], ["We chose this time because the RBD-specific antibody response was first detected 1-2 weeks after the second immunization (Fig. 2B ).", [["RBD", "GENE_OR_GENE_PRODUCT", 31, 34], ["RBD", "PROTEIN", 31, 34], ["the RBD", "TEST", 27, 34], ["specific antibody response", "TEST", 35, 61], ["the second immunization", "TREATMENT", 97, 120]]], ["We speculated that T cell responses were also generated at the same time.", [["T cell", "ANATOMY", 19, 25], ["T cell", "CELL", 19, 25], ["T cell responses", "TEST", 19, 35]]], ["As expected, significantly more SFCs of both IFN-c and IL-4 were detected in splenocytes from pcDNA3.1-S1 treated mice ( Fig. 3A and B ) than controls.", [["splenocytes", "ANATOMY", 77, 88], ["IFN-c", "GENE_OR_GENE_PRODUCT", 45, 50], ["IL-4", "GENE_OR_GENE_PRODUCT", 55, 59], ["splenocytes", "CELL", 77, 88], ["pcDNA3.1-S1", "GENE_OR_GENE_PRODUCT", 94, 105], ["mice", "ORGANISM", 114, 118], ["B", "CELL", 133, 134], ["IFN", "PROTEIN", 45, 48], ["IL-4", "PROTEIN", 55, 59], ["splenocytes", "CELL_TYPE", 77, 88], ["mice", "SPECIES", 114, 118], ["mice", "SPECIES", 114, 118], ["SFCs", "TEST", 32, 36], ["IFN", "TEST", 45, 48], ["IL", "TEST", 55, 57], ["splenocytes", "TEST", 77, 88], ["splenocytes", "ANATOMY", 77, 88]]], ["The frequencies of IFN-c-expressing CD4 + and CD8 + T cells in the mice injected with pcDNA3.1-S1 was significantly higher after MERS RBD stimulation (Fig. 3C and D) , and similar results were observed for IL-4-expressing CD4 + and CD8 + T cells ( Fig. 3E and F) .", [["CD4 + and CD8 + T cells", "ANATOMY", 36, 59], ["CD4 + and CD8 + T cells", "ANATOMY", 222, 245], ["IFN-c-", "GENE_OR_GENE_PRODUCT", 19, 25], ["CD4", "GENE_OR_GENE_PRODUCT", 36, 39], ["CD8", "GENE_OR_GENE_PRODUCT", 46, 49], ["mice", "ORGANISM", 67, 71], ["pcDNA3.1-S1", "GENE_OR_GENE_PRODUCT", 86, 97], ["IL-4", "GENE_OR_GENE_PRODUCT", 206, 210], ["CD4", "GENE_OR_GENE_PRODUCT", 222, 225], ["CD8", "GENE_OR_GENE_PRODUCT", 232, 235], ["IFN", "PROTEIN", 19, 22], ["CD4", "PROTEIN", 36, 39], ["CD8 + T cells", "CELL_TYPE", 46, 59], ["pcDNA3.1", "DNA", 86, 94], ["RBD", "PROTEIN", 134, 137], ["IL-4", "PROTEIN", 206, 210], ["CD4", "PROTEIN", 222, 225], ["CD8", "PROTEIN", 232, 235], ["T cells", "CELL_TYPE", 238, 245], ["mice", "SPECIES", 67, 71], ["mice", "SPECIES", 67, 71], ["IFN", "TEST", 19, 22], ["CD4", "TEST", 36, 39], ["CD8", "TEST", 46, 49], ["T cells", "PROBLEM", 52, 59], ["MERS RBD stimulation", "TEST", 129, 149], ["Fig. 3C and D)", "TEST", 151, 165], ["IL", "TEST", 206, 208], ["CD4", "TEST", 222, 225], ["CD8", "TEST", 232, 235]]], ["These results demonstrate that the pcDNA3.1-S1 DNA vaccine markedly increased the frequencies of antigenspecific CD4 + and CD8 + T cells.DNA vaccine-enhanced splenocyte cytokine secretionTo further investigate the antigen-specific cellular immune responses induced by pcDNA3.1-S1 DNA vaccine, cytokines secreted by splenocytes were assayed by ELISA.", [["antigenspecific CD4 + and CD8 + T cells", "ANATOMY", 97, 136], ["splenocyte", "ANATOMY", 158, 168], ["cellular", "ANATOMY", 231, 239], ["splenocytes", "ANATOMY", 315, 326], ["pcDNA3.1-S1", "GENE_OR_GENE_PRODUCT", 35, 46], ["DNA", "CELLULAR_COMPONENT", 47, 50], ["CD4", "GENE_OR_GENE_PRODUCT", 113, 116], ["CD8", "GENE_OR_GENE_PRODUCT", 123, 126], ["DNA", "CELLULAR_COMPONENT", 137, 140], ["splenocyte", "CELL", 158, 168], ["cellular", "CELL", 231, 239], ["pcDNA3.1-S1", "GENE_OR_GENE_PRODUCT", 268, 279], ["DNA", "CELLULAR_COMPONENT", 280, 283], ["splenocytes", "CELL", 315, 326], ["pcDNA3.1", "DNA", 35, 43], ["antigenspecific CD4 + and CD8 + T cells", "CELL_TYPE", 97, 136], ["splenocyte cytokine", "PROTEIN", 158, 177], ["cytokines", "PROTEIN", 293, 302], ["splenocytes", "CELL_TYPE", 315, 326], ["the pcDNA3.1-S1 DNA vaccine", "TEST", 31, 58], ["antigenspecific CD4", "TEST", 97, 116], ["CD8 + T cells", "PROBLEM", 123, 136], ["DNA vaccine", "TEST", 137, 148], ["enhanced splenocyte cytokine secretionTo", "TEST", 149, 189], ["the antigen", "TEST", 210, 221], ["S1 DNA vaccine", "TREATMENT", 277, 291], ["increased", "OBSERVATION_MODIFIER", 68, 77], ["T cells", "OBSERVATION", 129, 136], ["splenocyte", "ANATOMY", 158, 168]]], ["Levels of IL-2, IL-4, IL-10 and IFN-c of splenocytes in pcDNA3.1-S1 immunized group were all significantly higher than those in the controls (Fig. 4A-D) .", [["splenocytes", "ANATOMY", 41, 52], ["IL-2", "GENE_OR_GENE_PRODUCT", 10, 14], ["IL-4", "GENE_OR_GENE_PRODUCT", 16, 20], ["IL-10", "GENE_OR_GENE_PRODUCT", 22, 27], ["IFN-c", "GENE_OR_GENE_PRODUCT", 32, 37], ["splenocytes", "CELL", 41, 52], ["pcDNA3.1", "ORGANISM", 56, 64], ["IFN", "PROTEIN", 32, 35], ["splenocytes", "CELL_TYPE", 41, 52], ["Levels", "TEST", 0, 6], ["IL", "TEST", 10, 12], ["IL", "TEST", 16, 18], ["IL", "TEST", 22, 24], ["IFN", "TEST", 32, 35], ["splenocytes", "PROBLEM", 41, 52], ["pcDNA3", "TEST", 56, 62], ["splenocytes", "ANATOMY", 41, 52]]], ["These data demonstrate that pcDNA3.1-S1 DNA vaccine enhanced the secretion of both type 1 cytokines such as IL-2 and IFN-c, and type 2 cytokines such as IL-4 and IL-10 in splenocytes.Protection of MERS-CoV infected Ad5-hDPP4-transduced mice by DNA vaccine or immune serum transferThe Ad5-hDPP4-transduced mouse model was used to evaluate the protective immunity of the DNA vaccine and the efficacy of immune serum containing neutralizing antibodies against MERS-CoV as determined by virus load in the infected lungs.", [["splenocytes", "ANATOMY", 171, 182], ["serum", "ANATOMY", 266, 271], ["immune serum", "ANATOMY", 401, 413], ["lungs", "ANATOMY", 510, 515], ["pcDNA3.1-S1", "GENE_OR_GENE_PRODUCT", 28, 39], ["DNA", "CELLULAR_COMPONENT", 40, 43], ["IL-2", "GENE_OR_GENE_PRODUCT", 108, 112], ["IFN-c", "GENE_OR_GENE_PRODUCT", 117, 122], ["IL-4", "GENE_OR_GENE_PRODUCT", 153, 157], ["IL-10", "GENE_OR_GENE_PRODUCT", 162, 167], ["splenocytes", "CELL", 171, 182], ["MERS-CoV", "ORGANISM", 197, 205], ["Ad5", "ORGANISM", 215, 218], ["hDPP4", "GENE_OR_GENE_PRODUCT", 219, 224], ["mice", "ORGANISM", 236, 240], ["DNA", "CELLULAR_COMPONENT", 244, 247], ["serum", "ORGANISM_SUBSTANCE", 266, 271], ["Ad5", "GENE_OR_GENE_PRODUCT", 284, 287], ["hDPP4", "GENE_OR_GENE_PRODUCT", 288, 293], ["mouse", "ORGANISM", 305, 310], ["DNA", "CELLULAR_COMPONENT", 369, 372], ["serum", "ORGANISM_SUBSTANCE", 408, 413], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 457, 465], ["lungs", "ORGAN", 510, 515], ["type 1 cytokines", "PROTEIN", 83, 99], ["IL", "PROTEIN", 108, 110], ["IFN", "PROTEIN", 117, 120], ["type 2 cytokines", "PROTEIN", 128, 144], ["IL-4", "PROTEIN", 153, 157], ["IL-10", "PROTEIN", 162, 167], ["splenocytes", "CELL_TYPE", 171, 182], ["hDPP4", "PROTEIN", 219, 224], ["hDPP4", "PROTEIN", 288, 293], ["neutralizing antibodies", "PROTEIN", 425, 448], ["MERS-CoV", "PROTEIN", 457, 465], ["mice", "SPECIES", 236, 240], ["mouse", "SPECIES", 305, 310], ["MERS-CoV", "SPECIES", 197, 205], ["Ad5", "SPECIES", 215, 218], ["mice", "SPECIES", 236, 240], ["Ad5", "SPECIES", 284, 287], ["mouse", "SPECIES", 305, 310], ["MERS-CoV", "SPECIES", 457, 465], ["These data", "TEST", 0, 10], ["pcDNA3.1", "PROBLEM", 28, 36], ["S1 DNA vaccine", "TREATMENT", 37, 51], ["IL", "TEST", 108, 110], ["IFN", "TEST", 117, 120], ["type 2 cytokines", "PROBLEM", 128, 144], ["IL", "TEST", 153, 155], ["IL", "TEST", 162, 164], ["MERS", "PROBLEM", 197, 201], ["CoV infected Ad5", "TREATMENT", 202, 218], ["transduced mice", "TREATMENT", 225, 240], ["DNA vaccine", "TREATMENT", 244, 255], ["immune serum transfer", "TREATMENT", 259, 280], ["The Ad5", "TEST", 280, 287], ["transduced mouse model", "TREATMENT", 294, 316], ["the DNA vaccine", "TREATMENT", 365, 380], ["immune serum", "TEST", 401, 413], ["neutralizing antibodies", "TEST", 425, 448], ["MERS", "PROBLEM", 457, 461], ["CoV", "PROBLEM", 462, 465], ["splenocytes", "ANATOMY", 171, 182], ["infected", "OBSERVATION", 501, 509], ["lungs", "ANATOMY", 510, 515]]], ["Both the pcDNA3.1-S1 DNA vaccine and immune serum from pcDNA3.1-S1 vaccinated mice accelerated virus clearance.", [["immune serum", "ANATOMY", 37, 49], ["pcDNA3.1-S1", "GENE_OR_GENE_PRODUCT", 9, 20], ["DNA", "CELLULAR_COMPONENT", 21, 24], ["immune serum", "ORGANISM_SUBSTANCE", 37, 49], ["pcDNA3.1-S1", "ORGANISM", 55, 66], ["mice", "ORGANISM", 78, 82], ["pcDNA3.1", "DNA", 9, 17], ["mice", "SPECIES", 78, 82], ["mice", "SPECIES", 78, 82], ["S1 DNA vaccine", "TREATMENT", 18, 32], ["immune serum", "TEST", 37, 49], ["pcDNA3", "TEST", 55, 61], ["S1 vaccinated mice accelerated virus clearance", "TREATMENT", 64, 110]]], ["By day 3, virus titers had decreased 1-2 logs and by day 5, virus had been cleared in both groups ( Fig. 5A and B) .DiscussionHere, we aimed to develop a new vaccine able to elicit potent immune responses against MERS-CoV infection.", [["MERS-CoV infection", "DISEASE", 213, 231], ["MERS-CoV", "ORGANISM", 213, 221], ["MERS-CoV", "SPECIES", 213, 221], ["virus titers", "TEST", 10, 22], ["virus", "PROBLEM", 60, 65], ["a new vaccine", "TREATMENT", 152, 165], ["MERS", "PROBLEM", 213, 217], ["CoV infection", "PROBLEM", 218, 231], ["infection", "OBSERVATION", 222, 231]]], ["Considering that currently no studies have compared the immunogenicity of different S gene fragments in MERS DNA vaccines, we choose three mutants of MERS-CoV S protein as antigens: full-length S, SDCD, and extracellular domain S1.", [["extracellular", "ANATOMY", 207, 220], ["DNA", "CELLULAR_COMPONENT", 109, 112], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 150, 160], ["SDCD", "GENE_OR_GENE_PRODUCT", 197, 201], ["extracellular domain S1", "GENE_OR_GENE_PRODUCT", 207, 230], ["S gene fragments", "DNA", 84, 100], ["MERS-CoV S protein", "PROTEIN", 150, 168], ["antigens", "PROTEIN", 172, 180], ["full-length S", "PROTEIN", 182, 195], ["SDCD", "PROTEIN", 197, 201], ["extracellular domain S1", "PROTEIN", 207, 230], ["MERS-CoV", "SPECIES", 150, 158], ["studies", "TEST", 30, 37], ["different S gene fragments", "PROBLEM", 74, 100], ["MERS DNA vaccines", "TREATMENT", 104, 121], ["CoV S protein", "TEST", 155, 168], ["SDCD, and extracellular domain S1", "PROBLEM", 197, 230], ["S1", "ANATOMY", 228, 230]]], ["Of the three DNA vaccines (pcDNA3.1-S, pcDNA3.1-SDCD, and pcDNA3.1-S1) constructed, pcDNA3.1-S1 DNA vaccine was selected for further study since it elicited the highest antibody titer in immunized mice and contained major neutralizing epitopes [27] , which made it an effective and safe target for MERS vaccine development.", [["DNA", "CELLULAR_COMPONENT", 13, 16], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 27, 33], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 39, 45], ["1-SDCD", "GENE_OR_GENE_PRODUCT", 46, 52], ["pcDNA3.1-S1", "GENE_OR_GENE_PRODUCT", 58, 69], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 84, 90], ["DNA", "CELLULAR_COMPONENT", 96, 99], ["mice", "ORGANISM", 197, 201], ["pcDNA3", "DNA", 27, 33], ["1-S, pcDNA3", "DNA", 34, 45], ["SDCD", "DNA", 48, 52], ["pcDNA3.1", "DNA", 58, 66], ["S1", "DNA", 67, 69], ["pcDNA3", "DNA", 84, 90], ["mice", "SPECIES", 197, 201], ["mice", "SPECIES", 197, 201], ["the three DNA vaccines", "TREATMENT", 3, 25], ["pcDNA3", "TREATMENT", 27, 33], ["pcDNA3", "TREATMENT", 39, 45], ["pcDNA3", "TREATMENT", 84, 90], ["S1 DNA vaccine", "TREATMENT", 93, 107], ["further study", "TEST", 125, 138], ["major neutralizing epitopes", "PROBLEM", 216, 243], ["MERS vaccine development", "TREATMENT", 298, 322]]], ["Similar to our DNAbased vaccine, an adenovirus 5 (Ad5) vector-based vaccine, Ad5.", [["adenovirus 5", "ORGANISM", 36, 48], ["Ad5", "ORGANISM", 50, 53], ["Ad5", "ORGANISM", 77, 80], ["Ad5", "SPECIES", 50, 53], ["Ad5", "SPECIES", 77, 80], ["our DNAbased vaccine", "TREATMENT", 11, 31], ["an adenovirus", "TREATMENT", 33, 46], ["Ad5) vector-based vaccine", "TREATMENT", 50, 75]]], ["MERS-S1 expressing the MERS-CoV S1 extracellular domain, induced stronger neutralizing antibody responses when compared to the vector expressing full-length S [8] .", [["MERS-S1", "GENE_OR_GENE_PRODUCT", 0, 7], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 23, 31], ["MERS-S1", "PROTEIN", 0, 7], ["MERS-CoV S1 extracellular domain", "PROTEIN", 23, 55], ["MERS-CoV", "SPECIES", 23, 31], ["CoV S1 extracellular domain", "PROBLEM", 28, 55], ["induced stronger neutralizing antibody responses", "PROBLEM", 57, 105]]], ["This may be because the S1 fragment that can induce humoral immune responses more efficiently than full length S since it is soluble and can easily be taken up by B cells in lymph node follicles [34] [35] [36] [37] [38] .", [["B cells", "ANATOMY", 163, 170], ["lymph node follicles", "ANATOMY", 174, 194], ["B cells", "CELL", 163, 170], ["lymph node follicles", "MULTI-TISSUE_STRUCTURE", 174, 194], ["S1 fragment", "DNA", 24, 35], ["B cells", "CELL_TYPE", 163, 170], ["the S1 fragment", "PROBLEM", 20, 35], ["lymph node follicles", "TEST", 174, 194], ["S1", "ANATOMY", 24, 26], ["fragment", "OBSERVATION", 27, 35], ["lymph node follicles", "OBSERVATION", 174, 194]]], ["Of note, pcDNA3.1-SDCD immunization induced a slightly higher antibody response in mice than did pcDNA3.1-S, possibly because the SDCD mutant still contains the transmembrane region anchoring the S protein to the membrane.", [["transmembrane", "ANATOMY", 161, 174], ["membrane", "ANATOMY", 213, 221], ["1-S", "CHEMICAL", 104, 107], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 9, 15], ["SDCD", "GENE_OR_GENE_PRODUCT", 18, 22], ["mice", "ORGANISM", 83, 87], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 97, 103], ["SDCD", "GENE_OR_GENE_PRODUCT", 130, 134], ["transmembrane", "CELLULAR_COMPONENT", 161, 174], ["membrane", "CELLULAR_COMPONENT", 213, 221], ["pcDNA3", "DNA", 97, 103], ["SDCD mutant", "PROTEIN", 130, 141], ["transmembrane region", "PROTEIN", 161, 181], ["S protein", "PROTEIN", 196, 205], ["mice", "SPECIES", 83, 87], ["mice", "SPECIES", 83, 87], ["pcDNA3", "TREATMENT", 9, 15], ["SDCD immunization", "TREATMENT", 18, 35], ["a slightly higher antibody response", "PROBLEM", 44, 79], ["the SDCD mutant", "PROBLEM", 126, 141], ["transmembrane", "ANATOMY_MODIFIER", 161, 174], ["membrane", "ANATOMY_MODIFIER", 213, 221]]], ["Previous studies have shown that partial or complete removal of the SARS-CoV S cytoplasmic domain, or removal of the transmembrane domain along with the cytoplasmic domain from a DNA vaccine candidate increased the neutralizing antibody response in mice, indicating that removal of the cytoplasmic domain may result in a more native and more functionally relevant structure in vivo [38] .", [["cytoplasmic", "ANATOMY", 79, 90], ["transmembrane", "ANATOMY", 117, 130], ["cytoplasmic", "ANATOMY", 153, 164], ["cytoplasmic", "ANATOMY", 286, 297], ["SARS", "DISEASE", 68, 72], ["cytoplasmic", "ORGANISM_SUBSTANCE", 79, 90], ["transmembrane", "CELLULAR_COMPONENT", 117, 130], ["cytoplasmic", "ORGANISM_SUBSTANCE", 153, 164], ["DNA", "CELLULAR_COMPONENT", 179, 182], ["mice", "ORGANISM", 249, 253], ["cytoplasmic", "ORGANISM_SUBSTANCE", 286, 297], ["SARS-CoV S cytoplasmic domain", "PROTEIN", 68, 97], ["transmembrane domain", "PROTEIN", 117, 137], ["cytoplasmic domain", "PROTEIN", 153, 171], ["cytoplasmic domain", "PROTEIN", 286, 304], ["mice", "SPECIES", 249, 253], ["mice", "SPECIES", 249, 253], ["Previous studies", "TEST", 0, 16], ["the SARS", "PROBLEM", 64, 72], ["CoV S cytoplasmic domain", "PROBLEM", 73, 97], ["removal", "TREATMENT", 102, 109], ["the transmembrane domain", "PROBLEM", 113, 137], ["the cytoplasmic domain", "PROBLEM", 149, 171], ["a DNA vaccine", "TREATMENT", 177, 190], ["removal", "TREATMENT", 271, 278], ["the cytoplasmic domain", "PROBLEM", 282, 304], ["partial", "OBSERVATION_MODIFIER", 33, 40]]], ["We considered that besides the influence of expression level differences, such modifications of the MERS-CoV S protein may also be responsible for the increased generation of a neutralizing antibody response.DiscussionOur data show that the pcDNA3.1-S1 DNA vaccine induced antigen-specific immune responses (IgG production, neutralizing antibodies generation, and cytokines secretion) in mice.", [["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 100, 110], ["pcDNA3.1-S1", "GENE_OR_GENE_PRODUCT", 241, 252], ["DNA", "CELLULAR_COMPONENT", 253, 256], ["antigen", "GENE_OR_GENE_PRODUCT", 273, 280], ["IgG", "GENE_OR_GENE_PRODUCT", 308, 311], ["mice", "ORGANISM", 388, 392], ["MERS-CoV S protein", "PROTEIN", 100, 118], ["IgG", "PROTEIN", 308, 311], ["neutralizing antibodies", "PROTEIN", 324, 347], ["cytokines", "PROTEIN", 364, 373], ["mice", "SPECIES", 388, 392], ["MERS-CoV", "SPECIES", 100, 108], ["mice", "SPECIES", 388, 392], ["expression level differences", "PROBLEM", 44, 72], ["CoV S protein", "TREATMENT", 105, 118], ["a neutralizing antibody response", "PROBLEM", 175, 207], ["DiscussionOur data", "TEST", 208, 226], ["the pcDNA3.1", "TREATMENT", 237, 249], ["S1 DNA vaccine", "TREATMENT", 250, 264], ["antigen", "TEST", 273, 280], ["specific immune responses", "PROBLEM", 281, 306], ["IgG production", "TEST", 308, 322], ["neutralizing antibodies generation", "TREATMENT", 324, 358], ["cytokines secretion", "TEST", 364, 383]]], ["High levels of neutralizing antibodies were generated following three immunizations without adjuvant.", [["neutralizing antibodies", "PROTEIN", 15, 38], ["High levels of neutralizing antibodies", "PROBLEM", 0, 38], ["three immunizations", "TREATMENT", 64, 83], ["adjuvant", "TREATMENT", 92, 100], ["neutralizing antibodies", "OBSERVATION", 15, 38]]], ["Furthermore, both pcDNA3.1-S1 DNA vaccination and administration of immune serum from pcDNA3.1-S1 vaccinated mice accelerated virus clearance in the lungs, suggesting that neutralizing antibodies against MERS-CoV S1 protein were protective and the immune serum transfer did not mediate an antibody-dependent enhancement of infection in this Ad5-hDPP4-transduced mouse model (Fig. 5B) .", [["immune serum", "ANATOMY", 68, 80], ["lungs", "ANATOMY", 149, 154], ["immune serum", "ANATOMY", 248, 260], ["infection", "DISEASE", 323, 332], ["pcDNA3.1-S1", "GENE_OR_GENE_PRODUCT", 18, 29], ["DNA", "CELLULAR_COMPONENT", 30, 33], ["serum", "ORGANISM_SUBSTANCE", 75, 80], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 86, 92], ["mice", "ORGANISM", 109, 113], ["lungs", "ORGAN", 149, 154], ["MERS-CoV S1", "GENE_OR_GENE_PRODUCT", 204, 215], ["serum", "ORGANISM_SUBSTANCE", 255, 260], ["Ad5", "ORGANISM", 341, 344], ["hDPP4", "GENE_OR_GENE_PRODUCT", 345, 350], ["mouse", "ORGANISM", 362, 367], ["pcDNA3.1", "DNA", 18, 26], ["pcDNA3", "DNA", 86, 92], ["neutralizing antibodies", "PROTEIN", 172, 195], ["MERS-CoV S1 protein", "PROTEIN", 204, 223], ["hDPP4", "PROTEIN", 345, 350], ["mice", "SPECIES", 109, 113], ["mouse", "SPECIES", 362, 367], ["mice", "SPECIES", 109, 113], ["MERS-CoV", "SPECIES", 204, 212], ["Ad5", "SPECIES", 341, 344], ["mouse", "SPECIES", 362, 367], ["S1 DNA vaccination", "TREATMENT", 27, 45], ["immune serum from pcDNA3", "TREATMENT", 68, 92], ["S1 vaccinated mice accelerated virus clearance in the lungs", "PROBLEM", 95, 154], ["neutralizing antibodies", "TEST", 172, 195], ["MERS", "PROBLEM", 204, 208], ["CoV S1 protein", "TEST", 209, 223], ["the immune serum transfer", "TEST", 244, 269], ["an antibody", "TEST", 286, 297], ["dependent enhancement of infection", "PROBLEM", 298, 332], ["this Ad5", "TREATMENT", 336, 344], ["hDPP4", "TEST", 345, 350], ["virus", "OBSERVATION", 126, 131], ["lungs", "ANATOMY", 149, 154], ["neutralizing", "OBSERVATION", 172, 184], ["infection", "OBSERVATION", 323, 332]]], ["We chose 12 days post the third immunization to challenge our mice because we just had limited access to BSL-3 labs, and we speculated that since the antibody response reached the plateau and T cell response is probably at the peak at this time point as well, they would not diminish so quickly after the third immunization.", [["T cell", "ANATOMY", 192, 198], ["mice", "ORGANISM", 62, 66], ["BSL-3", "GENE_OR_GENE_PRODUCT", 105, 110], ["T cell", "CELL", 192, 198], ["mice", "SPECIES", 62, 66], ["mice", "SPECIES", 62, 66], ["the third immunization", "TREATMENT", 22, 44], ["BSL", "TEST", 105, 108], ["labs", "TEST", 111, 115], ["the antibody response", "TEST", 146, 167], ["the third immunization", "TREATMENT", 301, 323], ["cell response", "OBSERVATION", 194, 207]]], ["Long-term protection experiments are still required to evaluate the efficacy of this vaccine.DiscussionSince the emergence of MERS in 2012, some adaptive evolution of MERS-CoV strains has been reported [39, 40] .", [["MERS-CoV", "ORGANISM", 167, 175], ["MERS-CoV", "SPECIES", 167, 175], ["Long-term protection experiments", "TREATMENT", 0, 32], ["this vaccine", "TREATMENT", 80, 92], ["MERS", "PROBLEM", 167, 171], ["CoV strains", "PROBLEM", 172, 183]]], ["In the current study, the MERS-CoV S gene sequence from the Al-Hasa_15_2013 strain was selected for its high homology with other published strains.", [["MERS-CoV S gene sequence", "DNA", 26, 50], ["Al", "DNA", 60, 62], ["Al-Hasa_15_2013 strain", "SPECIES", 60, 82], ["the current study", "TEST", 3, 20]]], ["It is worth noting that in challenge experiments, DNA vaccine immunization protected mice infected with the MERS-CoV EMC strain, indicating that the pcDNA3.1-S1 DNA vaccine did indeed induce protective immunity against different MERS-CoV strains.DiscussionOverall, we constructed and examined a DNA vaccine encoding MERS-CoV S1 protein in this study.", [["DNA", "CELLULAR_COMPONENT", 50, 53], ["mice", "ORGANISM", 85, 89], ["MERS-CoV EMC", "ORGANISM", 108, 120], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 149, 157], ["DNA", "CELLULAR_COMPONENT", 161, 164], ["MERS-CoV strains", "ORGANISM", 229, 245], ["DNA", "CELLULAR_COMPONENT", 295, 298], ["MERS-CoV S1", "GENE_OR_GENE_PRODUCT", 316, 327], ["MERS-CoV S1 protein", "PROTEIN", 316, 335], ["mice", "SPECIES", 85, 89], ["mice", "SPECIES", 85, 89], ["MERS-CoV", "SPECIES", 108, 116], ["MERS-CoV", "SPECIES", 229, 237], ["MERS-CoV", "SPECIES", 316, 324], ["challenge experiments", "TREATMENT", 27, 48], ["DNA vaccine immunization", "TREATMENT", 50, 74], ["CoV EMC strain", "PROBLEM", 113, 127], ["the pcDNA3.1-S1 DNA vaccine", "TREATMENT", 145, 172], ["CoV strains", "PROBLEM", 234, 245], ["a DNA vaccine", "TREATMENT", 293, 306], ["this study", "TEST", 339, 349]]], ["Our data clearly demonstrate that the pcDNA3.1-S1 DNA vaccine induced a potent and protective immune response in mice, with the vaccinated animals showing no visible signs of adverse effects.", [["pcDNA3.1-S1", "GENE_OR_GENE_PRODUCT", 38, 49], ["DNA", "CELLULAR_COMPONENT", 50, 53], ["mice", "ORGANISM", 113, 117], ["mice", "SPECIES", 113, 117], ["mice", "SPECIES", 113, 117], ["Our data", "TEST", 0, 8], ["the pcDNA3.1-S1 DNA vaccine", "TREATMENT", 34, 61], ["the vaccinated animals", "TEST", 124, 146], ["adverse effects", "PROBLEM", 175, 190], ["no", "UNCERTAINTY", 155, 157]]], ["While the protective efficacy evaluation of pcDNA3.1-S1 DNA vaccine in non-human primates as well as camels must be considered in a future study, our results strongly support the use of the S1 protein of MERS-CoV for genebased vaccine development, as an effective target able to elicit antigen-specific humoral and cellular immune responses.Author contributionsSY, JZ and XX designed the experiments.", [["cellular", "ANATOMY", 315, 323], ["pcDNA3.1-S1", "GENE_OR_GENE_PRODUCT", 44, 55], ["DNA", "CELLULAR_COMPONENT", 56, 59], ["non-human primates", "ORGANISM", 71, 89], ["camels", "ORGANISM", 101, 107], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 204, 212], ["cellular", "CELL", 315, 323], ["pcDNA3.1", "DNA", 44, 52], ["S1 protein", "PROTEIN", 190, 200], ["MERS", "PROTEIN", 204, 208], ["MERS-CoV", "SPECIES", 204, 212], ["the protective efficacy evaluation", "TEST", 6, 40], ["pcDNA3.1-S1 DNA vaccine", "TREATMENT", 44, 67], ["a future study", "TEST", 130, 144], ["genebased vaccine development", "TREATMENT", 217, 246], ["antigen", "TEST", 286, 293]]], ["HC, XW, JZ, CW, WG and SP performed the experiment.", [["HC", "TEST", 0, 2]]], ["HC, JZ, HW and SP analyzed the data.", [["HC", "TEST", 0, 2]]]], "PMC7438977": [["Greater Healthcare NeedsChildren with developmental disabilities have higher healthcare needs compared to typically developing children.", [["developmental disabilities", "DISEASE", 38, 64], ["children", "ORGANISM", 127, 135], ["children", "SPECIES", 127, 135]]], ["This includes (1) higher prevalence of other medical conditions such as asthma, food and skin allergies and headaches (2) greater healthcare use and (3) greater burden of their illness on daily-life (such as in mobility and adaptive skills).(Schieve et al. 2012; Oeseburg et al. 2010) Yet these children have greater barriers in accessing healthcare due to an inadequate number of trained specialists, socio-economic status related disparities in access, complex medical comorbidities and barriers of geographical distances.(Soares and Langkamp 2012; Dougherty et al. 2006) Wait times for seeing a developmental behavioral pediatrician (DBP) average between 6 months and 1 year in most countries.(Schieve et al. 2012) These barriers are at risk of being heightened amidst the pandemic due to curtailment of non-critical medical care to preserve health system capacities for patients with COVID-19 and to also alleviate the risk of exposure to the virus.Greater Healthcare NeedsEven as the DBP community endeavors to use telehealth to continue care, this poses its own challenges.", [["skin", "ANATOMY", 89, 93], ["asthma", "DISEASE", 72, 78], ["food and skin allergies", "DISEASE", 80, 103], ["headaches", "DISEASE", 108, 117], ["illness", "DISEASE", 177, 184], ["COVID-19", "CHEMICAL", 888, 896], ["skin", "ORGAN", 89, 93], ["children", "ORGANISM", 295, 303], ["patients", "ORGANISM", 874, 882], ["children", "SPECIES", 295, 303], ["patients", "SPECIES", 874, 882], ["other medical conditions", "PROBLEM", 39, 63], ["asthma", "PROBLEM", 72, 78], ["food and skin allergies", "PROBLEM", 80, 103], ["headaches", "PROBLEM", 108, 117], ["complex medical comorbidities", "PROBLEM", 455, 484], ["non-critical medical care", "TREATMENT", 807, 832], ["COVID", "TEST", 888, 893], ["the virus", "PROBLEM", 943, 952], ["care", "TREATMENT", 1043, 1047], ["asthma", "OBSERVATION", 72, 78], ["skin", "ANATOMY", 89, 93], ["allergies", "OBSERVATION", 94, 103]]], ["Diagnostic evaluation in children with developmental disabilities often require close interaction and rapport building with the child.", [["developmental disabilities", "DISEASE", 39, 65], ["children", "ORGANISM", 25, 33], ["child", "ORGANISM", 128, 133], ["children", "SPECIES", 25, 33], ["Diagnostic evaluation", "TEST", 0, 21], ["developmental disabilities", "PROBLEM", 39, 65]]], ["The time sensitive nature of diagnosis with earlier commencement of early intervention being a consistent outcome predictor, (Hedvall et al. 2015) makes these delays in access to healthcare all the more concerning.", [["early intervention", "TREATMENT", 68, 86]]], ["Given the lifelong morbidity of developmental disabilities, such delays will arguably be against the best interests of these children.Dependency on Community-Based ServicesChildren with developmental disabilities receive therapy and support from intervention services at specialized centers as well as in schools.", [["developmental disabilities", "DISEASE", 32, 58], ["developmental disabilities", "DISEASE", 186, 212], ["children", "ORGANISM", 125, 133], ["children", "SPECIES", 125, 133], ["developmental disabilities", "PROBLEM", 32, 58], ["developmental disabilities", "TREATMENT", 186, 212], ["therapy", "TREATMENT", 221, 228], ["intervention services", "TREATMENT", 246, 267]]], ["Consistency and intensity of intervention is key.", [["intervention", "TREATMENT", 29, 41]]], ["This is why children often continue to receive therapy during school vacations.", [["children", "ORGANISM", 12, 20], ["children", "SPECIES", 12, 20], ["therapy", "TREATMENT", 47, 54]]], ["COVID-19 related curtailment of services within the community and school closures limits the provision of continued intervention services, including that of home-based therapy.", [["continued intervention services", "TREATMENT", 106, 137], ["home-based therapy", "TREATMENT", 157, 175]]], ["Video conferencing and telemedicine are being widely used to facilitate learning and therapy from home.", [["telemedicine", "TREATMENT", 23, 35], ["therapy", "TREATMENT", 85, 92]]], ["However, children with impairments in communication, attention and/or coordination, require specific accommodations to participate and learn effectively.(Ingersoll and Berger 2015) Within the home environment, caregivers may struggle to provide the same level of academic support without the training and expertise of an educator.", [["children", "ORGANISM", 9, 17], ["children", "SPECIES", 9, 17], ["academic support", "TREATMENT", 263, 279]]], ["Children with certain developmental disabilities like autism spectrum disorder (ASD) may also lack the cognitive flexibility to understand that parents are trying to play the role of their teachers or therapists and thus be less compliant.", [["developmental disabilities", "DISEASE", 22, 48], ["autism spectrum disorder", "DISEASE", 54, 78], ["ASD", "DISEASE", 80, 83], ["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8], ["certain developmental disabilities", "PROBLEM", 14, 48], ["autism spectrum disorder", "PROBLEM", 54, 78]]], ["Further, families with limited access to technological infrastructure and the internet, risk being cut off from support services.Mental Health ConcernsChildren with developmental disabilities may be less resilient to the mental health effects of the pandemic.", [["developmental disabilities", "DISEASE", 165, 191], ["support services", "TREATMENT", 112, 128], ["developmental disabilities", "PROBLEM", 165, 191], ["the pandemic", "PROBLEM", 246, 258]]], ["Mental health disorders such as generalized anxiety disorder, phobias, obsessive compulsive disorder (OCD), mood disorder and psychotic disorder are more common in persons with developmental disabilities compared to the general population.(de Bruin et al. 2007; Merikangas et al. 2015) Evidence has emerged illustrating an increase in levels of anxiety and depression among children in the general population during this pandemic compared to pre-pandemic times.(Duan et al. 2020) Fear of physical illness and home confinement with social isolation were cited as contributing factors.", [["Mental health disorders", "DISEASE", 0, 23], ["anxiety disorder", "DISEASE", 44, 60], ["phobias", "DISEASE", 62, 69], ["obsessive compulsive disorder", "DISEASE", 71, 100], ["OCD", "DISEASE", 102, 105], ["mood disorder", "DISEASE", 108, 121], ["psychotic disorder", "DISEASE", 126, 144], ["developmental disabilities", "DISEASE", 177, 203], ["anxiety", "DISEASE", 345, 352], ["depression", "DISEASE", 357, 367], ["Fear of physical illness", "DISEASE", 480, 504], ["persons", "ORGANISM", 164, 171], ["children", "ORGANISM", 374, 382], ["persons", "SPECIES", 164, 171], ["children", "SPECIES", 374, 382], ["Mental health disorders", "PROBLEM", 0, 23], ["generalized anxiety disorder", "PROBLEM", 32, 60], ["phobias", "PROBLEM", 62, 69], ["obsessive compulsive disorder", "PROBLEM", 71, 100], ["mood disorder", "PROBLEM", 108, 121], ["psychotic disorder", "PROBLEM", 126, 144], ["developmental disabilities", "PROBLEM", 177, 203], ["anxiety", "PROBLEM", 345, 352], ["depression", "PROBLEM", 357, 367], ["physical illness", "PROBLEM", 488, 504], ["social isolation", "TREATMENT", 531, 547], ["increase", "OBSERVATION_MODIFIER", 323, 331]]], ["Children with developmental disabilities are likely to be even more vulnerable to the negative mental health consequences of the pandemic as they may have limitations in understanding the rationale for pandemic-related changes such as disruptions to routine and school closures.", [["developmental disabilities", "DISEASE", 14, 40], ["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8], ["developmental disabilities", "PROBLEM", 14, 40], ["pandemic", "PROBLEM", 202, 210], ["routine and school closures", "TREATMENT", 250, 277]]], ["Specifically, children with OCD are susceptible to an increase in compulsive behaviors such as prolonged hand-washing fueled by the sudden emphasis on personal hygiene and anxiety over disease acquisition; this has recently been shown in adults with OCD.(Shafran et al. 2020; Davide et al. 2020) Further, a lack of access to psychologists and therapists during the pandemic, can contribute to worsening mental health status in these children.", [["hand", "ANATOMY", 105, 109], ["OCD", "DISEASE", 28, 31], ["compulsive behaviors", "DISEASE", 66, 86], ["anxiety", "DISEASE", 172, 179], ["OCD", "DISEASE", 250, 253], ["children", "ORGANISM", 14, 22], ["children", "ORGANISM", 433, 441], ["children", "SPECIES", 14, 22], ["children", "SPECIES", 433, 441], ["OCD", "PROBLEM", 28, 31], ["an increase in compulsive behaviors", "PROBLEM", 51, 86], ["anxiety over disease acquisition", "PROBLEM", 172, 204], ["OCD", "PROBLEM", 250, 253], ["worsening mental health status", "PROBLEM", 393, 423], ["increase", "OBSERVATION_MODIFIER", 54, 62], ["worsening", "OBSERVATION_MODIFIER", 393, 402]]], ["This in turn can exacerbate behavioral challenges in these children, adding to the myriad of challenges already faced by caregivers.Mental Health ConcernsParents of children with developmental disabilities, especially ASD, have greater levels of stress even at baseline, and also a higher divorce rate attributed to the challenges of raising a child with additional needs.", [["developmental disabilities", "DISEASE", 179, 205], ["ASD", "DISEASE", 218, 221], ["children", "ORGANISM", 59, 67], ["children", "ORGANISM", 165, 173], ["children", "SPECIES", 59, 67], ["children", "SPECIES", 165, 173], ["developmental disabilities", "PROBLEM", 179, 205], ["ASD", "PROBLEM", 218, 221], ["stress", "PROBLEM", 246, 252], ["a higher divorce rate", "PROBLEM", 280, 301]]], ["(Rivard et al. 2014) These relationships are at risk of further strain when there are mandated alternate work arrangements, financial stressors, uncertainty and lack of childcare support.", [["further strain", "PROBLEM", 56, 70], ["childcare support", "TREATMENT", 169, 186]]], ["Restriction of movements between households, with consequent loss of support from extended family members adds to the challenge in parenting.", [["movements", "OBSERVATION_MODIFIER", 15, 24]]], ["Given that these children are known to have higher rates of maltreatment (Hibbard and Desch 2007), the current confluence of stressors within the family is a further cause for concern.What Can We Do?Addressing the above factors will require coordinated multi-disciplinary efforts across national and societal systems, agencies, educational and healthcare institutions.", [["maltreatment", "DISEASE", 60, 72], ["children", "ORGANISM", 17, 25], ["children", "SPECIES", 17, 25]]], ["Some of the key mitigating measures will include the following:Maintaining access to outpatient diagnostic and intervention servicesIt is critical that healthcare facilities that serve children with developmental disabilities (for e.g. DBP clinics, child psychiatry clinics and community based intervention services) be considered essential and remain available.", [["developmental disabilities", "DISEASE", 199, 225], ["children", "ORGANISM", 185, 193], ["children", "SPECIES", 185, 193], ["intervention services", "TREATMENT", 111, 132]]], ["Whenever it is safe to do so, physical visits to these clinics and intervention services should be prioritized.", [["intervention services", "TREATMENT", 67, 88]]], ["Concurrently, continuing care via telemedicine should be actively explored during the pandemic and even beyond in conjunction with physical visits.", [["telemedicine", "TREATMENT", 34, 46]]], ["Technological infrastructure and training for telemedicine should be facilitated for providers and families.", [["telemedicine", "TREATMENT", 46, 58]]], ["Healthcare funding to support these aims should be rapidly sanctioned.Facilitating effective learning and therapyWhen planning online learning, educators should accommodate children with developmental disabilities with targeted strategies to address their difficulties.", [["developmental disabilities", "DISEASE", 187, 213], ["children", "ORGANISM", 173, 181], ["children", "SPECIES", 173, 181], ["therapy", "TREATMENT", 106, 113], ["developmental disabilities", "TREATMENT", 187, 213], ["targeted strategies", "TREATMENT", 219, 238]]], ["For example, children with ASD might require visual schedules, specific communication strategies and additional behavioral support to participate effectively during learning activities.", [["ASD", "DISEASE", 27, 30], ["children", "ORGANISM", 13, 21], ["children", "SPECIES", 13, 21], ["ASD", "PROBLEM", 27, 30], ["visual schedules", "TREATMENT", 45, 61], ["specific communication strategies", "TREATMENT", 63, 96], ["additional behavioral support", "TREATMENT", 101, 130]]], ["Therapy and/or educational packs containing these materials can be made available online for parents to print or be mailed to families.", [["Therapy", "TREATMENT", 0, 7], ["educational packs", "TREATMENT", 15, 32], ["these materials", "TREATMENT", 44, 59]]], ["For children with extremely challenging behaviors, school/center-based care should be made available as far as possible to provide much needed respite for caregivers and their families.Protecting mental health of children and caregiversPromoting parental awareness of the mental health needs of their children is important, especially since children may not be able to articulate their distress adequately.", [["children", "ORGANISM", 4, 12], ["children", "ORGANISM", 213, 221], ["children", "ORGANISM", 301, 309], ["children", "ORGANISM", 341, 349], ["children", "SPECIES", 4, 12], ["children", "SPECIES", 213, 221], ["children", "SPECIES", 301, 309], ["children", "SPECIES", 341, 349], ["their distress", "PROBLEM", 380, 394]]], ["Help children understand the changes around them, for example by using social stories which can facilitate adjustment to change.", [["children", "ORGANISM", 5, 13], ["children", "SPECIES", 5, 13]]], ["Community programs (e.g. parent support groups) can proactively check in on families with children with developmental disabilities.", [["developmental disabilities", "DISEASE", 104, 130], ["children", "ORGANISM", 90, 98], ["children", "SPECIES", 90, 98], ["Community programs", "TREATMENT", 0, 18]]], ["Similarly, physicians can opportunistically discuss children\u2019s mental wellbeing, and encourage caregiver self-care and respite.ConclusionChildren with developmental disabilities require continued services in a pandemic situation.", [["developmental disabilities", "DISEASE", 151, 177], ["children", "ORGANISM", 52, 60], ["Children", "ORGANISM", 137, 145], ["children", "SPECIES", 52, 60], ["Children", "SPECIES", 137, 145], ["developmental disabilities", "PROBLEM", 151, 177]]], ["This ongoing COVID-19 pandemic is unmatched in its sheer global scale of impact with sustained implications for all levels of society.", [["This ongoing COVID", "TEST", 0, 18], ["pandemic", "PROBLEM", 22, 30], ["society", "OBSERVATION", 126, 133]]], ["It is akin to a world-wide earthquake with repeated aftershocks lasting for months.", [["earthquake", "DISEASE", 27, 37]]], ["The severity and chronicity of COVID-19 will test the resilience and resourcefulness of communities, governments and countries.", [["The severity", "PROBLEM", 0, 12], ["COVID", "TEST", 31, 36], ["chronicity", "OBSERVATION_MODIFIER", 17, 27]]], ["Children with developmental disabilities are at risk of being lost amidst the hubbub of the pandemic.", [["developmental disabilities", "DISEASE", 14, 40], ["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8], ["developmental disabilities", "PROBLEM", 14, 40]]], ["Parents of children with disabilities have traditionally been the sole advocates for their children.", [["children", "ORGANISM", 11, 19], ["children", "ORGANISM", 91, 99], ["children", "SPECIES", 11, 19], ["children", "SPECIES", 91, 99]]], ["During this pandemic where parents themselves are struggling more than ever, education, health, early intervention and social services must keep these children in focus and collaborate to meet the challenges unique to this population of children.", [["children", "ORGANISM", 151, 159], ["children", "ORGANISM", 237, 245], ["children", "SPECIES", 151, 159], ["children", "SPECIES", 237, 245]]], ["The missed opportunities of serving children with developmental disabilities would only manifest in years to come.", [["developmental disabilities", "DISEASE", 50, 76], ["children", "ORGANISM", 36, 44], ["children", "SPECIES", 36, 44], ["developmental disabilities", "PROBLEM", 50, 76]]], ["During this unprecedented time for humanity, pediatricians must come together to care and advocate for nations and communities to include children with developmental disabilities in the equation.", [["developmental disabilities", "DISEASE", 152, 178], ["children", "ORGANISM", 138, 146], ["children", "SPECIES", 138, 146]]]], "PMC7110211": [["cDNA Library Construction and Sequencing. ::: Materials and MethodsThe cDNA library from A. glycines adults was constructed using cDNA Synthesis System kit (Roche Applied Science, Indianapolis, IN) and was sequenced on 454 GS Titanium platform.", [["A. glycines", "ORGANISM", 89, 100], ["cDNA", "DNA", 0, 4], ["cDNA library", "DNA", 71, 83], ["A. glycines", "SPECIES", 89, 100], ["A. glycines", "SPECIES", 89, 100], ["Methods", "TREATMENT", 60, 67], ["A. glycines adults", "TREATMENT", 89, 107], ["cDNA Synthesis System kit", "TREATMENT", 130, 155]]], ["More details on library construction, sequencing, and data analysis are provided previously (Bai et al. 2010).", [["data analysis", "TEST", 54, 67]]], ["The cDNA library of A. glycines contained 19,293 high-quality transcripts in total.", [["A. glycines", "ORGANISM", 20, 31], ["cDNA library", "DNA", 4, 16], ["A. glycines", "SPECIES", 20, 31], ["A. glycines", "TEST", 20, 31]]], ["Homology searches for transcript sequences were performed using Blast2GO software [E-value cut-off 10\u22123] (Conesa et al. 2005, Conesa and G\u00f6tz 2008; G\u00f6tz et al. 2008, 2011).", [["transcript sequences", "TEST", 22, 42]]], ["Based on information available on commonly used reference genes in the literature, we selected cDNA contigs of various candidate reference genes for A. glycines (Table 1).", [["A. glycines", "ORGANISM", 149, 160], ["reference genes", "DNA", 48, 63], ["cDNA contigs", "DNA", 95, 107], ["reference genes", "DNA", 129, 144], ["A. glycines", "SPECIES", 149, 160]]], ["The identity of putative cDNAs was further confirmed by Blastx search in GenBank (National Center for Biotechnology Information, Bethesda, MD).", [["cDNAs", "DNA", 25, 30], ["putative cDNAs", "OBSERVATION", 16, 30]]], ["The cDNA sequences of candidate reference genes were deposited in GenBank (for accession numbers, see Table 1).Insect Culture. ::: Materials and MethodsFor all qRT-PCR experiments, A. glycines insects were obtained from a laboratory colony, referred as biotype 1 (B1) that originated from insects collected from Urbana, IL (40\u00b0 06\u2032 N, 88\u00b0 12\u2032 W) in 2000 (Hill et al. 2004).", [["colony", "ANATOMY", 233, 239], ["A. glycines insects", "ORGANISM", 181, 200], ["cDNA sequences", "DNA", 4, 18], ["candidate reference genes", "DNA", 22, 47], ["A. glycines", "SPECIES", 181, 192], ["A. glycines", "SPECIES", 181, 192], ["The cDNA sequences", "TEST", 0, 18], ["Methods", "TEST", 145, 152], ["all qRT-PCR experiments", "TEST", 156, 179], ["A. glycines insects", "PROBLEM", 181, 200], ["Urbana", "TEST", 312, 318], ["IL", "TEST", 320, 322]]], ["At Ohio Agricultural Research and Development Center (Wooster, OH), a laboratory population of these insects is maintained on susceptible soybean seedlings [SD01-76R (2)] in a rearing room at 23\u201325\u00b0C and a photoperiod of 15:9 (L:D) h.qRT-PCR Analysis in A. glycines Fed With Resistant and Susceptible Plants. ::: Materials and MethodsFreshly hatched first-instar nymphs of A. glycines (60\u201370 individuals) were allowed to feed on resistant [LD-05 16060, contains Rag1] and susceptible soybean [SD01-76R (2)] plants (Tinsley et al. 2012).", [["SD01-76R (2)", "CHEMICAL", 157, 169], ["LD-05 16060", "CHEMICAL", 440, 451], ["soybean", "ORGANISM", 138, 145], ["C", "GENE_OR_GENE_PRODUCT", 198, 199], ["A. glycines", "ORGANISM", 373, 384], ["Rag1", "GENE_OR_GENE_PRODUCT", 462, 466], ["soybean", "SPECIES", 138, 145], ["A. glycines", "SPECIES", 254, 265], ["A. glycines", "SPECIES", 373, 384], ["soybean", "SPECIES", 484, 491], ["soybean", "SPECIES", 138, 145], ["A. glycines", "SPECIES", 254, 265], ["A. glycines", "SPECIES", 373, 384], ["soybean", "SPECIES", 484, 491], ["a photoperiod", "TEST", 204, 217], ["h.qRT", "TEST", 232, 237], ["PCR Analysis", "TEST", 238, 250], ["A. glycines", "TREATMENT", 373, 384], ["susceptible soybean", "TREATMENT", 472, 491], ["SD01", "TEST", 493, 497]]], ["After 12 h of feeding, insects were collected and placed in \u221280\u00b0C. There were three biological replications for each treatment.", [["each treatment", "TREATMENT", 112, 126]]], ["The collected insect samples were processed for total RNA extraction by using TRI reagent (Molecular Research Center Inc, Cincinnati, OH), following the protocol provided by the manufacturer.", [["samples", "ANATOMY", 21, 28], ["TRI", "CHEMICAL", 78, 81], ["The collected insect samples", "TEST", 0, 28], ["total RNA extraction", "TREATMENT", 48, 68], ["TRI reagent", "TREATMENT", 78, 89], ["the protocol", "TREATMENT", 149, 161]]], ["RNA samples were treated with TURBO DNase (Applied Biosystems/Ambion, Austin, TX) to remove any DNA contamination.", [["samples", "ANATOMY", 4, 11], ["DNase", "GENE_OR_GENE_PRODUCT", 36, 41], ["DNA", "CELLULAR_COMPONENT", 96, 99], ["DNase", "PROTEIN", 36, 41], ["RNA samples", "TEST", 0, 11], ["TURBO DNase", "TREATMENT", 30, 41], ["Ambion", "TREATMENT", 62, 68], ["TX", "TREATMENT", 78, 80], ["any DNA contamination", "PROBLEM", 92, 113]]], ["Using iScript cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA), first strand cDNA was prepared with 500 ng of RNA. qRT-PCR reactions were performed with iQ SYBR Green super mix on a CFX-96 thermocycler system (Bio-Rad Laboratories) (Bansal et al. 2011).", [["iScript cDNA", "DNA", 6, 18], ["Bio-Rad Laboratories", "PROTEIN", 34, 54], ["first strand cDNA", "DNA", 71, 88], ["Bio-Rad Laboratories", "TEST", 34, 54], ["Hercules", "TEST", 56, 64], ["CA", "TEST", 66, 68], ["first strand cDNA", "PROBLEM", 71, 88], ["PCR reactions", "TEST", 126, 139], ["a CFX", "TEST", 187, 192]]], ["Specific primers for each candidate reference gene were designed using Beacon Designer version 7.0 (Premier Biosoft, Palo Alto, CA) (Table 2).", [["candidate reference gene", "DNA", 26, 50]]], ["Each reaction was performed with 1 \u03bcl of cDNA, 0.5 \u03bcM of each primer, and 12.5 \u03bcl of iQ SYBR Green super mix in a 25-\u03bcl total volume.", [["cDNA", "DNA", 41, 45], ["Each reaction", "PROBLEM", 0, 13], ["cDNA", "TREATMENT", 41, 45]]], ["Each reaction was done in duplicate in a 96-well optical-grade PCR plates, sealed with optical sealing tape (Bio-Rad Laboratories).", [["Each reaction", "PROBLEM", 0, 13], ["well optical-grade PCR plates", "TREATMENT", 44, 73], ["optical sealing tape", "TREATMENT", 87, 107]]], ["The PCR amplifications were done with the following cycling conditions: one cycle at 95\u00b0C (3 min), followed by 35 cycles of denaturation at 95\u00b0C (30 s), annealing and extension at 55\u00b0C for 45 s.", [["The PCR amplifications", "TEST", 0, 22], ["denaturation", "TREATMENT", 124, 136]]], ["Finally, melt curve analyses were done by slowly heating the PCR mixtures from 55 to 95\u00b0C (1\u00b0C per cycle of 10 s) with simultaneous measurements of the SYBR Green signal intensities.", [["melt curve analyses", "TEST", 9, 28], ["the PCR mixtures", "TEST", 57, 73], ["simultaneous measurements", "TEST", 119, 144], ["signal intensities", "OBSERVATION", 163, 181]]], ["PCR amplification efficiencies and correlation coefficients (R2) for each primer pair were calculated as described in Real-Time PCR Applications Guide (catalog no. 170-9799, Bio-Rad Laboratories).qRT-PCR Analysis in A. glycines Tissues and Developmental Stages. ::: Materials and MethodsTo obtain selected tissue samples (gut, fat body, integument, and embryo developing inside adults), A. glycines adults (5 d old) were dissected out in phosphate-buffered saline, pH 8.0, under a dissecting microscope.", [["Tissues", "ANATOMY", 228, 235], ["tissue samples", "ANATOMY", 306, 320], ["gut", "ANATOMY", 322, 325], ["fat body", "ANATOMY", 327, 335], ["integument", "ANATOMY", 337, 347], ["embryo", "ANATOMY", 353, 359], ["phosphate", "CHEMICAL", 438, 447], ["phosphate", "CHEMICAL", 438, 447], ["tissue samples", "TISSUE", 306, 320], ["gut", "ORGANISM_SUBDIVISION", 322, 325], ["fat body", "TISSUE", 327, 335], ["integument", "TISSUE", 337, 347], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 353, 359], ["A. glycines", "ORGANISM", 387, 398], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 438, 463], ["primer pair", "DNA", 74, 85], ["A. glycines", "SPECIES", 387, 398], ["A. glycines", "SPECIES", 216, 227], ["A. glycines", "SPECIES", 387, 398], ["PCR amplification efficiencies", "PROBLEM", 0, 30], ["correlation coefficients", "TEST", 35, 59], ["each primer pair", "TEST", 69, 85], ["qRT", "TEST", 196, 199], ["PCR Analysis", "TEST", 200, 212], ["selected tissue samples", "TEST", 297, 320], ["phosphate-buffered saline", "TREATMENT", 438, 463], ["pH", "TEST", 465, 467], ["integument", "ANATOMY", 337, 347]]], ["During dissection, other tissues of A. glycines such as salivary glands and bacteriocytes were discarded.", [["tissues", "ANATOMY", 25, 32], ["salivary glands", "ANATOMY", 56, 71], ["bacteriocytes", "ANATOMY", 76, 89], ["tissues", "TISSUE", 25, 32], ["A. glycines", "ORGANISM", 36, 47], ["salivary glands", "ORGAN", 56, 71], ["bacteriocytes", "CANCER", 76, 89], ["A. glycines", "SPECIES", 36, 47], ["dissection", "TREATMENT", 7, 17], ["A. glycines", "PROBLEM", 36, 47], ["bacteriocytes", "TREATMENT", 76, 89], ["dissection", "OBSERVATION", 7, 17], ["salivary glands", "ANATOMY", 56, 71]]], ["To determine the expression of candidate reference genes in different developmental stages, all the four nymphal and adult samples were collected from insects feeding on susceptible soybean [SD01-76R (2)] plants.", [["adult samples", "ANATOMY", 117, 130], ["adult samples", "CANCER", 117, 130], ["candidate reference genes", "DNA", 31, 56], ["soybean", "SPECIES", 182, 189], ["soybean", "SPECIES", 182, 189]]], ["Both tissue and developmental stages' samples were processed for total RNA extraction, DNase treatment, first strand cDNA synthesis, and qRT-PCR as described in the previous section.", [["tissue", "ANATOMY", 5, 11], ["samples", "ANATOMY", 38, 45], ["tissue", "TISSUE", 5, 11], ["samples", "CANCER", 38, 45], ["DNase", "GENE_OR_GENE_PRODUCT", 87, 92], ["DNase", "PROTEIN", 87, 92], ["total RNA extraction", "TREATMENT", 65, 85], ["DNase treatment", "TREATMENT", 87, 102], ["first strand cDNA synthesis", "TREATMENT", 104, 131], ["qRT-PCR", "TEST", 137, 144], ["tissue", "ANATOMY", 5, 11]]], ["The first strand cDNA was prepared with 150 and 500 ng of RNA (DNA free) from tissue and developmental stages samples, respectively.Stability Analysis of Candidate Reference Genes. ::: Materials and MethodsTwo software algorithms, i.e., GeNorm (Vandesompele et al. 2002) and Normfinder (Andersen et al. 2004) were used to determine the stability of candidate reference genes.", [["tissue", "ANATOMY", 78, 84], ["samples", "ANATOMY", 110, 117], ["DNA", "CELLULAR_COMPONENT", 63, 66], ["tissue", "TISSUE", 78, 84], ["first strand cDNA", "DNA", 4, 21], ["Candidate Reference Genes", "DNA", 154, 179], ["candidate reference genes", "DNA", 349, 374], ["The first strand cDNA", "TREATMENT", 0, 21], ["software algorithms", "TEST", 210, 229]]], ["GeNorm calculated the M-score, and the lower the value for M is indicative of a more stable expression or low variation (Vandesompele et al. 2002).", [["indicative of", "UNCERTAINTY", 64, 77], ["low variation", "OBSERVATION_MODIFIER", 106, 119]]], ["This value is calculated by a geometric averaging of all the reference genes used in the study and mean pairwise variation of a reference gene from other reference genes.", [["reference gene", "DNA", 128, 142], ["reference genes", "DNA", 154, 169], ["This value", "TEST", 0, 10], ["the study", "TEST", 85, 94]]], ["It is important to note that the HKGs showing higher M value (M > 1.5) are not considered for normalization studies.", [["the HKGs", "TEST", 29, 37], ["normalization studies", "TEST", 94, 115]]], ["NormFinder also determines the expression stability but by taking account of intra- and intergroup variations for candidate reference genes (Andersen et al. 2004).", [["candidate reference genes", "DNA", 114, 139], ["stability", "OBSERVATION_MODIFIER", 42, 51]]], ["NormFinder provides the stability value for each gene, a direct measure for the estimated expression variation enabling evaluation of the systematic error introduced when using the gene for normalization (Andersen et al. 2004).GeNorm Analysis. ::: Results and DiscussionAmong the seven reference genes (SDFS, EF1a, HEL, GAPDH, RPS9, TBP, and UBQ), GeNorm revealed TBP to be stably expressed across the treatments, tissues, and developmental stages (Fig. 2A\u2013C, respectively).", [["tissues", "ANATOMY", 414, 421], ["SDFS", "GENE_OR_GENE_PRODUCT", 303, 307], ["EF1a", "GENE_OR_GENE_PRODUCT", 309, 313], ["HEL", "GENE_OR_GENE_PRODUCT", 315, 318], ["GAPDH", "GENE_OR_GENE_PRODUCT", 320, 325], ["RPS9", "GENE_OR_GENE_PRODUCT", 327, 331], ["TBP", "GENE_OR_GENE_PRODUCT", 333, 336], ["UBQ", "GENE_OR_GENE_PRODUCT", 342, 345], ["GeNorm", "GENE_OR_GENE_PRODUCT", 348, 354], ["TBP", "GENE_OR_GENE_PRODUCT", 364, 367], ["tissues", "TISSUE", 414, 421], ["reference genes", "DNA", 286, 301], ["SDFS", "DNA", 303, 307], ["EF1a", "DNA", 309, 313], ["HEL", "DNA", 315, 318], ["GAPDH", "DNA", 320, 325], ["RPS9", "DNA", 327, 331], ["TBP", "DNA", 333, 336], ["UBQ", "DNA", 342, 345], ["GeNorm", "DNA", 348, 354], ["TBP", "PROTEIN", 364, 367], ["evaluation", "TEST", 120, 130], ["SDFS", "TEST", 303, 307], ["EF1a", "TEST", 309, 313], ["HEL", "TEST", 315, 318], ["GAPDH", "TEST", 320, 325], ["RPS9", "TEST", 327, 331], ["TBP", "TEST", 333, 336], ["TBP", "PROBLEM", 364, 367]]], ["Although EF1a showed stable expression in both tissues and developmental stages, it had the least stability in insects fed on resistant and susceptible host plants.", [["tissues", "ANATOMY", 47, 54], ["EF1a", "GENE_OR_GENE_PRODUCT", 9, 13], ["tissues", "TISSUE", 47, 54], ["EF1a", "PROTEIN", 9, 13], ["EF1a", "TEST", 9, 13], ["developmental stages", "PROBLEM", 59, 79], ["stable", "OBSERVATION_MODIFIER", 21, 27], ["expression", "OBSERVATION", 28, 38], ["both tissues", "ANATOMY", 42, 54], ["developmental", "OBSERVATION_MODIFIER", 59, 72], ["stages", "OBSERVATION_MODIFIER", 73, 79], ["stability", "OBSERVATION_MODIFIER", 98, 107], ["host plants", "OBSERVATION", 152, 163]]], ["GeNorm determined the gene stability measure (M) among all the reference genes tested.", [["stability", "OBSERVATION_MODIFIER", 27, 36]]], ["Except for the EF1a in treatments, all the HKGs assayed in the current study displayed M < 1.5.", [["EF1a", "GENE_OR_GENE_PRODUCT", 15, 19], ["EF1a", "DNA", 15, 19], ["the EF1a in treatments", "TREATMENT", 11, 33], ["the HKGs", "TEST", 39, 47], ["the current study", "TEST", 59, 76]]], ["This trend of dissimilar ranking of reference genes across treatments, tissues, and developmental stages is quite a common phenomenon observed in several gene expression studies in insects (Hiel et al. 2009, Hornakova et al. 2010, Jiang et al. 2010, Lord et al. 2010, Mamidala et al. 2011, Rajarapu et al. 2011).", [["tissues", "ANATOMY", 71, 78], ["tissues", "TISSUE", 71, 78], ["reference genes", "DNA", 36, 51], ["a common phenomenon", "PROBLEM", 114, 133]]], ["Hence, it is highly recommended to determine the stably expressed reference gene for a given sample as normalization is critical and a significant component of final data interpretation.GeNorm Analysis. ::: Results and DiscussionAlthough a single reference gene which is stable and highly expressed suffices the requirement of quantifying mRNA transcript levels for a gene of interest, it also is recommended to use at least two to three reference genes for effective normalization of gene expression data (Vandesompele et al. 2002).", [["mRNA transcript", "RNA", 339, 354], ["mRNA transcript levels", "TEST", 339, 361], ["stable", "OBSERVATION_MODIFIER", 271, 277]]], ["The requirement of optimal number of HKGs can be obtained from the pairwise variation (V), wherein Vandosomplele et al. (2002) proposed a cut-off value (0.15), below which the inclusion of other reference genes are not required.", [["HKGs", "GENE_OR_GENE_PRODUCT", 37, 41], ["reference genes", "DNA", 195, 210], ["HKGs", "TEST", 37, 41]]], ["Results in the current study showed that the application of at least two stable reference genes maintains proper normalization irrespective of treatment, tissue, and development stages' samples (Fig. 3A\u2013C, respectively).", [["tissue", "ANATOMY", 154, 160], ["samples", "ANATOMY", 186, 193], ["tissue", "TISSUE", 154, 160], ["reference genes", "DNA", 80, 95], ["the current study", "TEST", 11, 28], ["treatment", "TREATMENT", 143, 152], ["stable", "OBSERVATION_MODIFIER", 73, 79]]], ["Because the pairwise variation was calculated by adding candidate genes stepwise according to rankings shown in Fig. 2, two of the most stable genes identified for a particular experimental condition (Fig. 2) should be able to be combined for normalization.", [["candidate genes", "DNA", 56, 71], ["the pairwise variation", "PROBLEM", 8, 30], ["stable", "OBSERVATION_MODIFIER", 136, 142], ["genes", "OBSERVATION", 143, 148]]], ["The candidate genes having lower stability in a given treatment (Fig. 2) should be avoided for normalization even if it is to be used in combination with other reference gene given the suitability and availability of other reference genes.", [["candidate genes", "DNA", 4, 19], ["reference genes", "DNA", 223, 238], ["lower stability", "PROBLEM", 27, 42], ["treatment (Fig.", "TREATMENT", 54, 69], ["lower", "OBSERVATION_MODIFIER", 27, 32], ["stability", "OBSERVATION_MODIFIER", 33, 42]]], ["For example, GeNorm analysis suggests that for qRT-PCR normalization in A. glycines fed with resistant and susceptible soybean, both TBP and RPS9 could be used together.", [["A. glycines", "ORGANISM", 72, 83], ["soybean", "ORGANISM", 119, 126], ["TBP", "GENE_OR_GENE_PRODUCT", 133, 136], ["RPS9", "GENE_OR_GENE_PRODUCT", 141, 145], ["TBP", "PROTEIN", 133, 136], ["RPS9", "PROTEIN", 141, 145], ["soybean", "SPECIES", 119, 126], ["A. glycines", "SPECIES", 72, 83], ["soybean", "SPECIES", 119, 126], ["GeNorm analysis", "TEST", 13, 28], ["qRT", "TEST", 47, 50], ["PCR normalization", "TEST", 51, 68], ["susceptible soybean", "TREATMENT", 107, 126], ["both TBP", "TREATMENT", 128, 136], ["RPS9", "TREATMENT", 141, 145]]], ["Similarly, for normalization among different developmental stages and among tissues of A. glycines, TBP and EF1a could be combined.", [["tissues", "ANATOMY", 76, 83], ["tissues", "TISSUE", 76, 83], ["A. glycines", "ORGANISM", 87, 98], ["TBP", "GENE_OR_GENE_PRODUCT", 100, 103], ["EF1a", "GENE_OR_GENE_PRODUCT", 108, 112], ["TBP", "PROTEIN", 100, 103], ["EF1a", "PROTEIN", 108, 112], ["A. glycines", "SPECIES", 87, 98], ["A. glycines", "TREATMENT", 87, 98], ["EF1a", "TREATMENT", 108, 112]]], ["It is interesting to note that various HKGs (RPS9, GAPDH, HEL, and UBQ) were not consistently ranked in terms of their stability under different experimental conditions, that is also the case observed in other insect studies (Hiel et al. 2009, Hornakova et al. 2010, Jiang et al. 2010, Lord et al. 2010, Mamidala et al. 2011).", [["HKGs", "GENE_OR_GENE_PRODUCT", 39, 43], ["RPS9", "GENE_OR_GENE_PRODUCT", 45, 49], ["GAPDH", "GENE_OR_GENE_PRODUCT", 51, 56], ["HEL", "GENE_OR_GENE_PRODUCT", 58, 61], ["UBQ", "GENE_OR_GENE_PRODUCT", 67, 70], ["HKGs", "PROTEIN", 39, 43], ["RPS9", "PROTEIN", 45, 49], ["GAPDH", "PROTEIN", 51, 56], ["HEL", "PROTEIN", 58, 61], ["UBQ", "PROTEIN", 67, 70], ["various HKGs", "TEST", 31, 43], ["RPS9", "TEST", 45, 49], ["GAPDH", "TEST", 51, 56], ["HEL", "TEST", 58, 61], ["stability", "OBSERVATION", 119, 128]]], ["Therefore, care should be taken in determining which HKG to use depending on experimental conditions.NormFinder Analysis. ::: Results and DiscussionNormFinder showed similar results to GeNorm, wherein TBP was shown to have low stability value (lower variation of gene expression) across all the samples (Fig. 4), further indicating the potential for this gene as a HKG for gene expression studies in A. glycines.", [["samples", "ANATOMY", 295, 302], ["TBP", "GENE_OR_GENE_PRODUCT", 201, 204], ["HKG", "GENE_OR_GENE_PRODUCT", 365, 368], ["A. glycines", "ORGANISM", 400, 411], ["TBP", "PROTEIN", 201, 204], ["HKG", "DNA", 365, 368], ["A. glycines", "SPECIES", 400, 411], ["NormFinder Analysis", "TEST", 101, 120], ["DiscussionNormFinder", "TEST", 138, 158], ["wherein TBP", "TEST", 193, 204], ["low stability value", "PROBLEM", 223, 242], ["low stability", "OBSERVATION_MODIFIER", 223, 236]]], ["Although there are discrepancies between the GeNorm and Normfinder output, TBP was shown to be the best ranking reference gene with both methods among treatments, tissues, and developmental stages (Fig. 2 and 4).", [["tissues", "ANATOMY", 163, 170], ["TBP", "GENE_OR_GENE_PRODUCT", 75, 78], ["tissues", "TISSUE", 163, 170], ["TBP", "PROTEIN", 75, 78], ["discrepancies between the GeNorm", "PROBLEM", 19, 51], ["Normfinder output", "TEST", 56, 73], ["TBP", "TEST", 75, 78], ["discrepancies", "OBSERVATION", 19, 32], ["GeNorm", "ANATOMY", 45, 51], ["Normfinder output", "OBSERVATION", 56, 73]]], ["Also, both of these analyses displayed RPS9 as an appropriate HKG across the treatments (Figs.", [["RPS9", "GENE_OR_GENE_PRODUCT", 39, 43], ["RPS9", "PROTEIN", 39, 43], ["these analyses", "TEST", 14, 28], ["RPS9", "TREATMENT", 39, 43]]], ["The different ranking of other HKGs (EF1a, GAPDH, HEL, and UBQ) by both GeNorm and NormFinder clearly demonstrates the expression stability of HKGs is influenced spatially, temporally, and also on experimental treatment.NormFinder Analysis. ::: Results and DiscussionIn conclusion, the HKG gene TBP showed stable expression across all the samples and did not seem to be influenced by treatments (A. glycines fed with resistant and susceptible host plants), among the various tissues and developmental stages included.", [["samples", "ANATOMY", 339, 346], ["tissues", "ANATOMY", 475, 482], ["HKGs", "GENE_OR_GENE_PRODUCT", 31, 35], ["EF1a", "GENE_OR_GENE_PRODUCT", 37, 41], ["GAPDH", "GENE_OR_GENE_PRODUCT", 43, 48], ["HEL", "GENE_OR_GENE_PRODUCT", 50, 53], ["UBQ", "GENE_OR_GENE_PRODUCT", 59, 62], ["HKGs", "GENE_OR_GENE_PRODUCT", 143, 147], ["HKG", "GENE_OR_GENE_PRODUCT", 286, 289], ["TBP", "GENE_OR_GENE_PRODUCT", 295, 298], ["A. glycines", "ORGANISM", 396, 407], ["tissues", "TISSUE", 475, 482], ["HKGs", "PROTEIN", 31, 35], ["EF1a", "PROTEIN", 37, 41], ["GAPDH", "PROTEIN", 43, 48], ["HEL", "PROTEIN", 50, 53], ["UBQ", "PROTEIN", 59, 62], ["GeNorm", "PROTEIN", 72, 78], ["HKGs", "PROTEIN", 143, 147], ["HKG gene", "DNA", 286, 294], ["TBP", "PROTEIN", 295, 298], ["A. glycines", "SPECIES", 396, 407], ["other HKGs", "TEST", 25, 35], ["EF1a", "TEST", 37, 41], ["GAPDH", "TEST", 43, 48], ["HEL", "TEST", 50, 53], ["the expression stability of HKGs", "PROBLEM", 115, 147], ["experimental treatment", "TREATMENT", 197, 219], ["NormFinder Analysis", "TEST", 220, 239], ["the HKG gene TBP", "TEST", 282, 298], ["A. glycines", "TREATMENT", 396, 407], ["resistant and susceptible host plants", "TREATMENT", 417, 454], ["stability", "OBSERVATION_MODIFIER", 130, 139], ["stable", "OBSERVATION", 306, 312], ["various tissues", "ANATOMY", 467, 482]]], ["Therefore, it could be used to normalize the mRNA transcript levels of candidate genes in A. glycines.", [["A. glycines", "ORGANISM", 90, 101], ["candidate genes", "DNA", 71, 86], ["A. glycines", "SPECIES", 90, 101]]], ["The TBP is a transcription factor that binds specifically to a DNA sequence called the TATA box and is well documented for its use as reference gene in several studies (Radonic et al. 2005, Jung et al. 2007, Nygard et al. 2007).", [["TBP", "GENE_OR_GENE_PRODUCT", 4, 7], ["DNA", "CELLULAR_COMPONENT", 63, 66], ["TBP", "PROTEIN", 4, 7], ["transcription factor", "PROTEIN", 13, 33], ["DNA sequence", "DNA", 63, 75], ["TATA box", "DNA", 87, 95], ["a DNA sequence", "TEST", 61, 75], ["the TATA box", "TREATMENT", 83, 95], ["several studies", "TEST", 152, 167]]], ["In addition, for experiments with A. glycines fed with resistant and susceptible host plants, RPS9 may be considered.", [["RPS9", "CHEMICAL", 94, 98], ["A. glycines", "ORGANISM", 34, 45], ["RPS9", "GENE_OR_GENE_PRODUCT", 94, 98], ["RPS9", "PROTEIN", 94, 98], ["A. glycines", "SPECIES", 34, 45], ["A. glycines fed", "TREATMENT", 34, 49], ["resistant and susceptible host plants", "TREATMENT", 55, 92], ["RPS9", "TREATMENT", 94, 98], ["host plants", "OBSERVATION", 81, 92]]], ["Similarly, for normalization among tissues and developmental stages, EF1a also can be used along with TBP.", [["tissues", "ANATOMY", 35, 42], ["tissues", "TISSUE", 35, 42], ["EF1a", "GENE_OR_GENE_PRODUCT", 69, 73], ["TBP", "GENE_OR_GENE_PRODUCT", 102, 105], ["EF1a", "PROTEIN", 69, 73], ["TBP", "PROTEIN", 102, 105], ["normalization among tissues", "PROBLEM", 15, 42], ["developmental stages", "PROBLEM", 47, 67], ["EF1a", "TREATMENT", 69, 73], ["TBP", "TEST", 102, 105]]], ["The identified reference genes in the current study may potentially serve as ideal internal controls in other closely related aphid species.", [["reference genes", "DNA", 15, 30], ["the current study", "TEST", 34, 51], ["aphid species", "OBSERVATION", 126, 139]]], ["However, the order of the gene stability should be revised for using a species specific study.", [["a species specific study", "TEST", 69, 93]]]], "42f9a8115fb3649febfdfe74c857a18b9966240f": [["M a n u s c r i p tINTRODUCTIONSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that causes coronavirus disease 2019 (COVID-19), emerged in December 2019 in Wuhan, China [1] .", [["acute respiratory syndrome coronavirus", "DISEASE", 38, 76], ["coronavirus disease", "DISEASE", 105, 124], ["SARS-CoV-2", "ORGANISM", 80, 90], ["SARS-CoV-2", "SPECIES", 80, 90], ["r i p tINTRODUCTIONSevere acute respiratory syndrome coronavirus", "PROBLEM", 12, 76], ["SARS-CoV", "TEST", 80, 88], ["coronavirus disease", "PROBLEM", 105, 124], ["acute", "OBSERVATION_MODIFIER", 38, 43], ["respiratory syndrome", "OBSERVATION", 44, 64], ["coronavirus disease", "OBSERVATION", 105, 124]]], ["It has since been declared a global pandemic with over 1,000,000 cases reported as of April 3, 2020 [2] .", [["global", "OBSERVATION_MODIFIER", 29, 35], ["pandemic", "OBSERVATION_MODIFIER", 36, 44]]], ["Person-to-person transmission has been established [3] [4] [5] [6] [7] [8] , and asymptomatic transmission of SARS-CoV-2 has been reported [9] .", [["SARS", "DISEASE", 110, 114], ["[3] [4] [5] [6] [7", "SIMPLE_CHEMICAL", 51, 69], ["person", "SPECIES", 10, 16], ["SARS-CoV", "SPECIES", 110, 118]]], ["However, studies on the potential transmission of SARS-CoV-2 by asymptomatic persons and those with mild illness have been limited [10] .", [["SARS", "DISEASE", 50, 54], ["illness", "DISEASE", 105, 112], ["SARS-CoV-2", "ORGANISM", 50, 60], ["persons", "ORGANISM", 77, 84], ["persons", "SPECIES", 77, 84], ["SARS-CoV", "SPECIES", 50, 58], ["SARS", "TEST", 50, 54], ["CoV", "TEST", 55, 58], ["mild illness", "PROBLEM", 100, 112]]], ["Herein, we report a 3-family cluster study of eight patients associated with asymptomatic and pauciasymptomatic (one mild symptom only) SARS-CoV-2 transmission in Shandong Province, China.Epidemiological InvestigationThe first positive SARS-CoV-2 patients in this cluster were identified on January 21, 2020 triggering an epidemiological investigation by the local center for disease control and prevention.", [["SARS", "DISEASE", 136, 140], ["patients", "ORGANISM", 52, 60], ["SARS-CoV", "ORGANISM", 236, 244], ["patients", "ORGANISM", 247, 255], ["patients", "SPECIES", 52, 60], ["patients", "SPECIES", 247, 255], ["SARS-CoV", "SPECIES", 236, 244], ["asymptomatic and pauciasymptomatic (one mild symptom", "PROBLEM", 77, 129], ["SARS", "PROBLEM", 136, 140], ["Epidemiological Investigation", "TEST", 188, 217], ["an epidemiological investigation", "TEST", 319, 351], ["disease control", "TREATMENT", 376, 391]]], ["To identify the possible infective source, the epidemiological investigation focused on exposure history before the onset of illness, such as travel history to Wuhan or Hubei Province, visiting live animal markets, and contact history with febrile persons.", [["illness", "DISEASE", 125, 132], ["febrile", "DISEASE", 240, 247], ["persons", "ORGANISM", 248, 255], ["persons", "SPECIES", 248, 255], ["infective source", "PROBLEM", 25, 41], ["the epidemiological investigation", "TEST", 43, 76], ["illness", "PROBLEM", 125, 132], ["febrile persons", "PROBLEM", 240, 255], ["possible", "UNCERTAINTY", 16, 24], ["infective", "OBSERVATION_MODIFIER", 25, 34]]], ["Medical records were also closely reviewed to verify the timelines of events and clarify clinical progressions.Epidemiological InvestigationTo examine possible environmental contamination of SARS-CoV-2 in households, select surfaces that may be frequently touched by family members were sampled in the bedroom (door handle, bedside light switch, and sliding of wardrobe door), kitchen (door handle, faucet switch, light switch, rice cooker plug), and bathroom (door handle, handrail, the surface of the toilet bowl, sink).Epidemiological InvestigationOne swab per site (room) with multiple surfaces was collected.Epidemiological InvestigationAll close contacts of SARS-CoV-2 positive patients were traced, including family members who lived with the patients and individuals who had contact with the patients within 1 meter without wearing proper personal protection.", [["surface", "ANATOMY", 488, 495], ["SARS", "DISEASE", 191, 195], ["SARS", "DISEASE", 664, 668], ["SARS-CoV-2", "ORGANISM", 664, 674], ["patients", "ORGANISM", 684, 692], ["patients", "ORGANISM", 750, 758], ["patients", "ORGANISM", 800, 808], ["rice", "SPECIES", 428, 432], ["patients", "SPECIES", 684, 692], ["patients", "SPECIES", 750, 758], ["patients", "SPECIES", 800, 808], ["SARS-CoV", "SPECIES", 191, 199], ["rice", "SPECIES", 428, 432], ["SARS-CoV", "SPECIES", 664, 672], ["Epidemiological Investigation", "TEST", 111, 140], ["SARS", "PROBLEM", 191, 195], ["faucet switch", "TREATMENT", 399, 412], ["Epidemiological Investigation", "TEST", 522, 551], ["Epidemiological Investigation", "TEST", 613, 642]]], ["Close contacts were quarantined at home and monitored for fever (\u226538\u00b0C) and symptoms.", [["fever", "DISEASE", 58, 63], ["fever", "PROBLEM", 58, 63], ["symptoms", "PROBLEM", 76, 84]]], ["In addition, nasopharyngeal swabs of close contacts were collected every 24 A c c e p t e d M a n u s c r i p t 5 hours from day 1 to 14 to detect SARS-CoV-2 by molecular assay.", [["nasopharyngeal swabs", "ANATOMY", 13, 33], ["nasopharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 13, 33], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 147, 157], ["SARS-CoV", "SPECIES", 147, 155], ["nasopharyngeal swabs", "TEST", 13, 33], ["a n u s", "TEST", 94, 101], ["SARS", "TEST", 147, 151], ["CoV", "TEST", 152, 155], ["nasopharyngeal", "ANATOMY", 13, 27]]], ["If any close contact had positive detection of SARS-CoV-2, they were sent to a hospital for isolation and treatment.SARS-CoV-2 Molecular Detection, Sequencing, and Phylogenetic AnalysisAll collected environmental and patient samples were stored at \u221280\u00b0C before being transported using cold chain to a biosafety level 2 enhanced laboratory to perform molecular detection of SARS-CoV-2.SARS-CoV-2 Molecular Detection, Sequencing, and Phylogenetic AnalysisA real-time reverse transcriptase PCR (rRT-PCR) Test Kit (GZ-D2RM, Shanghai GeneoDx Biotech Co., Ltd) targeting the ORF1ab and N genes of SARS-CoV-2 was used.", [["samples", "ANATOMY", 225, 232], ["SARS", "DISEASE", 47, 51], ["SARS", "DISEASE", 373, 377], ["patient", "ORGANISM", 217, 224], ["C", "GENE_OR_GENE_PRODUCT", 252, 253], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 373, 383], ["ORF1ab", "GENE_OR_GENE_PRODUCT", 569, 575], ["SARS-CoV-2", "ORGANISM", 591, 601], ["ORF1ab and N genes", "DNA", 569, 587], ["SARS-CoV-2", "DNA", 591, 601], ["patient", "SPECIES", 217, 224], ["SARS-CoV", "SPECIES", 47, 55], ["SARS-CoV", "SPECIES", 373, 381], ["SARS-CoV", "SPECIES", 591, 599], ["SARS", "PROBLEM", 47, 51], ["isolation", "TREATMENT", 92, 101], ["treatment", "TREATMENT", 106, 115], ["SARS", "TEST", 116, 120], ["CoV", "TEST", 121, 124], ["Molecular Detection", "TEST", 127, 146], ["Sequencing", "TEST", 148, 158], ["Phylogenetic Analysis", "TEST", 164, 185], ["patient samples", "TEST", 217, 232], ["molecular detection", "TEST", 350, 369], ["SARS", "PROBLEM", 373, 377], ["CoV", "TEST", 378, 381], ["SARS", "TEST", 384, 388], ["CoV", "TEST", 389, 392], ["Molecular Detection", "TEST", 395, 414], ["Sequencing", "TEST", 416, 426], ["Phylogenetic AnalysisA", "TEST", 432, 454], ["transcriptase PCR", "TEST", 473, 490], ["rRT", "TEST", 492, 495], ["PCR", "TEST", 496, 499], ["Test Kit", "TEST", 501, 509], ["GZ", "TEST", 511, 513], ["the ORF1ab", "TEST", 565, 575], ["SARS", "PROBLEM", 591, 595], ["CoV", "TEST", 596, 599]]], ["A cycle threshold (Ct) value less than 37 was interpreted as positive for SARS-CoV-2 RNA and a Ct value of 40 or more was defined as a negative test.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 74, 84], ["SARS-CoV-2 RNA", "RNA", 74, 88], ["SARS-CoV", "SPECIES", 74, 82], ["A cycle threshold (Ct) value", "TEST", 0, 28], ["SARS", "PROBLEM", 74, 78], ["CoV", "TEST", 79, 82], ["a Ct value", "TEST", 93, 103]]], ["A medium load (weakly positive), defined as a Ct value of 37 to less than 40, required confirmation by retesting.", [["A medium load", "TEST", 0, 13], ["a Ct value", "TEST", 44, 54], ["medium load", "OBSERVATION_MODIFIER", 2, 13]]], ["Positive samples were sequenced directly from the original specimens as previously described [11] .", [["samples", "ANATOMY", 9, 16], ["specimens", "ANATOMY", 59, 68], ["specimens", "CANCER", 59, 68], ["Positive samples", "PROBLEM", 0, 16]]], ["The maximum likelihood phylogenetic tree of the complete genomes was conducted by using RAxML software (version 8.2.9) [12] with 1000 bootstrap replicates, employing the general time-reversible nucleotide substitution model.Description of SARS-CoV-2 Positive PatientsPatients 1 (62-year-old woman) and 2 (65-year-old man) were a couple who lived with their son (Patient 3), daughter-in-law (Patient 4), and two grandchildren.", [["nucleotide", "CHEMICAL", 194, 204], ["nucleotide", "CHEMICAL", 194, 204], ["SARS-CoV-2", "ORGANISM", 239, 249], ["Patients", "ORGANISM", 259, 267], ["Patients", "ORGANISM", 267, 275], ["woman", "ORGANISM", 291, 296], ["man", "ORGANISM", 317, 320], ["Patients", "SPECIES", 259, 267], ["Patients", "SPECIES", 267, 275], ["woman", "SPECIES", 291, 296], ["man", "SPECIES", 317, 320], ["Patient", "SPECIES", 362, 369], ["Patient", "SPECIES", 391, 398], ["SARS-CoV", "SPECIES", 239, 247], ["the general time-reversible nucleotide substitution model", "TREATMENT", 166, 223], ["SARS", "PROBLEM", 239, 243], ["maximum", "OBSERVATION_MODIFIER", 4, 11], ["likelihood", "OBSERVATION_MODIFIER", 12, 22], ["phylogenetic", "OBSERVATION_MODIFIER", 23, 35], ["tree", "OBSERVATION_MODIFIER", 36, 40], ["nucleotide substitution", "OBSERVATION", 194, 217]]], ["Patient 1 presented with cough, rhinorrhea, and sputum on January 12, 2020 ( Figure 1 ).", [["sputum", "ANATOMY", 48, 54], ["cough", "DISEASE", 25, 30], ["rhinorrhea", "DISEASE", 32, 42], ["Patient", "SPECIES", 0, 7], ["cough", "PROBLEM", 25, 30], ["rhinorrhea", "PROBLEM", 32, 42], ["sputum", "PROBLEM", 48, 54], ["cough", "OBSERVATION", 25, 30], ["rhinorrhea", "OBSERVATION", 32, 42]]], ["On January 15, she visited a health clinic and was diagnosed with a common cold.", [["a common cold", "PROBLEM", 66, 79]]], ["She was prescribed intravenous infusions of ampicillin and sulbactam, ribavirin, and traditional medicine for five days.", [["intravenous", "ANATOMY", 19, 30], ["ampicillin", "CHEMICAL", 44, 54], ["sulbactam", "CHEMICAL", 59, 68], ["ribavirin", "CHEMICAL", 70, 79], ["ampicillin", "CHEMICAL", 44, 54], ["sulbactam", "CHEMICAL", 59, 68], ["ribavirin", "CHEMICAL", 70, 79], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 19, 30], ["ampicillin", "SIMPLE_CHEMICAL", 44, 54], ["sulbactam", "SIMPLE_CHEMICAL", 59, 68], ["ribavirin", "SIMPLE_CHEMICAL", 70, 79], ["intravenous infusions", "TREATMENT", 19, 40], ["ampicillin", "TREATMENT", 44, 54], ["sulbactam", "TREATMENT", 59, 68], ["ribavirin", "TREATMENT", 70, 79], ["traditional medicine", "TREATMENT", 85, 105]]], ["On January 16, she developed a fever (38\u00b0C).", [["fever", "DISEASE", 31, 36], ["a fever", "PROBLEM", 29, 36], ["fever", "OBSERVATION", 31, 36]]], ["On January 17, Patient 2 reported symptoms of fever (37.8\u00b0C), cough, sputum, earache, and upset stomach.", [["sputum", "ANATOMY", 69, 75], ["stomach", "ANATOMY", 96, 103], ["fever", "DISEASE", 46, 51], ["cough", "DISEASE", 62, 67], ["stomach", "ORGAN", 96, 103], ["symptoms", "PROBLEM", 34, 42], ["fever", "PROBLEM", 46, 51], ["cough", "PROBLEM", 62, 67], ["sputum, earache, and upset stomach", "PROBLEM", 69, 103], ["stomach", "ANATOMY", 96, 103]]], ["He was also diagnosed with a common cold at the health clinic and received the same prescription as Patient 1 for three days.", [["He", "ORGANISM", 0, 2]]], ["However, their symptoms did not resolve at the conclusion of the treatment regimen leading both to seek care at a local hospital on January 21.Description of SARS-CoV-2 Positive PatientsNasopharyngeal swabs were collected from both patients at the hospital and confirmed positive for The infant had no clinical symptoms before, during, or after hospitalization.Description of SARS-CoV-2 Positive PatientsThe chest CT images on admission or hospitalization showed that Patients 1-6 had ground-glass opacities.", [["Nasopharyngeal swabs", "ANATOMY", 186, 206], ["SARS-CoV-2", "ORGANISM", 158, 168], ["Patients", "ORGANISM", 178, 186], ["Nasopharyngeal swabs", "CANCER", 186, 206], ["patients", "ORGANISM", 232, 240], ["infant", "ORGANISM", 288, 294], ["Patients", "ORGANISM", 396, 404], ["Patients", "SPECIES", 178, 186], ["patients", "SPECIES", 232, 240], ["infant", "SPECIES", 288, 294], ["Patients", "SPECIES", 396, 404], ["Patients", "SPECIES", 468, 476], ["SARS-CoV", "SPECIES", 158, 166], ["SARS-CoV", "SPECIES", 376, 384], ["their symptoms", "PROBLEM", 9, 23], ["the treatment regimen", "TREATMENT", 61, 82], ["SARS", "PROBLEM", 158, 162], ["CoV", "TEST", 163, 166], ["Nasopharyngeal swabs", "TEST", 186, 206], ["clinical symptoms", "PROBLEM", 302, 319], ["SARS", "PROBLEM", 376, 380], ["CoV", "TEST", 381, 384], ["The chest CT images", "TEST", 404, 423], ["ground-glass opacities", "PROBLEM", 485, 507], ["Nasopharyngeal", "ANATOMY", 186, 200], ["chest", "ANATOMY", 408, 413], ["glass opacities", "OBSERVATION", 492, 507]]], ["However, no significant abnormalities were observed for Patients 7 and 8 (Supplemental A c c e p t e d M a n u s c r i p t 9DISCUSSIONWe report a unique three-family cluster of infection with SARS-CoV-2, in which eight of 15 members were confirmed with SARS-CoV-2 infection.", [["infection", "DISEASE", 177, 186], ["SARS", "DISEASE", 192, 196], ["SARS-CoV-2 infection", "DISEASE", 253, 273], ["Patients", "ORGANISM", 56, 64], ["SARS-CoV-2", "ORGANISM", 192, 202], ["SARS-CoV-2", "ORGANISM", 253, 263], ["Patients", "SPECIES", 56, 64], ["SARS-CoV", "SPECIES", 192, 200], ["SARS-CoV-2", "SPECIES", 253, 263], ["significant abnormalities", "PROBLEM", 12, 37], ["infection", "PROBLEM", 177, 186], ["SARS", "PROBLEM", 253, 257], ["2 infection", "PROBLEM", 262, 273], ["no", "UNCERTAINTY", 9, 11], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["abnormalities", "OBSERVATION", 24, 37], ["infection", "OBSERVATION", 177, 186], ["infection", "OBSERVATION", 264, 273]]], ["Particularly interesting is that of 6 secondary patients, two were asymptomatic, one was paucisymptomatic, and three were symptomatic.", [["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["asymptomatic", "PROBLEM", 67, 79], ["paucisymptomatic", "PROBLEM", 89, 105], ["symptomatic", "PROBLEM", 122, 133], ["symptomatic", "OBSERVATION_MODIFIER", 122, 133]]], ["Our findings show that the transmission of SARS-CoV-2 by individuals with asymptomatic or paucisymptomatic infections is possible.", [["SARS", "DISEASE", 43, 47], ["infections", "DISEASE", 107, 117], ["SARS-CoV-2", "ORGANISM", 43, 53], ["individuals", "ORGANISM", 57, 68], ["SARS-CoV", "SPECIES", 43, 51], ["SARS", "PROBLEM", 43, 47], ["CoV", "TEST", 48, 51], ["asymptomatic", "PROBLEM", 74, 86], ["paucisymptomatic infections", "PROBLEM", 90, 117], ["paucisymptomatic", "OBSERVATION_MODIFIER", 90, 106], ["infections", "OBSERVATION", 107, 117]]], ["Patients 1 and 2 were likely first exposed to SARS-CoV-2 after visiting their hometown in Xiaogan Hubei Province, China.", [["SARS", "DISEASE", 46, 50], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Their son (Patient 3) and daughter-in-law (Patient 4, asymptomatic), whom they live with, were later found to be infected with SARS-CoV-2.", [["SARS", "DISEASE", 127, 131], ["SARS-CoV-2", "ORGANISM", 127, 137], ["Patient", "SPECIES", 11, 18], ["Patient", "SPECIES", 43, 50], ["SARS-CoV", "SPECIES", 127, 135], ["infected", "OBSERVATION", 113, 121]]], ["Patient 5 (asymptomatic) was identified to be infected with SARS-CoV-2 after frequent contact with Patients 3 and 4 during work and home visits.", [["SARS", "DISEASE", 60, 64], ["Patients", "ORGANISM", 99, 107], ["Patient", "SPECIES", 0, 7], ["Patients", "SPECIES", 99, 107], ["SARS-CoV", "SPECIES", 60, 68], ["infected", "OBSERVATION", 46, 54]]], ["She transmitted the virus to her son (symptomatic) whom she lives with.", [["She", "ORGANISM", 0, 3]]], ["Patient 7 (paucisymptomatic) was found to be infected with SARS-CoV-2 after frequent contact with Patient 3 during work.", [["SARS", "DISEASE", 59, 63], ["SARS-CoV-2", "ORGANISM", 59, 69], ["Patient", "SPECIES", 0, 7], ["Patient", "SPECIES", 98, 105], ["SARS-CoV", "SPECIES", 59, 67], ["SARS", "PROBLEM", 59, 63], ["infected", "OBSERVATION", 45, 53]]], ["He likely transmitted the virus to his daughter (Patient 8, asymptomatic).", [["He", "ORGANISM", 0, 2], ["Patient", "SPECIES", 49, 56]]], ["In addition, consistent with previous studies [5] [6] [7] [8] , the transmission of SARS-CoV-2 during the incubation period of Patient 3 likely occurred.", [["SARS", "DISEASE", 84, 88], ["[5] [6] [7] [8]", "SIMPLE_CHEMICAL", 46, 61], ["Patient", "SPECIES", 127, 134], ["previous studies", "TEST", 29, 45], ["SARS", "TEST", 84, 88], ["CoV", "TEST", 89, 92], ["consistent with", "UNCERTAINTY", 13, 28]]], ["Patients 5 and 7 were infected after their exposures to a presymptomatic Patient 3 during working or home visits.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["Patient", "SPECIES", 73, 80]]], ["These findings may help explain the rapid spread of SARS-CoV-2 between person-to-person.DISCUSSIONThe currently available evidence shows that SARS-CoV-2 is transmitted between people through droplets and close contact [13] .", [["SARS", "DISEASE", 52, 56], ["SARS", "DISEASE", 142, 146], ["SARS-CoV-2", "ORGANISM", 52, 62], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 142, 152], ["people", "ORGANISM", 176, 182], ["person", "SPECIES", 71, 77], ["person", "SPECIES", 81, 87], ["people", "SPECIES", 176, 182], ["SARS-CoV", "SPECIES", 52, 60], ["the rapid spread of SARS", "PROBLEM", 32, 56], ["SARS", "PROBLEM", 142, 146], ["rapid", "OBSERVATION_MODIFIER", 36, 41], ["spread", "OBSERVATION_MODIFIER", 42, 48]]], ["A recent study showed extensive environmental contamination by a SARS-CoV-2 patient [14] , suggesting the contaminated environment as a potential medium of transmission.", [["SARS", "DISEASE", 65, 69], ["SARS-CoV-2", "ORGANISM", 65, 75], ["patient", "ORGANISM", 76, 83], ["CoV-2 patient", "SPECIES", 70, 83], ["SARS-CoV", "SPECIES", 65, 73], ["A recent study", "TEST", 0, 14], ["extensive environmental contamination", "PROBLEM", 22, 59], ["a SARS", "TEST", 63, 69], ["extensive", "OBSERVATION_MODIFIER", 22, 31], ["environmental contamination", "OBSERVATION", 32, 59]]], ["In this study, we detected SARS-CoV-2 in two environmental swabs from the household of Patient 3.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 27, 37], ["SARS-CoV", "SPECIES", 27, 35], ["this study", "TEST", 3, 13], ["SARS", "PROBLEM", 27, 31], ["CoV", "TEST", 32, 35]]], ["Such detection of SARS-CoV-2 in contaminated environments of the household may provide an additional contribution to virus transmission among family members as the virus can remain viable and infectious on the surface up to seven days [15] .", [["surface", "ANATOMY", 210, 217], ["SARS", "DISEASE", 18, 22], ["SARS-CoV-2", "ORGANISM", 18, 28], ["SARS-CoV", "SPECIES", 18, 26], ["SARS", "PROBLEM", 18, 22], ["CoV", "TEST", 23, 26], ["the virus", "PROBLEM", 160, 169], ["infectious", "OBSERVATION", 192, 202]]], ["However, the direct researchbased evidence describing exactly how SARS-CoV-2 is transmitted is limited, and further studies are required.DISCUSSIONWe cannot rule out the possibility of unknown COVID-19 patients (e.g., asymptomatic carriers) transmitting the virus.", [["SARS", "DISEASE", 66, 70], ["SARS-CoV-2", "ORGANISM", 66, 76], ["patients", "ORGANISM", 202, 210], ["patients", "SPECIES", 202, 210], ["SARS-CoV", "SPECIES", 66, 74], ["further studies", "TEST", 108, 123], ["asymptomatic carriers", "PROBLEM", 218, 239], ["the virus", "PROBLEM", 254, 263]]], ["However, according to screening protocols implemented by the provincial, municipal, and county-level Center for Disease Control and Prevention, all close contacts were A c c e p t e d M a n u s c r i p t 10 traced, and all patients with positive rRT-PCR results in this study were confirmed by whole-genome sequencing, including those who were asymptomatic or pauciasymptomatic (Patients 4, 5, 7, and 8).", [["patients", "ORGANISM", 223, 231], ["patients", "SPECIES", 223, 231], ["Patients", "SPECIES", 379, 387], ["Disease Control", "TREATMENT", 112, 127], ["a n u s", "TEST", 186, 193], ["this study", "TEST", 265, 275], ["asymptomatic", "PROBLEM", 344, 356], ["pauciasymptomatic", "PROBLEM", 360, 377]]], ["M a n u s c r i p t 11AcknowledgmentsWe thank all patients involved in the study.", [["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58], ["the study", "TEST", 71, 80]]], ["We also thank Dr. Hong-Guang Ren from Beijing Institute of Biotechnology for generating phylogenetic tree.", [["phylogenetic tree", "OBSERVATION", 88, 105]]]]}